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ABSTRACT
Spinal cord injury (SCI) is a significant health issue resulting in life-long disability and
associated secondary complications, affecting approximately 300,000 individuals in the United
States. Primary barriers to functional recovery after SCI include the formation of a growth inhibitory
astrocyte scar at the lesion border and a lack of a supportive stroma within the defect allowing for axon
regeneration. Interestingly, in animals capable of spinal cord regeneration, astrocytes create a tissue
bridge across the injury site to facilitate the regeneration of axons through the defect and thus enable
functional recovery.
The overall goal of this thesis was to develop an injectable collagen-genipin (Col-Gen)
hydrogel to facilitate the intrinsic regenerative response after SCI by promoting the population of the
defect with astrocytes through a provisional scaffold pennissive of astrocyte migration. The specific aims
of the thesis involved: 1) development and materials characterization of an injectable collagen hydrogel
for neural tissue regeneration, capable of undergoing covalent crosslinking in vivo; 2) evaluation of the
permissiveness of Col-Gen gels with and without Fibroblast growth factor-2 (FGF-2), a known astrocyte
chemoattractant, incorporated within lipid microtubules (LMTs) to infiltration by primary astrocytes
using an in vitro cellular outgrowth assay; 3) evaluation of select formulations of the gel, based on the in
vitro findings, in a standardized hemi-resection defect in the rat spinal cord. Functional, locomotor, and
histopathological outcome measures, recorded up to 4 weeks post-SCI were correlated with each other
and with micro MRI studies.
In vivo, the implantation of Col-Gen gels containing FGF-2 LMTs resulted in the enhancement of
astrocyte, blood vessel, and laminin infiltration of the defect; increased the amount of spinal cord tissue
spared from secondary degeneration; and increased functional recovery, at four weeks post injury as
compared to control or Col-Gen treatment groups. Micro MRI was found to be a suitable modality to non-
destructively observe the features of the injury in situ. This work commends an injectable, covalently
cross-linkable formulation of collagen gel incorporating FGF-2-releasing LMTs for further investigation
for the treatment of SCI.
Thesis Supervisor: Myron Spector
Title: Professor of Orthopedic Surgery (Biomaterials), Harvard Medical School. Senior Lecturer,
Department of Mechanical Engineering, MIT
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Chapter 1:
Introduction
8
Spinal cord injury (SCI) is an extremely debilitating condition often resulting in complete or
partial paralysis. In the United States there are approximately 12,000 new cases per year with an
additional 232,000-316,000 people currently living with SCI [1]. Since most SCI patients are young, with
an average age at injury of 40.7 years, the lifetime cost to care for these individuals is high, ranging from
$300,000 for incomplete motor function at any level to over $4,000,000 for high tetraplegia [1]. Currently,
there are no clinically available treatments to restore significant function after injury.
SCI presents a complex regenerative problem due to the multiple facets of growth inhibition that
occur following trauma to the cord parenchyma and stroma. Clinically, SCI is further complicated by the
heterogeneity in the size, shape, and extent of human injuries. Many of these injuries do not breach the
dura mater and have continuous viable axons through the injury site that can later lead to some degree of
functional recovery. In these cases, surgical manipulation of the spinal cord by implanting a preformed
scaffold or drug delivery device may lead to further damage. Given these circumstances, utilizing in
situ-forming scaffolds are an attractive approach for SCI regeneration. These synthetic or natural
polymers undergo a rapid transformation from liquid to gel upon injection into the cord tissue,
conforming to the individual lesion site and directly integrating with the host tissue. Injectable materials
can be formulated to have mechanical properties that closely match the native spinal cord extracellular
matrix, and this may enhance axonal ingrowth. Such materials can also be loaded with cellular and
molecular therapeutics to modulate the wound environment and enhance regeneration.
Overall goal of this thesis is to develop an injectable gel capable of undergoing covalent cross-
linking in vivo, which can modulate the native tissue response to spinal cord injury, allowing for the
formation of a regenerative template of astrocytes and blood vessels within the defect formed after spinal
cord injury.
In order to enhance the infiltration of the gel-filled defect with astrocytes, a known
chemoattractant for these cells, fibroblast growth factor (FGF)-2, was incorporated into the collagen
solution prior to its injection. In addition to acting as a chemoattractant for astrocytes, FGF-2 is
commended for use in this study for its ability to: promote revascularization of the injury site and act as a
neuroprotective factor for the spared tissue. The gel formulations were evaluated in a hemi-resection
defect model in the rat spinal cord.
The specific aims of the thesis involve: 1.) Development of an injectable collagen hydrogel for
neural tissue regeneration, capable of undergoing covalent crosslinking in vivo. . 2.) Enhancement of
astrocyte infiltration into Col-Gen gels through the sustained delivery of fibroblast growth factor 2 (FGF-
2) encapsulated within lipid microtubules (LMTs). 3.) In vivo histological and behavioral study of the
9
acute- early chronic tissue response to injection of Col-Gen gels in a standardized hemi-resection defect
in the rat spinal cord.
The overall hypothesis is that by designing a provisional matrix with the proper attractive cues
for axon supportive cellular ingrowth (i. e. astrocytes and endothelial cells), a regenerative template will
be formed within the spinal cord defect, allowing for the ingrowth of axons.
This thesis consists of several chapters, summarized below, which provide a detailed background,
methods, results, and discussion of the present study:
Chapter 2 details the background and motivation underlying the work performed in this thesis. It includes
a through literature review of the pathophysiology of SCI, current treatments, the role of injectable
therapies in SCI, the design parameters and classes of materials appropriate for use as injectable gels for
SCI, and finally an overview of the prior in vivo studies using injectable collagen gels for the treatment of
SCI. A majority of the content in this chapter has been published in Biomedical Materials [2].
Chapter 3 characterizes the injectable collagen-genipin gel in terms of its mechanical behavior, cross-
linking kinetics (via absorbance and fluorescence measurements), resistance to enzymatic degradation,
and cell viability when incorporated into these gels. A majority of the content in this chapter has been
published in Advanced Functional Materials [3].
Chapter 4 describes the cellular outgrowth assay used to assess the permissiveness of select collagen-
genipin gel formulations containing FGF-2 to astrocyte infiltration. This chapter also provides insight in
to the phenotype of the astrocytes in response to FGF-2, the benefits of sustained release of FGF-2 via
lipid microtubules (LMTs), the effects of genipin on astrocytes, and the role of proliferation and viability
in the observed response. A majority of the content in this chapter has been published in Biomaterials [4].
Chapter 5 describes a pilot in vivo biocompatibility study in a standardized rodent hemi-resection model
of SCI using collagen-genipin gels with and one without FGF-2 LMTs. The formulations used in this
study were guided by the experiments in chapters 3 and 4. The animals were assessed at one and four
weeks post injury and evaluated histologically and behaviorally.
Chapter 6 describes a full in vivo study of the biomaterials-tissue interaction of collagen-genipin gels in a
standardized rodent hemi-resection model of SCI. Histologic and behavioral analysis was performed on
three groups: control, collagen-genipin gel, and collagen-genipin gel with FGF-2 LMTs, at four weeks
post injury. The formulations of the collagen-genipin gels were determined based on the pilot study in
chapter 5.
10
Chapter 7 details a pilot ex vivo magnetic resonance imaging study of the hemi-resection defect with and
without implanted gel at 1 day, 1 week, and 4 weeks post injury. The results correlate features of the
injury, gel localization, and tissue remodeling with histology on the same samples.
Chapter 8 lists the conclusions that are supported by the work presented in this thesis.
Chapter 9 discusses the limitations of the worked performed and identifies areas for future investigation.
Following the main chapters of the thesis is an appendix with detailed protocols for the fabrication and
assays performed in the thesis.
References:
[ 1] Center NSCIS. Spinal cord injury facts and figures at a glance. Birmingham Alabama: University of
Alabama at Birmingham; February 2012.
[2] Macaya D, Spector M. Injectable hydrogel materials for spinal cord regeneration: a review. Biomed
Mater. 2012;7:012001.
[3] Macaya D, Ng KK, Spector M. Injectable Collagen-Genipin Gel for the Treatment of Spinal Cord
Injury: In Vitro Studies. Adv Funct Mater. 2011;21:4788-97.
[4] Macaya DJ, Hayakawa K, Arai K, Spector M. Astrocyte infiltration into injectable collagen-based
hydrogels containing FGF-2 to treat spinal cord injury. Biomaterials. 2013;34:3591-602.
11
Chapter 2:
Background and Motivation
12
2.1. Introduction to SCI
2.1.1. Pathology and current treatment
An understanding of the pathophysiology of SCI is essential for the rational development of
therapeutic strategies. We now have available a wide array of agents which can be employed as
treatments for SCI individually or in combination: biomaterials; exogenous cells of various types; protein
regulators of cell function (e.g., growth factors and chemoattractants), and their genes; antagonists of
inflammation and nerve growth inhibitors; and enzymes for extracellular matrix (ECM) molecules which
interfere with the regenerative process. The informed selection of specific agents and the timing of their
administration require an understanding of the intrinsic components of the response to SCI that prevent or
interfere with a regenerative response.
The mechanism of SCI is usually a mechanical insult to the spinal cord parenchyma following a
fractured vertebra or disk intruding into the spinal canal [1]. This results in various degrees of contusion,
laceration, and in very rare cases a complete transection of the spinal cord tissue [1-3]. Human cases of
SCI vary widely with respect to the site and degree of tissue destruction, and may involve multiple lesions
with sizes smaller than a single vertebral segment [31 SCI rarely results in a complete disruption of tissue
through the lesion site [1]. Approximately 61% of SCIs are classified as incomplete, meaning that there is
still a degree of function in segments of the spinal cord innervated below the injury [4]. Complete injuries
may also have continuous parenchyma through the lesion, although there is no function in distal segments
[1, 3, 5]. Taken together, these studies show that after injury, the protective dural covering of the spinal
cord may be intact and there is almost always some amount of viable tissue traversing the site of the
lesion. Given these observations, minimally invasive therapies are an attractive treatment option for SCI.
Although our knowledge of the pathology of human SCI is limited, it is believed that most
injuries are caused by cord contusion. In one classification system, a contusion/compression type SCI
presents with extensive damage and cyst formation in the cord parenchyma with no breach or disruption
in the surface anatomy or adhesions to the dura [2]. Another class of SCI, solid cord injury, appears
normal grossly but displays tissue that is clearly damaged histologically [2].
One of the challenges in the treatment of SCI is that such injuries may not show gross
morphological changes until hours post injury, but eventually encompass 1-2 vertebral segments proximal
and distal to the lesion site [6]. The major clinical manifestations of the injury result from damage and
subsequent degeneration of the ascending and descending white matter tracks (axons) [1]. In the case of a
contusion injury, viable and intact axons are still present at the injury site but are rendered virtually
useless from demyelination due to oligodendrocyte loss, which greatly reduces their conduction velocity
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[7]. While some plasticity may be observed, the function of areas innervated by segments below the
injury is lost.
Current treatment for SCI addresses 2 features of the injury: the persistent mechanical
compression of the cord and the acute inflammatory response. Surgical decompression of the injured
segments is immediately followed by the administration of steroids to neutralize acute inflammation and
decrease swelling to further reduce compression on any remaining neurons [8, 9].
2.1.2. Chronology ofpathophysiological changes
SCI pathology can be divided into immediate, acute (0-7 days), sub-acute (7-14 days), and
chronic (months/years) stages [9]. The microenvironment of the injured spinal cord presents many
significant obstacles to regeneration at these various stages (Table 2-1). The initial injury causes necrotic
cell death due to direct mechanical trauma and ischemia from vascular disruption and hemorrhage.
During the acute phase, a cascade of secondary injury processes occurs that leads to further cell death,
scarring, and loss of function. Continued vascular injury, ischemia, inflammation, free-radical
production, and the massive release of excitatory neurotransmitters by the injured cells cause secondary
necrosis, apoptosis, and swelling 1-2 segments above and below the original lesion site. Supportive glial
astrocytes at the lesion periphery begin to hypertrophy and proliferate into a "reactive" phenotype that
contains the injury [10]. The most widely used indicator of the reactive astrocytic response to injury is
cellular hypertrophy and the enhanced expression the intermediate filament, glial fibrillary acidic protein
(GFAP) [11]. The cytoskeletal intermediate filaments, vimentin and nestin, which are typically found in
immature astrocytes, and the following non-cytoskeletal proteins are also expressed in reactive astrocytes:
class II histocompatibility antigens, glutamine synthetase, and glutamine transporters [11, 12].
Table 2-1: Key cellular and molecular events after SCI
Event Type Timeframe Underlying Pathological Mechanism
Necrosis min-hours Oxidative stress, edema, hemorrhage and
disruption of BBB, ischemia, physical trauma,
excitatory neurotransmitters, infiltration of acute
Apoptosis days/week inflammatory cells.
Oxidative stress, limited ability to replace
damaged glia & neurons via endogenous
progenitors. Activation of apoptotic pathways.
Demyelination days-months Oligodendrocyte loss
Glial scar formation days-weeks Reactive astrocytes, ECM remodeling
Axon degeneration days-months Loss/block of function (signaling)
Inhibitory/repulsive environment blocks
regrowth
(Nogo, OMG, MAG, CSPG)
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In the sub-acute phase, microglia begin to clear the injured area of debris leaving behind a cystic
cavity, which is subsequently surrounded by a glial scar consisting of reactive astrocytes. The glial scar is
composed of long astrocytic processes that interweave to form a dense mesh and ECM material including
chondroitin sulfate proteoglycans (CSPGs) [13, 14]. Macrophages, fibroblasts, and Schwann cells are
also known to infiltrate the wound from outside of the CNS, usually from the spinal nerve roots,
especially in the case of laceration injuries where the dura is disrupted [3, 15].
Finally, in the chronic phase, the astrocytic scar stabilizes around cysts/syrinxes and extends
down the path of degenerated axons [16]. Depending on the extent of fibroblast infiltration, there may
also be a dense collagenous scar within the injury site. The fibrous scar formed after SCI can present a
greater barrier to regeneration than glial scarring due to its dense framework and ability to bind growth
inhibitory molecules [17]. Over the course of the next few months, oligodendrocyte populations continue
to undergo apoptosis, which leads to progressive demyelination of axons. Wallerian degeneration, the
destruction of the distal end of severed axons, also occurs over the next few months-years leaving behind
a trail of myelin debris that further inhibits axon growth [16, 18]. Additionally, Schwannosis, the
infiltration of Schwann cells and their associated axons from the peripheral nervous system (PNS), is
prevalent in human SCI after approximately four months and is attributed to the loss of astroglial
framework at the injury site[3]. This ingrowth by elements of the PNS potentially serves as an
impediment to neurite outgrowth and may cause pain, spasticity, and other abnormal physical responses.
Unlike experimental models of SCI, human injuries are highly heterogeneous and the exact
pathology and time course of events will vary depending on the type of injury [1, 2]. It is worth noting
that the time course of human SCI is typically extended with respect to rodents [19]. In humans, the loss
of myelin in degenerating axon tracts takes approximately 2-3 years, as opposed to months in rodents
[18]. Schwann cell invasion of the lesion is seen as early as I week in rodents but is not noted in humans
until 3 weeks [15]. Interestingly, human SCI exhibits less glial scarring and CSPGs are mainly localized
to the lesion site. There is also a lower incidence of chronic demyelination in humans when compared to
rodents [15, 19]. Such variation in pathology between human and animal models should be considered
when designing and testing potential therapies for SCI (Table 2-2) [19].
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Table 2-2: Differences in pathophysiology between rodent models and clinical human spinal cord injury.
From Hagg et al.
Rodent aUmwan
Degenerative processes
Vascular response Hemorrhage. angiogenesis Hemorrhage angiogenesis
Inflammation Extensive Much less pronounced. despite
similar cytokine expression
Demyelination Yes Yes, but perhaps less pronounced
Axonal degeneration Some die-back and Wallerian Wallerian degeneration much
degeneration more protracted
Glial scar Extensive, with astroglial CSPG Not extensive. CSPGs mostly
in blood vessels
Cyst formation Rat yes; mouse no Yes
Schwann cell response Some invasion Extensive Schwannosis
Regenerative processes
Sprouting Yes Yes
Remyelination Yes Yes
Plasticity of uninjured systems Yes Yes
CSPG. chondroitin sulphate proteoglycan.
2.1.3. Inflammatory and vascular events after SCI
The time course of inflammatory cell infiltration after injury is illustrated in Figure 2-1 [20].
Further detail about the contributions of specific inflammatory cells to injury and tissue repair is
summarized in Table 2-3 [20].
One specific inflammatory cell type, the macrophage has been extensively studied due to its role
as an important modulator of tissue injury and repair after SCI. Macrophages are recruited to the site of
injury immediately after SCI, reach a peak density at 14 days post injury, and finally decrease to an
elevated by stable value by 3-4 weeks post injury and remain around the injury site indefinitely [20-22].
Interestingly, chondroitin sulfate proteoglycans (CSPGs) most noted for their role in axon inhibition,
actually have a pivotal role in spatially and temporally controlling the activity of infiltrating blood-borne
monocytes and resident microglia during the acute phase after the injury. Rolls et al. demonstrated that
immediate inhibition of CSPG production after SCI in mice caused a dramatic effect on the spatial
organization of infiltrating macrophages and an alteration in their cytokine/growth factor release leading
to enhanced tissue destruction and decreased functional recovery [23]. In contrast, allowing CSPG
synthesis during the first 2 d post injury, followed by inhibition, improved recovery.
Two main phenotypes of macrophages, M I and M2 can be seen after SCI. M 1 macrophages
(pro-inflammatory) clear tissue debris from the injury site and areas of Wallerian degeneration but may
contribute to the axonal retraction and secondary tissue damage after SCI. M2 macrophages (anti-
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inflammatory) secrete a variety of neurotropic factors may be responsible for neuroprotection,
angiogenesis, and the promotion of axon growth however, an excessive or prolonged presence of M2
macrophages may result in fibrosis and scarring, which could hinder axon regeneration [21]. Therefore,
an important balance must be struck between MI and M2 macrophages to achieve the clearance of tissue
debris, reduce secondary tissue damage, and promote repair.
Recent work by Kigerl et al. suggests that after injury to the cord there is a transient appearance
I Tk& rw rO
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Figure 2-1: Time course of inflammatory cell infiltration of the defect site after rodent spinal cord
injury with relation to major pathogenic and wound healing events. From Trivedi et al.
of M2 macrophages early (1-7 days) after injury with 40-50% of the macrophages adopting an M2
phenotype [21]. However, by 28 days post injury, fewer than 10% of the macrophages are M2. This
work shows that the environment of SCI is conducive to MI macrophage polarization despite the
phagocytosis of red blood cells and cellular debris, which normally promote a M2 phenotype. Within the
M2 phenotype there are three subtypes, which modulate different aspects of the inflammatory response,
however these have been poorly characterized in the context of SCI.
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The vascular events after spinal cord injury play a critical role in the degree of secondary damage,
which occurs after the primary injury. Mechanical trauma to the spinal cord (contustion, compression,
lasceration) causes vasospasm of superficial vessels and intraparenchymal hemorrhage particularly in the
highly vascular central gray matter [24]. There is also a disruption of the blood-spinal cord barrier
leading to edema, an alteration of tissue perfusion from the release of vasoactive molecules, and a loss of
autoregulation (the ability to maintain blood flow despite differences in perfusion pressure).
Additionally, there may be post-traumatic systemic events, which affect blood flow such as hypotension,
bradycardia, and decreased cardiac output [24]. Together, these events lead to ischemia and necrosis
within the spinal cord parenchyma. The resulting cell death further initiates a cascade of events such as
the release of excitotoxicity neurotransmitters from dead/dying cells and the generation of free radicals
from the reperfusion if ischemic tissue or degradation of hemoglobin, which results in additional
(secondary) damage to previously viable spinal cord tissue.
Cell Type Type of Immunity Pro-inflammatory molecules Mediators of cell injury/ Pro-regeneration/
__________ Innate _ (4)_ death wound healing events
Neulrophils Innate4) Express receptors for various Produce Phagocytosis
chemokines and cvtokines, metalloproteinases,
MMP-9 reactive oxygen and
nitrosyl radicals
neutronhil elastase
Dendritic cells Innate and Produce TNF-agr, IL-1, IL-2 Function as antigen Production of
adaptive IL-6- IL-12, lL-18. IFN-y presenting cells neurotrophin-3
Monocytes/ Innate Produce TNF-agr;. IL-I. IL-2 Produce reactive oxygen Phagocytosis. production
Macrophages IL-6, IL-12, 1L-18 species and nitrosyl of trophic factors. IL-10,
radicals TGF-B
Microglia/ Innate and Produce TNF-agr;, IL-I. IL-2 Function as antigen Phagocytosis, production
Macrophages adaptive IL-6, IL-12, IL-1 presenting cells; produce of trophic factors. IL-10,
reactive oxygen species TGF-s
and nitrosyl radicals
B- Adaptive Express receptors for various Produce antibodies Unknown
Ly'phOCyts chemokines and cytokines
T- Adaptive Express receptors for various Pro-inflammatory Production of trophic
Lymphocytes chemoknes and cytokmes, cytokines and factors, IL-10, ILAE _ __________ _ IFN-. TGF-6 chemokines IL-13
Abbreviations: matrix inetalloproteinase-9 - MMP-9; tumor necrosis factor-alpha - TNF-agr; interleukn - IL; interferon-gamma - IFN--y; transforming
growth factor-beta - TGF-p;
Table 2-3: Overview of inflammatory cells, their inflammatory mediators, and mechanism of tissue
destruction or wound healing. From Trivedi et al.
The hemorrhage which occurs after vascular injury to the spinal cord is greatest at the injury
epicenter and can be seen extending into the dorsal columns both rostral and caudal to the injury [24].
Zhang et al, studied the regenerative response within these dorsal column lesions and found they were
extensively infiltrated by macrophages and the beginnings of blood vessel growth by 1 week [25]. By 2
weeks, there was a network of blood vessels and clusters of glial cells within the defect and regenerating
nerve fibers could be seen at the interface of the lesion and adjacent normal tissue.
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1.3. Considerations for regeneration
There are a number of intrinsic and extrinsic factors that lead to regenerative failure in the CNS.
Therefore, one may consider multiple targets for intervention (Figure 2-2).
Mylin Node of Ranvier
Grav Matter
A
Microglia Inhibitors of Axonal Growth Figure. 2-2. A) A fluid-filled cystic cavity
in a spinal cord resulting from injury,
surrounded by a glial scar (white circle)
shown in more detail in (B). The glial scar
(B) is made up of activated astrocytes and
contains inhibitors of axonal growth
(depicted as yellow dots).
Illustration C 2011 Edmond Alexander,
alexanderandturner.com
Severed Oligodendrocyte Activated Astrocyte
Axons
Unlike the CNS, the PNS is capable of spontaneous regeneration. Nerve grafts and guidance
tubes have been shown to enable severed axons to grow through large gaps in the PNS and promote
recovery [26, 27]. After a PNS injury, the axons at the distal end degenerate while those at the proximal
end begin to sprout, elongate, develop growth cones, and eventually reform synapses to nerves/muscles.
The major support and myelinating cell of the PNS (Schwann cell) assists the process by re-myelinating
axons, secreting growth factors and synthesizing ECM (laminin, fibronectin), and guiding axon growth
[28-30]. There is a 1:1 ratio of axons to Schwann cells in the PNS and after injury cells from the
degenerated portions of axons assist in the regeneration process. In contrast in the CNS, oligodendrocytes
myelinate between one and eighteen axons, making the loss of these cells detrimental to a larger
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proportion of nerve fibers [31]. Perhaps the most interesting example of the difference between the
regenerative potential of the CNS and PNS relates to the dorsal root ganglia (DRG). DRGs are areas
beside the spinal cord where the bodies of sensory neurons are located. Although these neurons have
axons within the spinal cord and the PNS, they can only regenerate their peripheral process [32]. In the
case of complete SCI, Schwann cells infiltrate the spinal cord and associated PNS axons can be seen
growing within the former spinal cord parenchyma [15].
As noted above, in the CNS, the major support and myelinating cell, the oligodendrocyte is
associated with multiple neurons. Consequently, after injury, many of these cells die; demyelinating their
associated neurons and greatly reducing the support for regenerating axons. Degraded myelin contains
potent growth inhibitors such as Nogo-A, oligodendrocyte myelin glycoprotein (OMG), and myelin-
assisted glycoprotein (MAG) [33-35]. In the PNS these products are cleared by macrophages and
Schwann cells, but in the CNS, microglia cells are much slower in clearing this debris which may be
present as long as 3 years post injury [18].
The cyst and glial scar formed after injury to the CNS also act as significant physical and
chemical barriers to spontaneous regeneration. But the astrocytic response can be beneficial as well as
detrimental to regeneration [10, 36]. At early times, it serves limit further damage by: reestablishing the
blood brain barrier (BBB) and ionic homeostasis; limiting immune cell infiltration; and containing
excitatory neurotransmitters. At later times, however, the dense scar and associated CSPGs are inhibitory
towards regeneration. Reactive astrocytes secrete an ECM containing chondroitin sulfate proteoglycans
(CSPGs), which have been implicated as a major growth inhibitory molecule for neurons [37-39]. In
cases of SCI where there is disruption of the dura, there is also substantial fibrous infiltration of the spinal
cord, which leads to an even greater physical and chemical barrier to axon regeneration.[17, 40]
Although there are many barriers to regeneration in the CNS, it has the potential for repair. CNS
white matter can support axon regeneration in uninjured as well as degenerating white matter tracts in
rodents [41, 42]. The inhibitory factors deposited at sites of chronic SCI do not form absolute boundaries.
Early work by David, et al., using a peripheral nerve graft, demonstrated it was possible to achieve
significant axon elongation through a lesion site in the spinal cord by providing a permissive environment
for growth similar to the PNS [43]. Axons can regenerate through scars into sites of chronic SCI using
diffusible signals such as neurotrophin (NT)-3 from modified mesenchymal stem cells (MSCs) [44].
Numerous others have shown that neurotrophic factors, antibodies against myelin debris receptors, and
CSPG degrading enzymes can promote regeneration and axonal sprouting after SCI [45].
The regeneration of a large number of tracts may not be necessary to promote substantial
recovery after SCI. Signals can be re-routed to downstream targets over other pathways through neural
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plasticity. Significant neurological function may be preserved with as few as 5-10% of the original
number of axons present in the white matter [46]. Basso, et al., showed that after a graded contusion by a
weight drop, an increase in spared white matter from 5% to 10% allowed rats to go from not supporting
their own weight to supporting their own weight and exhibiting consistent stepping [47]. This ability has
also been noted in humans. Cordotomy procedures for the relief of pain following cancer showed that the
anterior half of the thoracic cord could be cut without any disturbance to motility, and cutting one lateral
corticospinal tract (CST) and 85-90% of the opposite tract and the reticulospinal fibers anterior to the tract
caused total paralysis of the lower limbs which recovered over 2 months so that the patient eventually
walked again [48].
In sum, the local environment after SCI plays a significant role in the regenerative response of
neurons. If a minimally invasive therapy is utilized to spare viable axons, reduce the amount of
secondary damage after the insult, and promote axon regeneration and collateral sprouting, a significant
amount of functional recovery can potentially occur. By addressing the multiple facets of growth
inhibition in SCI, it may be possible to restore a healing response similar to that of the PNS.
2.2. Injectable materials for SCI: Overview
Research into injectable biomaterials holds great promise in the fields of tissue engineering and
regenerative medicine. A wide variety of injectable materials have been developed for various tissue
specific applications such as bone, cartilage, intervertebral disk, brain, and spinal cord [49-51]. Each
tissue poses its own unique set of properties and challenges that must be addressed by the scaffold
material. In particular, the CNS presents a complex regenerative obstacle due to the multiple
mechanisms of degeneration and growth inhibition that occur after injury. These obstacles require a
combinational approach utilizing scaffolds, cellular, and molecular therapies tailored to the specific injury
at hand.
2.2.1. Current status of injections into the spinal cord
The injection of substances directly into the spinal cord or surrounding tissue has been used
clinically for a variety of scenarios. Intrathecal infusion of medication via catheters has been used for
chronic/severe pain relief [52]. For drug delivery applications, mini-pumps and catheters are sub-optimal
for sustained delivery as they are prone to blockage and subsequent infection [53]. Currently, there are a
few clinical trials are underway for the injection of cells into the spinal cord including autologous
macrophages, olfactory ensheathing cells, oligodendrocyte progenitor cells [7, 54, 55].
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2.2.2. Advantages of injectable materials
Hydrogels are natural or synthetic hydrophilic polymers capable of binding large percentages (50-
99.9% by wt.) of water. Hydrogels are viscoelastic materials resulting from the physical or chemical
bonding of molecules in a liquid state: physical gels by van der Waals interactions and hydrogen bonding,
and for the purpose of this review, ionic bonding; and chemical gels by covalent crosslinking. The
conversion of the injected liquid into a physical or chemical gel in vivo enables the filling of small defects
such as the cavities/cysts, which form after SCI or the space between transected parts of the spinal cord.
The gel, serving as a scaffold, can eliminate void spaces and form a regenerative template to direct
cellular infiltration and matrix deposition towards repair of the injured region.
Injectable materials that form scaffolds in situ can conform to the shape of the defect and create
an integrative implant-tissue interface to restore the continuity of the tissue and reduce significant
contraction/deformation of the scaffold [56]. This injectable gel property obviates the need to create
preformed scaffolds for each individual patient and avoids excising viable tissue at the injury site to
accommodate implantation of the preformed scaffold, which could cause further tissue damage and loss
of functionality. Poor graft integration is often the cause of graft failure and pathological changes in the
host spinal cord including extensive glial-connective scar and cyst formation [57]. For incomplete cases
of SCI where the BBB has not been disrupted and the dura mater is intact, injectable therapies will be
beneficial since they will not further disrupt the dura. Damage to this important structure has been
implicated in scar formation, cellular invasion, and cystic cavity formation after SCI [40].
Injectable materials, in their liquid state, can be uniformly mixed with cells and other therapeutics
prior to delivery within the spinal cord defect. Spatial and temporal control over the release of these
agents can be tailored through multiple mechanisms including incorporation within secondary release
vehicles such as micro- and nano-particles, liposomes, and microtubules [50, 58], covalent tethering to the
gel with subsequent enzymatic release [59], or harnessing the ability of macromolecules such as heparin
to bind growth factors such as NT-3 and platelet derived growth factor (PDGF) [60].
The mechanical properties of gel scaffolds can more closely match the properties of the native
spinal cord tissue, compared to most preformed biomaterial matrices. The implications of this include
providing a permissive substrate for neuronal growth and will be discussed in subsequent sections.
For patients, injectable therapies hold the promise of minimally invasive procedures. The prime
and most clinically practical window for intervention may not be immediately after injury but delayed
until the sub-acute stage (7-14 days post injury), when the initial inflammatory response has subsided [7,
61]. Having flexibility on the time course of administration could enhance the clinical outcome of
22
patients without risking further damage.
2.2.3. Requirements for injectable systems
2.2.3.1. Main functions
The development of injectable therapies for spinal cord regeneration may be designed with a
focus on three broad functions.
1) Scaffolding for cellular infiltration and axonal ingrowth. The gel material itself will serve to
bridge the lesion site. Scaffolding acts to reduce cyst formation, inflammation, and the associated
secondary cell damage, while accommodating the infiltration of supportive cell populations and the
growth of axons into the gel-filled lesion site [62]. The gelation kinetics, final gel microstructure,
mechanical properties, degradation rate, and bioactive properties of the scaffold can be tuned to optimize
its regenerative potential.
2) Encapsulation of drugs and maintenance of bioactivity throughout gelation and release.
Therapeutics such as neurotrophic factors, antibodies against degrading myelin products, chondroitin
sulfate-degrading enzymes, and others, can stimulate axonal regeneration through lesion and encourage
neural plasticity [63]. Injectable systems can provide a sustained and tunable delivery of these agents
locally to the lesion site. This is especially important for therapeutics such as NT-3, which has an in vivo
half-life of only 30 minutes, but have a therapeutic effect when delivered over the course of days to weeks
[64, 65].
3) Support of suspended cell populations prior to injection, throughout solidification process, and
within in the lesion site. The incorporation of transplanted cell populations have been shown to enhance
functional recovery after SCI in animal models by providing necessary trophic factors and extracellular
cues for axon regeneration, myelination, and a source to restore lost cell populations [66, 67]. Cellular
therapies are more effective when delivered and maintained locally in the injured area as opposed to
delivered systemically.
2.2.3.2. Design parameters
It should be noted that in most polymer systems it is difficult to isolate crosslink and macromer
concentration-dependent material properties such as mechanical stiffness, mesh or pore size, degradation
rate, and bioactive ligand density. Therefore several group have created multi-component systems to
study the effects of each variable on neuronal behavior [68-70].
Biocompatibility. The reactants and degradation products of the material must be non-toxic and
non-immunogenic to reduce excessive inflammation at the injury site leading to additional cellular
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damage. Materials obtained from natural sources should be carefully screened and treated to reduce the
risk of disease transmission and immunological responses. Initiators, crosslinkers, or other additives
required for scaffold formation should not adversely affect encapsulated cells or cross-react with
therapeutics.
Solidification Solidification of the injectable material should occur under mild conditions to
avoid additional tissue damage at the lesion site, adversely affecting encapsulated cell populations, or
sensitive drug compounds. The speed of gelation must be rapid enough to contain the material within the
injection site and maintain the localization of incorporated cells or therapeutic agents. Ideal solidification
times are on the order of seconds to minutes depending on the initial viscosity of the injectable material.
Factors affecting the gelation time include, temperature, crosslinker concentration, ionic strength, pH,
light, surface area, among others [50].
Porosity/mesh size The overall mesh size of nanoporous fibrillar scaffolds, and the porosity, and
pore diameter and interconnectivity of microporous scaffolds are crucial for tissue ingrowth, the removal
of nutrients and waste, and the diffusion of therapeutic agents from the polymer matrix. A growth-
permissive substrate for endogenous/exogenous cell populations may recapitulate the three-dimensional
(3-D) organization of the native ECM. In situ-forming scaffolds typically have >99% water content and a
typical mesh/pore size on the order of 0.1-10 Itm. Neurons are 20-30 [tm in length with approximately 1-
[tm diameter growth cones [71, 72]. The relative dimensions of the growth cones and mesh opening may
hinder cell motility unles the material can be moved or degraded by the cells [68, 73]. For example,
agarose gels with decreasing mesh size and increasing stiffness severely inhibited neurite outgrowth
below a mesh opening of 150 nm [74]. Additionally, decreasing the mesh size of collagen gels from 7.2
ptm at 0.4 mg/ml to 3.1 [tm at 2.0 mg/ml impeded neurite extension of encapsulated DRG cells [73]. The
polymer size and concentration of the monomer/polymer, as well as the initiator and crosslinker
concentrations, can be used to control the mesh or pore size of injectable scaffolds.
Mechanical properties The mechanical properties of the gel should match the native tissue to
withstand in vivo forces, maintain structural integrity, and transmit physiological forces until it can be
replaced by native tissue. While the spinal cord itself is not a load-bearing structure, injected materials
should not collapse under the weight of the surrounding tissue. Additionally, the mechanical properties of
substrates have a profound effect on cell behavior especially in the CNS [70, 75, 76]. The soft and
viscoelastic nature of native CNS tissue and hydrogels make rheology an ideal technique to study their
mechanical properties. In this regard, the shear modulus is often reported as the measure of "stiffness."
Numerous model systems using several materials have been created to investigate the effects of
substrate stiffness on neurite behavior. Flanagan, et aL., created a system to isolate the mechanical effects
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on primary mouse spinal cord neurons using polyacrylamide gels coated with matrigel to provide a
constant mesh size and number of adhesion ligands. Neurons exhibited a high branching density on
substrates of 50Pa-350 Pa which is on the order of bovine (50 Pa) or human (200 Pa) spinal cord tissue
[70]. In comparison, the branching frequency on 550 Pa gels was reduced, and was similar to glass.
Similarly, Leach, et al., used a 2-D polyacrylamide gel with a constant fibronectin density to explore
neurite outgrowth and branching of PC12 cells induced to a neuronal phenotype [77]. Unlike Flanagan's
experiment, the cells displayed a threshold response to substrate stiffness from a shear modulus of 100 -
10,000 Pa. In this stiffness range, a greater percentage of cells expressed neurites, which were also longer
and more branched than the softer gels (<0.1 kPa).
Wilits, et al., cultured DRG cells in 3-D collagen gels of varying protein content, ranging in shear
modulus from 2.2-17 Pa and found that maximum lengths of neurites occurred in softer gels [73]. It
should be noted that increasing the collagen concentration had multiple effects, which factored into the
observed results including a decreased interfiber spacing, increased ligand density, and increased shear
modulus. Using a 3-D agarose culture of DRG cells, Balgude, et al., found the average rate of axon
elongation was inversely correlated to the concentration of the agarose gel, which ranged in modulus from
5-130 Pa [71]. Banerjee, et al., explored a greater range of gel stiffness -180-20,000 Pa with alginate
gels encapsulating neural stem cells (NSCs) and found that the softest gels, which were on the order of
magnitude of the stiffness of brain tissue, resulted in significantly higher NSC proliferation and neuronal
differentiation (B-tubulin III staining) than stiffer gels [78]. Seidlits, et al., used acrylated high molecular
weight hyaluronic acid (HA) gels to investigate ventral midbrain neural progenitor cell (NPC)
differentiation and spinal astrocyte behavior in a 3-D culture environment with tunable mechanical
properties [79]. By adjusting the degree of acrylate substitution, the compressive modulus could be
modified between 3-10 kPa, which is similar to adult rat spinal cord (8.1 ± 1.1 kPa). After 3 weeks in
culture, NPCs on the softest gels were furthest differentiated towards the neuronal phenotype and
exhibited 0-III tubulin-positive long branching processes while NPCs on the stiffest gels did not survive
the full 3 weeks. On the other hand, spinal astrocytes survived the full 3 weeks in all gels and only
showed evidence of migration on the stiffest gel.
Overall, the difference in the observed optimal stiffness for neurite branching among the different
studies is due to specific factors, which have an effect on the response of cells to compliant substrates,
such as: the cell type (i.e., PC12, DRG, primary neurons); material type and adhesive ligand density;
mesh/pore size; and range of modulus investigated. Interestingly, glia, which are implicated in scarring
after SCI, had poor survival on soft substrates [70]. Other groups demonstrated that DRG neurons tend to
elongate processes down gradients in stiffness and fibroblasts, implicated in mesenchymal scarring,
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preferentially migrate back towards stiffer areas of patterned hydrogels [80-82].
Degradation rate The degradation rate of injectable scaffolds should proceed on the time scale
of tissue formation so that axons are provided with a constant stable platform for growth. If the scaffold
degrades prematurely, the injury site will also be subject to compressive stresses that would cause further
inflammation and glial scaring [83], and there will be lack of sufficient stromal support for the ingrowth
of axons. If the scaffolding degrades too slowly, it will impinge on new tissue formation and hinder
axonal growth. Mahoney, et al., investigated the process of extension of neural tissue into polyethylene
glycol (PEG)-polylactic acid (PLA) gel matrices with controllable degradation rates. The group was able
to control the time course of neurite extension from 1-3 weeks depending on the degradation rate of the
polymer and concomitant change in the matrix mesh size [68]. Subsequent work by this group showed a
relationship between the degradable macromer content of the PEG-PLA matrix and the cellular
proliferation of neural cells cultured within the material after 7 days [84]. In rodents, degradation rates on
the order of weeks to months would be appropriate. This timeframe corresponds to the rate of axon
sprouting from the CST, which can be observed 3 weeks to 3 months after injury [85, 86].
Additionally, neuronal growth cones secrete serine proteases and calcium dependent matrix
metalloproteinases that assist in matrix remodeling for axonal path finding during development and
regeneration [87, 88]. Pittier, et al., showed that inhibiting serine proteases greatly decreased neurite
extension in fibrin matrices [89]. Therefore, synthetic material with bioactive sequences sensitive to these
enzymes as well as natural materials such as collagen can be specifically remodeled by the regenerating
axons. To this point, Straley, et al., engineered protein polymers containing bioactive sequences for
serine protease specific degradation (see section 3.3.3) [69]. By altering the bioactive sequence, scaffolds
could be fabricated with a 200-fold difference in degradation half-lives. However, using PC 12 cells, the
difference in degradation rate of the scaffolds had no significant effect on cell morphology or neurite
extension after 6 days of exposure to neuronal differentiation media.
The degradation mechanisms of biomaterials will influence their behavior in vivo. Since total
body water is conserved, materials undergoing hydrolytic degradation have the advantage of having low
animal-animal and location variability, however the degradation is non-specific. Enzymatic mechanisms
can respond to local changes in cell behavior during the regenerative process but may suffer from high
individual variability [69]. For drug delivery applications, the biodegradability also determines the
release of incorporated drugs within the scaffold matrix.
Bioactivity Scaffolds should present specific soluble and insoluble cues to direct cell behavior,
such as adhesion ligands present in the natural ECM. Injectable scaffolds have a high pore volume,
interconnectivity, and a 3-D architecture, which allow for significant cell-surface interactions. For
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scaffolding applications, cell adhesion is crucial as neurons are anchorage-dependent for their growth and
survival and will undergo apoptosis when detached from the ECM [90]. Straley, et al., found the density
of the cell-adhesive RGD peptide present in the protein directly affected cell adhesion and neurite
outgrowth of undifferentiated and differentiated PC 12 cells [69]. However, the effect was still smaller
than the control collagen gels suggesting that cues other than RGD motifs are important for controlling
neuronal cell behavior.
Neurites are sensitive to environmental cues, which can both promote and inhibit their growth.
To explore the interaction of neurites with bioactive cues, Kofron, et al., cultured DRG explants at the
interface between a 3-D collagen matrix and a glass coverslip coated with laminin or CSPGs, a promoter
and inhibitor of neurite outgrowth, respectively [91]. The coating was arranged as either a uniform layer
or patterned tracks. They found that most of the neurites extended away from the coverslip and into the
collagen gel when CSPGs were present, while most of the neurites extended at the surface of the gel when
laminin was present. There was also an alignment of the neurites to the tracks of laminin on patterned
surfaces [91]. Extending this work to a 3-D system, Yu, et al., used DRG cells cultured in layered
agarose hydrogels to explore the chemical effects of neurite extension. They found that at the interface of
unmodified agarose gels and agarose gels with covalently bound chondroitin sulfate B (CS-B), neurite
extension was significantly inhibited as compared to homogeneous gels. The inhibition was significantly
decreased by either degradation of CS-B with chondroitinase (Ch) ABC or addition of laminin-1 to the
CS-B containing hydrogels [92].
Additionally, for drug delivery applications to the intrathecal space, materials with limited
adhesion ligands should be used to avoid cellular infiltration. The material-drug interactions will play a
role in their release kinetics depending on their relative size, charge, and hydrophobicity to one another.
The material also needs to preserve the bioactivity of the encapsulated drug.
2.2.4. Considerations for administration in the context of SCI
Therapies for SCI must take into account the timeframe of intervention and the specific condition
of the cord during administration. The injured spinal cord presents a dynamic environment that evolves
through years after injury. The composition of the ECM, cytokines, excitatory neurotransmitters,
inhibitory molecules, degree of necrosis, and cellular makeup change with time after injury. This will
affect which therapeutic agents would be most beneficial to incorporate into the device. Additionally, the
size and location of cysts within the lesion site may affect how an injectable therapy is administered. In
the acute phase of SCI, fluid filled cysts will not be present in significant number while during the sub-
acute phase, the necrotic cyst defects will present as cavities to fill with an injectable material. In later
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stages of SCI, there may be extensive Schwannosis and connective tissue scarring will result in dense
tissue difficult to inject into.
Once the material is injected, the final space-filling morphology of the implant may affect its
behavior. The gel may completely fill a defect/cavity or intermix with the remaining parenchymal tissue.
The material should be delivered so that it can set without extruding back out of the needle tract or
collapsing under the weight of the surrounding tissue in the case of hemisection injury. To address this,
groups have used multiple injections of material at different lesion depths and left the needle in place until
gelation is complete [86, 93], or used artificial dura such as agarose or collagen sheets [86, 93, 94].
Finally, to extend the clinical usefulness and application of injectable scaffolds for SCI, it must be
shown that these materials can be injected without adverse effects into intact CNS tissue. This is
important, particularly for acute and chronic cases where the disruption of intact neural tissue in and
around the lesion site may lead to further functional deficits.
2.3. Classes of injectable hydrogel materials for SCI
Injectable materials may be in the form of chemical or physical gels, which form through a
variety of mechanisms.
2.3.1. Natural vs. synthetic materials
Natural polymers, i.e., biopolymers, are advantageous as many contain intrinsic amino acid
motifs for cell adhesion and are readily degraded by the body [58, 95]. Gels made from biopolymers
closely simulate the morphology and mechanical properties of the native ECM and are conducive to
neuronal and axonal growth. These materials are composed of proteins and/or polysaccharides and can be
formed into 3-D nanofilament networks with high water content allowing for the migration of cells and
diffusion of nutrients and waste through the material. They can be easily obtained and may be composed
of materials naturally present in the ECM of the spinal cord such as HA [96]. Gels of natural materials
have been used extensively to culture and study CNS cell behavior in vitro and in vivo [97, 98]. The
disadvantages of natural materials include the risk of disease transmission and the ability to provoke an
immune response if left untreated for pro-inflammatory antigens. The mechanical properties, adhesion
sites, and degradation rate are difficult to decouple from one another. Additionally, the degradation rate
of natural scaffolds can be difficult to control as enzyme levels vary among species, individuals, and
injection location.
Synthetic materials can be custom made with specific bioactive sequences and degradation
mechanisms. Synthetic materials do not suffer from batch-to-batch source variations and have more
controllable final properties. Disadvantages of synthetic materials include the biocompatibility of the
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material and degradation products, and the lack of adhesion sites for integrins. Synthetic materials are
also currently unable to recapitulate the complexity of organization and bioactive motifs present in natural
ECM materials.
2.3.2. In situ physical gels
Physical gels formed from synthetic or natural polymers can undergo a transition from liquid to a
gel upon a change in environmental conditions such as temperature, ionic concentration, or pH, or other
condition such as mixing two components. Physical gels are attractive for injectable materials because
the gelation reaction is mild and occurs from an aqueous solution without the addition of crosslinking
agents, which could lead to additional damage at the site of injection due to un-reacted monomers,
initiators, or exothermic reactions [50]. The system is compatible with cells and sensitive therapeutic
agents and the reaction rate can be tuned to occur rapidly upon injection into the body. Although initial
reactions are able to confine the material to the injection site, full setting of the material may take up to an
hour in some systems. Physical gels are typically weak with moduli on the order of tens to hundreds of
Pascals, which is on par with the mechanical properties of the spinal cord and is best suited for promoting
neuronal growth and deterring scar formation [99].
2.3.2.1. Thermogels
The most common form of physical gel utilized in SCI regenerative approaches are thermo-
gelling polymers. Thermo-gelling systems are aqueous monomer/polymer solutions, which have the
ability to form a gel upon temperature change [49]. These systems either undergo gelation/solidification
as the temperature decreases or have an inverse gelling property characterized by a lower critical solution
temperature (LCST) at which the material undergoes a sol-gel phase transition and forms a solid network.
For biomedical applications, thermo-gelling injectable systems with an LCST around or below 37*C
would be ideal, as they would transform from a solution to a gel upon injection into a body cavity.
Collagen Type I collagen is a major component of tissue ECM throughout the body and is used
in a number of U.S. Food and Drug Administration - approved medical devices [100]. It has been widely
shown to support the growth and differentiation of neurons in vitro and has been applied as a gel scaffold
numerous times in vivo [72, 73, 101-103]. Collagen can also inhibit glial proliferation which may
decrease glial scarring after SCI [104]. Collagen displays an inverse gelation reaction where soluble
collagen triple helixes aggregate under physiologic conditions (pH and ionic strength) to form a fibrillar
gel network. The reaction kinetics are temperature dependent and depending on the volume may take up
to 30 minutes. Additionally, the telopeptide regions between triple helixes play an important role in
crosslinking between molecules during gel formation. However, these telopeptides are also implicated in
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antigenicity of collagen and are usually removed for medical grade materials resulting in slightly weaker
gels [105]. Collagen is readily degraded by endogenous proteases secreted at the tips of neuronal growth
cones [87].
Agarose Agarose is a polysaccharide derived from seaweed. It does not cause adverse reactions
when implanted in vivo and can support neurite extension in vitro. Since the average mesh size decreases
exponentially as the concentration of agarose increases, neurites cannot extend processes over a threshold
of 1.25% [74]. Also the hydrophilic chains are poor substrates for cell attachment and will limit
outgrowth and viability over time [72]. Agarose is thermally induced to form a gel through
intermolecular hydrogen bonding interactions as it is cooled. Solidification upon cooling presents an
obstacle for applications that require injection into the body. To overcome this, Jain, et al., utilized a
nitrogen cooling system to gel hydroethylanated agarose with a gelation temperature of 17*C within 30
seconds in situ [106]. It is also not broken down naturally by mammalian cells so it persists in vivo until
the chains dissociate and are excreted. Its inability to degrade may hinder the migration of neurons
through agarose gels.
Methyl cellulose (MC) MC is a natural polysaccharide from plant sources. It is non-cell
adhesive and does not elicit an immune response. It displays an inverse gelling property above
physiologic temperatures, which can take on the order of minutes or hours to complete. As the
temperature increases, hydrogen bonds between the polymer and surrounding water break and
hydrophobic junctions form to produce a gel. MC alone forms a weak gel in at 37*C in water and does
not form quickly enough for drug or protein delivery applications. However, the gelation temperature
decreases with increasing salt concentration due to a decrease in the solubility of MC molecules [107].
Through ionic and hydrogen bonding with other polymers such as HA and chitosan, methyl cellulose
mixtures can gel at lower temperatures (even below room temperature) and behave more gel-like then the
constituent components [108, 109]. Shearing the mixture (via injection) can break these hydrogen bonds
resulting in a shear thinning property that facilitates injection even if the material is in gel form prior to
delivery. MC disperses and is excreted fairly quickly under physiological conditions if it is not
previously crosslinked [109].
Hyaluronic acid (HA) - HA is a non-immunogenic, biocompatible anionic glycosaminoglycan
native to connective, epithelial, and neural tissue [110]. On its own, it is non-cell adhesive but may be
used in conjunction with other natural polymers to create an ECM-like scaffold that supports neuronal
cell populations [102]. The long chains form random coils and gel due to molecular entanglements. This
imparts HA with a shear thinning property as under shear force, the molecules align with the direction of
stress and flow. Typically HA alone is highly water-soluble and disperses when injected into an aqueous
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environment therefore physical gels must be made by combining HA with other polymers such as MC
before gelation [109, 111]. The molecular weight (MW) of HA is also believed to affect its biological
activity with high MW HA resulting in reduced astrocyte proliferation and CSPG deposition after SCI
[112].
Chitosan is a natural linear cationic polysaccharide derived from shellfish and insects [113]. Its
mechanical properties can be tuned to match the native ECM. It offers limited support for neuronal cells
in its natural form and must be coupled with another bioactive polymer or peptide. [113] The gelation of
chitosan is typically pH dependent but a pH-neutral chitosan solution was developed by adding a
glycerophosphate salt, which forms a gel scaffold in approximately 30 minutes when raised to 37*C
[114]. Crompton, et al., investigated the optimization of neuronal survival and outgrowth in injectable
chitosan- glycerophosphate scaffolds copolymerized with poly-L-Lysine [113]. Functionalization with
poly-L-Lysine did not significantly affect cell survival as compared to chitosan in 2-D culture and
provided a slight benefit in 3-D culture.
Poly(N-isopropylacrylamide) (PNIPAAm)-PEG PNIPAAm-PEG is a synthetic inverse-gelling
block copolymer with an LCST of 29-32*C due to hydrophobic interactions [115]. Gelation takes
approximately an hour to complete. This polymer may have applications for drug delivery due to its
unique structure and properties. Unlike most hydrogels, it did not have a large interconnected porous
structure and its hydrophobic chains prevent water from rapidly diffusing through the scaffold, which
inhibits the transport of hydrophilic drugs [115]. In vitro experiments showed a sustained released of
bioactive NT-3 and brain-derived neurotrophic factor (BDNF) from the scaffold, which promoted chick
embryo DRG process extension in an explant assay after 31 days of incubation in the scaffold. Since
there are no intrinsic cell adhesion motifs, human MSCs seeded in the scaffold did not attach until 14
days but survived through 31 days [115].
Tetronic-oligolactide (TL) TL is a coplymer thermogel, which is liquid at room temperature but
gels in seconds at temperatures close to 37*C. The main structure consists of a thermo-sensitive poly
propylene oxide (PPO) and polyethylene oxide (PEO) block connected to a degradable lactide oligomer.
Go, et al., coupled heparin to TL to create a cell compatible scaffold capable of growth factor delivery
[116]. Kang, et al., explored a TL scaffold containing the anti-inflammatory agent minocycline in a
hemisection model of SCI [117].
2.3.2.2 Ionic crosslinking
Alginate- is a naturally linear anionic polysaccharide derived from algae. An aqueous solution of
alginate can undergo a gelation in the presence of divalent cations such as Ca2+ and Zn2+ by forming ionic
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inter-chain bridges between guluronic acid blocks of adjacent alginate chains [118]. The reaction occurs
in about 30 minutes. The resulting gel is biocompatible, ECM-like, and has tunable properties via
regulation of the cation and alginate concentrations, and the molecular weight of alginate. While
injectable alginates have not been directly used in in vivo studies of SCI, it is a candidate material for SCI
regenerative approaches. Like other non-animal polysaccharides, alginate does not support robust
neuronal survival and outgrowth [119]. Alginate hydrogel inhibited the metabolic activity of olfactory
ensheathing cells (OECs), Schwann cells (SCs), and bone marrow-derived MSCs in culture as well as
DRG neurite outgrowth. This was improved after enriching alginate with fibronectin or cell adhesive
peptides [119, 120]. Alginate is also slow to dissolve and dissolution occurs by the diffusion of cations
out of the polymer matrix.
2.3.2.3. Enzymatic
Fibrin is the main component of blood clots. It results from the rapid polymerization of soluble
fibrinogen monomers by the activation of the proteolytic enzyme thrombin under physiological
conditions. Endogenous plasmin enzymes subsequently degrade fibrin. The advantages of fibrin include
the following: extremely elastic resisting a 5x deformation from its resting length without breaking;
forms a soft scaffold; contains ligands for CNS cell integrins; and binds growth factors, fibronectin, and
protease inhibitors [121]. The gelation rate and mechanical properties of fibrin can be tuned by adjusting
the ratio of fibrinogen and thrombin in the injection mix. Fibrin glue has been used in in vivo applications
as a preformed gel to stabilize intercostal nerve grafts and to deliver acidic FGF or NT-3 to a model of
SCI [122-124]. In another study, dorsal root axons regenerated across the dorsal root-spinal cord
interface of rats with fibrin glue containing NT-3, BDNF, or ciliary neurotrophic factor, and entered the
spinal cord. However, only a few axons regenerated into the spinal cord of animals with fibrin glue
implants that lacked neurotrophic factor, and their growth within the spinal cord was extremely limited
[123]. In a series of studies, Johnson, et al., evaluated fibrin scaffolds implanted two weeks after a dorsal
hemisection model of SCI [60, 125-127]. The scaffolds were pre-polymerized into a sphere on the tip of
a pipette before implantation and stabilized in place by a second injection of fibrin allowed to polymerize
in situ on top of the sphere. This two-step procedure was performed because fully in situ-polymerized
fibrin scaffolds were assumed to be completely degraded after one week and could not be visualized in
the lesion [126]. Fibrin alone showed an increase in neural fiber staining at the lesion site at 2 and 4
weeks post treatment and delayed the accumulation of reactive astrocytes [126]. Neural fiber density
within the lesion site was significantly increased by the controlled release of 500 ng/ml NT-3 via a
heparin binding delivery system (HBDS) incorporated within the fibrin scaffolds [125]. Further work
used the scaffolds to deliver embryonic stem cell-derived neural progenitor cells (ESNPCs) along with the
32
growth factors, NT-3 and PDGF-AA, which were added directly to the scaffold or entrapped within the
HBDS [60]. The presence of the growth factors (with or without the delivery system) increased the
number of implanted cells at 2 weeks and the presence of the delivery system resulted in more NeuN-
positive neurons derived from the ESNPCs.
Fibrin has also been investigated as a fully injectable biomaterial scaffold and drug delivery
system for SCI (see section 4). Briefly, King, et al., examined fibrin and fibronectin based injectable
scaffolds in a dorsal hemisection model of SCI, and Hyatt, et al., explored highly concentrated fibrin gels
as a delivery vehicle for ChABC [128, 129].
The disadvantages of fibrin use in vivo include the potential for an immune response and disease
transmission. Fibrin also degrades very rapidly in vivo: -25 % remained after a 9-day implantation
period. The degradation rate of fibrin is subject to variations in plasmin concentrations [123]. Non-
mammalian sources of fibrin, such as from salmon, are promising for their reduced antigenicity, lower
clotting temperature and in vitro enhancement of neurite outgrowth in comparison to bovine or human
fibrin [130].
2.3.2.4 Self-assembling peptide systems
Self-assembling peptides are synthetic amino acid based molecules that undergo a sol-gel
transition within seconds when brought to neutral pH and ionic concentration. The resulting gel is a
nanofibrous mesh similar in some respects to the native ECM [131]. Several types of self-assembling
peptides have been found to be biocompatible and non-cytotoxic, and not to cause immunologic reactions
like some natural materials. They are broken down into L-amino acids and excreted in urine within 3-4
weeks of implantation [86]. These systems do not use crosslinking agents so they can safely encapsulate
cells and/or drugs without exposing them to toxic agents. The fiber density can be tuned by the initial
concentration of peptide in solution. Drawbacks of these systems include: lack of adhesion sites for
integrins; low mechanical strength; and non-tunable crosslinking density. Some peptide systems also
exhibit a low initial pH that must be rapidly buffered to prevent cytotoxic conditions [132].
Self-assembled peptide-amphiphiles (PA) PAs have hydrophobic and hydrophilic domains,
and upon injection into a neutral ionic aqueous environment can self assemble into a nanofiber gel
composed of peptide nanofilaments. These molecules can be modified with bioactive peptides such as the
neuronal integrin-binding motif IKVAV [133]. A 1 wt% PA solution mixed in a 1:1 ratio with a
suspension of NPCs in media resulted in a transparent gel-like solid within seconds. The same occurs
upon injection into a physiologic environment. Self-assembled PAs are capable of presenting a high
density of IKVAV epitopes, 103 fold higher than native ECM molecules like laminin [133]. These
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IKVAV-presenting PAs support neuronal cell growth and differentiation from progenitors towards
neuronal cell types in vitro and have been used as a regenerative scaffold for SCI in vivo [86].
Self-assembling peptide nanofiber scaffolds (SAPNSs) SAPNSs are synthetic biomaterials
formed of ionic self-complementary peptides (alternating positive and negative L-amino acids). One such
SAPNS, RADA16-1, commercially available under the name PuraMatrix" (3DM, Inc., Cambridge, MA,
USA), is a 16-amino acid peptide which assembles into P-sheets with alternating charges [134]. The
gelation process is charge dependent and these materials rapidly form nanofilamentous, highly-hydrated
scaffolds in physiological ionic or pH conditions. RADA16-1 supports neuronal growth and development
in vitro [135]. A main disadvantage of this material is its low pH, which must be buffered to avoid cell
necrosis. While SAPNSs have been injected into the brain of guinea pigs in vivo with successful
regenerative results, the low buffering ability of the spinal cord resulted in a severe inflammatory reaction
when a SAPNS was used as an in situ scaffold in a model of SCI [132, 136]. This severe reaction was
not, however, observed by Cigognini, et al., when using a SAPNS modified with bone marrow homing
protein (BMHP) [93].
Amphiphilic diblock copolypeptide hydrogels (DCHs) DCHs are synthetic polymers,
composed of lysine, homoarginine, or glutamate combined with leucine, which physically associate in
water into elastic gels with porous fibril-like nanostructures by hydrophobic association [137]. These gels
have a shear thinning property, which allows them to be injected. The properties of the gel can be altered
by the copolymer chain length or composition, and the amino acid side chains of DHCs allow for further
functionalization with bioactive molecules. Injections of DCHs into the mouse forebrain showed no
detectable toxicity or inflammatory response compared with injections of physiological saline, for up to 8
weeks. The gel exhibited good tissue integration, and a timedependent ingrowth of blood vessels, glia,
and a limited ingrowth of nerve fibers.
Mixing induced two component protein gels (MITCHs) MITCHs are synthetic protein gels
can be fabricated to undergo gelation in the absence of specific external environmental cues. Using
protein-protein interactions between specific peptide domains, Foo, et al., prepared a two-component
protein gel containing multiple repeats of WW (tryptophan residues) and proline-rich peptide domains,
which undergo a sol-gel phase transition in upon mixing [138]. The shear modulus of the gel could be
varied from 9-50 Pa by the frequency of repeated association domains per chain and the association
energy between the domains. The physical hydrogel which is formed is shear thinning and "self-healing,"
which allows it to be reformed after injection through a syringe. Functionalizing the backbone of the
MITCH material with the cell adhesive sequence, RGDS, supported the 3-D culture and proliferation of
PC-12 human umbilical vein endothelial cells, and murine adult neural stem cells. Neural stem cells
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encapsulated in these gels were able to self-renew, differentiate, and sprout extended neurites.
2.3.3. In situ chemical gels
Chemical crosslinking imparts mechanical integrity and degradation resistance to otherwise weak
materials. It can occur through a variety of mechanisms, but principally involves covalent bonding which
utilizes a reactive moiety that can either be conjugated to the pre-polymers or added as a small
molecule/enzyme to create the free radicals to form covalent bonds between adjacent polymer chains.
Unlike preformed scaffolds, the crosslinking agent contained in the injectable gel cannot be washed away
or quenched prior to implantation, so all reactants must be non-cytotoxic at the concentrations that they
are employed.
2.3.3.1 Photoinitiated polymerization and crosslinking
Photo-initiated polymerization and crosslinking typically utilizes ultraviolet (UV) light and a
photo-initiator molecule, which react to create free radicals and subsequent covalent bonding via reacting
groups such as acrylates. The wavelength of light, concentration of photo-initiator, and monomer
chemistry are used in order to achieve a rate-controlled procedure with control over the final gel
morphology. The reaction can be completed with seconds or minutes. The main limitations of photo-
crosslinking polymers are concerns for cell viability and the inability to use such systems in minimally
accessible areas such as deep within tissue. Free radical-induced cell death by photo-initiators is
dependent on concentration as well as the cell type; specifically, cells with higher proliferation rates are
more sensitive to photo-initiator-induced cell death [139]. A cytocompatibility study of a common water
soluble photo-initiator, 12959, with NPCs showed a significantly decreased cell survival at concentrations
in culture above 2.5 mg/ml (0.25%) which would be required for rapid polymerization in vivo [140].
However, when the NPCs were encapsulated within a PEG-poly-L-lysine (PEG-PLL) gel polymerized
with 5 mg/ml 12959, the cells showed minimal apoptosis following the photo-polymerization reaction,
most likely due to the rapid polymerization of the macromers. Given these concerns, there exists a
balance among properties such as solidification time and crosslink density and cytotoxicity.
Acrylated PLA-PEG-PLA PLA-PEG-PLA is a tri-block copolymer (ABA) containing
degradable PLA and non-degradable PEG units. The macromers are then end-capped by methacrylated
groups to allow for photo-polymerization. This material degrades by a hydrolytic mechanism and is less
sensitive to the variation in enzymes at injection sites. For drug delivery applications, the crosslink
density, number of degradable PLA units, and hydrophobicity of the encapsulated drug can tune the
release rate of drugs. In vivo injection of this material containing NT-3 into rodent spinal cords showed
sustained delivery of the neurotrophic factor for a period of two weeks [1411. This material is also
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capable of encapsulating cells and has been used as a model system for studying the effects of select
properties on neural cell types (see section 2.3.2). The degradation products of PLA-PEG-PLA may also
have a therapeutic benefit themselves. Neural cell populations cultured in a copolymer mix of PEG and
PLA-PEG-PLA hydrogels had higher metabolic activity and proliferation with increasing percentage of
the degradable PLA-PEG-PLA component [84]. It was proposed that the lactic acid released upon
degradation had a positive effect on encapsulated neural cell populations due to its radical-scavenging
effects.
PEG-poly-L-lysine (PLL) PEG-PLL is a photo-polymerizable copolymer scaffold consisting of
PEG and PLL. In vitro results show that these gels support NPC survival and differentiation due to the
presence of PLL segments [140]. The gelation reaction occurred in 4-10 minutes and the mechanical
properties of the gel could be tuned to match the native spinal cord ECM. The morphology (pore size) of
the resulting scaffold was larger than ECM analogous scaffolds (20-200 [tm) and degraded very slowly
since PEG-PEG linkages are not enzymatically cleavable.
Acrylated hyaluronic acid (HA) High molecular weight HA gels were used to investigate
ventral midbrain NPC differentiation and spinal astrocyte behavior in a 3-D culture environment with
tunable mechanical properties (see section 2.3.2) [79]. In a subsequent experiment, pre-formed hydrogels
with stiffness matching the native spinal cord were then implanted in a dorsal hemisection rat model of
SCI [142]. In the acute setting, the hydrogel resulted in a decreased number of immune cells around the
lesion site and lower CSPG expression. By 9 weeks post injury, the tissue adjacent to the implants
exhibited a significantly decreased astrocytic response but no significant difference in CSPG deposition.
Few cells were found to infiltrate the gels, most likely due to the non cell adhesive nature of HA and the
very small amount of gel. No significant degradation of the gel occurred over the 9-week study. It
should be noted that in these experiments, hydrogels were pre-formed and rinsed of excess photo-initiator
before implantation or promptly after contact with cells. For cell encapsulation experiments, low UV
irradiation times were used to preserve NPC viability.
PEGylated fibrinogen Covalently modifying fibrinogen with PEG macromolecules results in a
biosynthetic hydrogel with separate control over mechanical properties via PEG and degradation rate and
bioactivity via fibrinogen [143]. 3-D neurite outgrowth of DRG explants from the hydrogels could be
controlled with relatively small changes in either fibrinogen concentration or PEG content. Cell
outgrowth was increased with decreasing fibrinogen concentration or ratio of PEG to fibrinogen. It was
proposed that the dominant mechanism controlling outgrowth was the physical obstruction of the polymer
network (mesh size, stiffness, and proteolytic resistance of fibrinogen). Higher ratios of PEG reduced
fibrinogen's susceptibility to degradation, and increased fibrinogen content increased the hydrogel
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modulus and slowed the invasion of neurites and non-neuronal cells from the explant. Interestingly, at
low PEG concentrations, the non-neuronal outgrowth from the DRGs lagged behind the neurite
extensions implying that it may be possible to tune the movement of individual cell types within the
material.
2.3.3.2 Molecular/chemical crosslinking
Chemical crosslinking results in the formation of covalent bonds of varying length among fibers
of polymeric scaffolds depending on the length of the crosslinking molecule and its ability to oligomerize.
A common method of crosslinking pre-formed scaffolds is though the addition of amine or carboxylic
acid reactive small molecules such as aldehydes, diepoxy compounds, N-hydroxysulfosuccinimid (NHS),
and 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). However these molecules are highly
cytotoxic even at low concentrations, and are not feasible to use in an injectable scaffold [144, 145]. As
an alternative, less toxic small molecules like the iridoid compound, genipin, and naturally occurring
ECM crosslinking enzymes such as lysyl oxidase and transglutaminase have been investigated to
crosslink biopolymers such as collagen and fibrin [129, 146-148]. Studies of genipin-crosslinked
collagen gels showed good cytocompatability with mesencyhmal and neural stem cells even though free
genipin was in direct contact with the cells throughout the gelation process [149]. Additionally, cross-
linking of collagen with genipin induces colorimetric and flourometric changes within the gel, which can
be correlated to crosslink-dependent properties such as shear modulus and degradation resistance [149,
1501.
Elastin-like protein Elastin-lile protein can be used to prepare a highly tunable scaffold which
can be designed to contain: bioactive sequences for serine protease specific degradation; RGD sequences
for cell adhesion; and lysine residues incorporated in the elastin-like regions as sites for polymer
crosslinking [69]. In this system, the degree of crosslinking could be modulated by the frequency and
location of lysine residues and the ratio of lysine to NHS esters formed by reacting the polymer with
bifunctional crosslinker disuccinimidyl suberate. This compartmentalizing of functionality allowed for
independent tuning of initial elastic modulus, degradation rate, and cell adhesive ligand density. By
altering the degradation-sensitive sequences, scaffolds could be fabricated with a 200-fold difference in
degradation half-life. These gels could support the growth and differentiation of PC 12 cells. However,
the chemical crosslinking method is highly cytotoxic, and required a rinse step before the introduction of
cells into the material, which is not feasible for an injectable material.
PEG-star heparin Star shaped PEG (star-PEG) and heparin can be crosslinked using EDC/NHS
chemistry to create a hybrid material with independently tunable mechanical and bioactive properties
[151]. The mesh size, swelling, and elastic modulus could be tuned by the degree of gel component
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crosslinking while keeping the heparin content constant. Heparin was used to non-covalently bind
fibroblast growth factor-2 (FGF-2), a modulator of neural stem cell and astrocyte response. Heparin was
further covalently modified with RGD peptides to promote cell adhesion. The gel was assayed using
primary nerve cells and neural stem cells. Injection of 2 [d of the gel intothe striatum of rats caused a
transient nonspecific reaction to the brain injury and no chronic inflammatory processes.
2.4. In vivo studies of injectable materials for SCI
In contrast to the many investigations of preformed scaffolds, relatively few studies have
explored the use of injectable materials for SCI repair (Table 2-4). The primary functions of the
injectable materials can be divided into two categories: scaffolding for cellular in growth and drug
delivery.
Table 2-4: In vivo studies of injectable materials in SCI
Material Injury model(s)ab Vo. Formulation(s) Degradation time Ref.
Scaffolding
Collagen - TS-T1O Tx 5 [d Collagen 4 weeks [128,
(1-1.5 mm) (2.4 mg/ml) 152-
- T8-T10 Hx +vmM glyoxal 8 weeks (glyoxal) 1561
- T1O Tx (3 mm), 10 +.0144%
days after 200 g/cm condroitin-6-sulfate 6 months (C-6-S,
Ct (C-6-S) CD)
- T8-T1O Tx +.024%
(3-4 mm) carbodiimide (CD)
SAPNS Dorsal column C6- 5 id 1% aqueous 3 weeks [93,
(RADA-16) C7 Tx (Imm) solution (solid) 132]
(RADA-16-I- T9 moderate Ct (log 3 [I 8 weeks
4G-BMHP1) rod/25 mm height)
IKVAV-PA T10 Ct (24 g 2.5 [d 1% solution in 3 weeks [86]
modified aneurysm isotonic glucose
clip 1 minute-
therapy applied 24
hours after injury)
Fibrin T9 Dorsal 10 [d 10 mg/ml < 7days [126]
hemisection 1.2 mm fibrinogen, 12.5
depth U/ml thrombin
Fibrin & T7-T9 Dorsal "filled 10 mg/ml 4 weeks [128]
Fibronectin hemisection (2xlxl lesion" fibrinogen, 2
mm) mg/mi FN, 5.4
U/ml thrombin
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Drug delivery
Collagen T2 Ct: (20g or 35 g 20 [d Collagen >8 weeks [157]
modified aneurysm (24-28 mg/ml)
clip 1 minute +22.7 ptg/ml EGF
Intrathecal injection & FGF-2
of therapy at T2
level)
hyaluronic T2 Ct: (35 g 10 pl 2% HA:7% MC 7 days [109,
acid- modified aneurysm +lOOU/pl EPO 158]
methylcellulose clip 1 minute + PLGA
(HA-MC) Intrathecal injection nanoparticles
of therapy at T2
level)
Agarose T8-T10 Dorsal Hx 5 [d Agarose >6 weeks [94,
(2x2x1.5 mm) + BDNF, ChABC, 1061
NT-3 loaded
microtubules
PLA-PEG-PLA T8 hx (1.5 mm 10 pd 10% pre-polymer 3 weeks [141]
depth) +100 Rg /ml NT-3 (in vitro)
Fibrin C4 scissor cut to 2 8 Id 108 mg/ml Not examined [129]
mm depth fibrinogen + 0.29
IU thrombin + 2.5
ptg genipin + 0.25
U ChABC
Tetronic- T7-T8Dorsal Hx 20[d 35% TL + 7 days [117]
oligolactide minocycline (0.5, 5
RM)
a. Tx= transection, Hx= hemisection, Ct= contusion.
b. Dimensions after injury model represent amount of tissue removed
2.4.1 Major findings and correlations between in vivo studies
2.4.1.1. Cellular interaction with injectable scaffolds is beneficial for decreasing the
astrocytic response and scar formation, and for the promotion of axonal growth after SCI. In situ-
forming scaffolds are capable of bonding directly to the host, thus restoring the continuity of the spinal
cord and allowing for cellular infiltration. Scaffolds permissive to cellular migration do not exhibit a cap
of GFAP+ astrocytes at the host-graft interface. Instead, astrocytic processes extend within the gel to
form a framework that may be associated with ingrowing axons. The overall astrocyte reactivity and
production of CSPGs is lower in permissive gels as when compared to controls or non-permissive
substrates. The initial studies employed collagen in complete transection models with tissue resection
that led to extensive invasion by fibroblasts. Despite the formation of mesenchymal ECM, collagen
scaffolds redirected the tissue formation from a dense scar towards a loosely connected highly
vascularized tissue that was conducive to axonal ingrowth [152]. IKVAV-PA had a decreased astroglial
response, decreased apoptosis, and axonal growth long after it was degraded showing that modulating the
glial response after SCI may drive the reparative process away from scarring and towards regeneration.
2.4.1.2. Cellular infiltration of scaffolds is dependent on scaffold microstructure,
degradability, and the presence of soluble or insoluble cues for cell growth. Non-cell adhesive
materials such as methylcellulose, tetronic-oligolactide or PLA-PEG-PLA, or non-permissive
morphologies such as agarose and high concentration collagen showed no cellular ingrowth unless
neurotrophic factors were present. For example, BDNF was able to promote astrocyte and axon growth
within otherwise non-permissive agarose. However, the intensity of neurofilament staining in BDNF-
loaded agarose scaffolds significantly dropped off by 500 [tm into the scaffold, which is shorter than
expected for optimal conditions after 6 weeks [106]. Poorly cell adhesive PLA-PEG-PLA scaffolds had
no effect on the astrocytic response after SCI and little axon regrowth was seen in gels releasing
phosphate buffered saline [141]. This was likely due to the lack of cell adhesion motifs or mesh sizes too
small to allow for growth cone movement.
Under optimal conditions such as those existing during development, neurites can extend up to 1
mm a day [159]. That rate of axonal growth, however, was not achieved in these gel studies. There
appeared to be a balance between the persistence of scaffolding material and the rate of axon elongation.
Rapidly degrading scaffolds such as PAs showed good axon elongation; however, this occurred in a
contusion model, which maintained a residual structure of the spinal cord and was not highly prone to
infiltration from cells outside of the CNS (viz., fibroblasts and Schwann cells). Collagen scaffolds with
different degrees crosslinking demonstrated the importance of maintaining structural rigidity in
hemisection and transection models of SCI to prevent the organization of newly formed ECM into scar-
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like tissue. No scaffolds showed axon re-growth before 3 weeks and regenerating axons could be seen at
high densities within several implants at 2-3 months, suggesting that the scaffold should continue to
provide a provisional matrix through this period.
2.4.1.3. Placement of DDS determines release profile and localization of the therapeutics
Injectable DDSs provide advantages over bolus injection and implantable mini-pumps/catheters.
Depending on the extent of injury, the blood flow in the spinal cord and intrathecal space may result in
different release profiles. The local CSF and blood flow after injury is greatly decreased which leads to
more localized delivery. Penetration of the therapeutic into the cord also depends on the actual drug and
the interaction with the delivery system (ionic or hydrophobic interactions). Another consideration is the
placement of the DDS. A non-scaffold DDS may impede on axon growth if injected into the lesion cavity
while cell permissive scaffolds may cause cellular buildup in unwanted areas such as the intrathecal
space. The therapeutic window will also determine what type of DDS would be most beneficial.
2.4.1.4. Combinational approaches will be required to achieve significant recovery after SCI
Neurotrophic, anti-inflammatory, CSPG degrading, and cellular therapies hold great promise to
enhance recovery after SCI and should be used in conjunction with scaffolding to enhance spinal cord
regeneration. It was noted in the scaffolding studies that a low proportion of any regenerating axons
crossed through the lesion site into the distal cord suggesting that the growth inhibitory environment
outside of the lesion site must be addressed to promote full regeneration. A multifaceted approach
delivering therapeutics inside the graft as well as distal to the lesion may overcome this barrier.
While, the collagen and PA systems showed enhanced axonal ingrowth they are too porous to
provide a sustained release of therapeutics to the injury site and could benefit from the addition of drug
delivery systems such as microparticles or heparin binding. Conversely, the PLA based drug delivery
system showed excellent release profiles with little axon growth through the graft and most recovery
coming from collateral sprouting distal to the lesion site. The incorporation of synthetic or natural
biopolymers with adhesive motifs (e.g., fibronectin, collagen, or synthetic peptides with RGD or IKVAV
sequences) would enhance cellular interaction with the material. In the reviewed literature, there are few
examples of scaffolds incorporating a separate drug delivery device. The BDNF-loaded microtubules
within the alginate gel provided a chemotactic gradient which caused the initially non-cell permissive
agarose scaffold to become infiltrated by astrocytes and neurites [106]. Similarly, ChABC- and NT-3-
loaded microtubules synergistically improved axonal growth by addressing two growth inhibitory barriers
[94]. Additionally, PLGA nano/microparticles have been used to encapsulate a number of neurotrophic
factors (GDNF, CTNF, BDNF, NT-3) and have been injected alone or within hydrogels [158, 160, 161].
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Modular therapies with the individual components optimized towards the specific functions of
scaffolding, drug delivery, and cell encapsulation/delivery will provide a substantial advantage for
regenerative approaches.
2.4.2 Description ofprior studies using collagen as a scaffoldfor SCI
There were significant commonalities among the six in situ gelling collagen studies reviewed in
this chapter [128, 152-156]. All of the studies used a liquid collagen gel, which polymerized in situ to
form a fibrillar scaffold. Additionally three studies further investigated alternative forms of collagen
scaffolds for comparison with solubilized collagen implants. Marchand, et al., examined three additives
to enhance the stability of the collagen gels in vivo, including chondroitin-6-sulfate (C-6-S), and the
crosslinking agents, glyoxal and carbodiimide (CD) [152, 156]. Joosten, et al., compared the in situ-
forming collagen scaffold to a preformed solid collagen scaffold of the same concentration [155].
Studies by Marchand and Joosten provide extensive histological descriptions of the graft-host
environment throughout the acute to early chronic time course of SCI progression in rodents. Liquid
collagen injected directly into the spinal cord was able to gel sufficiently fast to localize the material and
form a continuous interface between the graft and host tissue in hemisection or transection lesions. It was
important to have a "clean" lesion site with little hemorrhage or contusion so gelation was not impeded.
The laceration injury model resulted in significant mesenchymal cell infiltration from the pial
surfaces. Control saline-injected rodents had cystic cavities at the edges of the defect and a proliferative
scar of variable thickness and orientation consisting of astrocytes, fibroblasts, and microglia. Collagen
gel-treated animals formed a loose highly vascularized connective tissue matrix that became populated by
a heterogeneous group of cells including ingrowing axons.
During the acute phase (<8 days) the in situ collagen implants behaved similarly regardless of
additives. Rapid angiogenesis occurred and the implants were invaded by a heterogeneous group of cells
including fibroblasts and Schwann cells. In the collagen-treated groups, this did not lead to the creation
of a dense scar or extensive Schwannosis. The astrocytic response was also modulated in collagen-treated
groups. The overall reactivity and proliferative response of the astrocytes was decreased as compared to
control injections. Instead of astrocytes forming a cap around the ends of transected axons, astrocytes
migrated into the graft and were noted to extend long processes within the matrix. This was partially
attributed to the presence of a permissive scaffold for cellular migration and may be related to the ability
of type I collagen inhibits glial proliferation in vitro [162].
At four weeks, the grafts were heavily infiltrated by a heterogeneous group of cells including
astrocytes, microglia, and fibroblasts [152]. Thick randomly oriented collagen bundles and astrocytic
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processes bridged the inter-stump gap creating continuity between the ends of the host tissue. The
structure of the newly synthesized collagenous ECM was studied using polarized light microscopy
enhanced by sirius red staining [156]. At four weeks, collagen-only implants contained more numerous
thick red birefringent type I collagen bundles. The CD- and C-6-S-collagen gels on the other hand
showed disorganized thin green collagen fibers by polarized microscopy. Collagen fiber organization into
thick yellow and red bundles could be seen starting at the surface of the lesion near the meninges and
extended gradually towards the center of the lesion.
There was no ingrowth of labeled CST axons until approximately 4 weeks post injury when a
cellular and ECM support structure was in place. Marchand noted that the ingrowth of axons tended to
follow the collagen architecture and microcysts within the collagen matrix. A collagen and a carbohydrate
rich fibrogranular material was deposited in and around the follicular shaped microcysts, and astrocytic
processes bent around the walls of these cysts. At 4 weeks, several long axonal processes could be seen
extending into the C-6-S-collagen implant. The histological results suggested that axon regeneration
occurred only after a secondary carbohydrate-rich matrix containing glial cells and processes formed in
place of the primary matrix. In area of the C-6-S-collagen matrix, several axons were reported to extend
through the distal tissue-implant interface and re-enter the spinal cord [156].
From 4-8 weeks, there was an increase in the number of axons growing from the lesion ends into
the matrix in longitudinal fascicles. Collagen crosslinked with the addition of 1mM glycoxi showed
better stability than collagen alone during cellular infiltration phase, and the also displayed the
establishment of a newly formed ECM. At 2 months, the implant site of the glycoxl-crosslinked collagen
group exhibited a tissue-like framework spanning the defect, while the defect site of the non-crosslinked
collagen group appeared highly disorganized. Beyond 2 months, the defect filled with crosslinked
collagen was profusely invaded by regenerating nerve fibers originating from both grey and white
matters. The maturation of the endogenously produced collagen extended into the whole lesion site and
into the adjacent spinal tissue. The pattern of deposition and maturation of the endogenous collagen was
similar in normal and glyoxal-treated collagen.
Marchand noted that at about 2-3 months, the collagen-only implants became highly disorganized
and contained thick collagen aggregates, which was detrimental to axon regeneration. In comparison, at 3
months, axons could be seen in both C-6-S- and CD-collagen implants and by 6 months numerous axons
had grown into the lesions in the C-6-S- and CD-collagen groups. There was a greater number of axons in
the C-6-S-collagen gels and their path was more rectilinear. These hydrogels were also still visible at the
lesion site. The C-6-S-collagen implant had a more open structure and showed less endogenous collagen
deposition and aggregation than the CD-collagen scaffolds. This was because the C-6-S-collagen matrix
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delayed the formation of thick collagen aggregates for a longer period than the CD-collagen samples.
The extent of collagen aggregation in both samples was still lower than control or collagen only implants.
Except in the case of C-6-S-collagen implants, axons were not noted caudal to the lesion (-8
weeks) suggesting the persistence of an inhibitory environment outside of the graft. However, De La
Torre, et al., demonstrated that 90 days after a full transection and implantation of a similar collagen
implant, sensory evoked potential showed early wave-forms suggesting some re-growth through the graft
[153].
Overall, the presence of the collagen hydrogel attenuated scar formation following injury. The
stability of the collagen gel was important for preventing contraction and maintaining a loose vascularized
matrix within the lesion, which allowed for the ingrowth of glia and axons. These studies show that there
may be a relationship between the mechanical properties of the primary matrix and the tendency for dense
scar formation; increasing the mechanical stability of the collagen implant could prevent scar formation.
To further this point, a study by King, et al., examining injectable collagen scaffolds in a knife-cut model
of SCI, showed that by 1 week, the material had dense inclusions, which inhibited axonal infiltration as
well as various other cellular and non-cellular elements [128]. It was proposed the dense inclusions were
due to uneven gelation of the material within the lesion or focal contraction by infiltrating cells.
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2.5. Summary
In situ-gelling systems are promising therapeutic interventions after SCI. They are capable of
filling the heterogeneous defects, which occur after human SCI and can modulate the wound environment
to decrease scarring and encourage regeneration. A multitude of other cellular and molecular therapeutics
can also be encapsulated and released by the gel to enhance regeneration, sprouting, and recovery of
functional axon connections.
In vivo studies unveiled some of the obstacles for in situ gel therapies. It is important that the
scaffold persists until a native ECM framework can be synthesized to support and guide cellular growth.
Gels are intrinsically soft and weak structures, and while their relatively low moduli may be beneficial for
axon ingrowth, their attendant degradation rate may be too rapid. Further work needs to be conducted to
find non-toxic in situ covalent crosslinkers for materials such as collagen, HA, and self-assembled
peptides. Other materials such as alginate, agarose, and chitosan, which have longer persistence but lack
cell adhesiveness and supportive domains, can be copolymerized with other bioactive polymers or
peptides. The pore size, stiffness, degradation rate, and bioactivity of all scaffold materials must be finely
tuned to allow for cellular ingrowth of both supportive glia and axons throughout the course of
regeneration through the lesion, which is on the order of several weeks.
Drug delivery systems should consider the site of application, target the therapeutic agents and
release profile to maximize the regenerative potential of the therapy. Many of the studies revealed a
distinct increase in axon regeneration when combining therapeutic agents with scaffolding materials.
Further development of modular therapies (i.e., drug delivery systems incorporated within a scaffold
polymer) would allow for independent tuning of gelation kinetics, stiffness, degradation rate, and
bioactivity of scaffolds as well as their drug release kinetics. In the reviewed literature, there was also
virtually no mention of incorporating cells within the scaffolds.
The flexibility of using injectable systems would allow therapies to be administered during the
most suitable time for regeneration. The sub-acute stage ,7-14 days post injury, may be a prime
intervention time. As described earlier, this period is after the cascade of initial inflammation and at the
point of a beneficial astrocyte response. The microenvironment would be less harsh for exogenous cells
and for the damaged axons beginning to re-extend growth cones towards the lesion site after having
initially retracted after the injury [159].
While animal models are essential for in vivo comparison of the behavior of candidate materials
in standardized defects, there are understandably shortcomings to the models of SCI, as there are to
animal models for all human diseases and traumatic conditions. While many animal species and injury
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types have been explored, each have distinct differences in relation to the pathology of human SCI [163].
It is also difficult to compare studies with different injury models since transection and resection of tissue
may hinder axon elongation through a scaffold and the mechanisms of sprouting and regeneration are
different between transection and contusion type SCI [46, 159]. It is challenging in some studies to
differentiate actual axon regeneration from sprouting (e.g., based on time frame, labeling, or tortuosity),
and there is question as to which is more beneficial for functional recovery. There is also currently no
reliable ex vivo model to assay or screen for application-specific properties of injectable materials prior to
in vivo studies.
Over the past 10 years there have been dramatic and encouraging results of in vivo investigations
of biomaterials and therapeutic agents for the treatment of SCI. It seems clear that there will be a role for
multifunctional injectable gels, serving as scaffolds for endogenous cell migration into the gel-filled
lesion and as delivery vehicles for therapeutic agents. There is hope that these gels along with our
deepening understanding of the pathophysiology of SCI will result in advances in the treatment of SCI in
human subjects in the next 10 years.
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Chapter 3:
Development and characterization of an
injectable collagen-genipin gel
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3.1. Introduction
As highlighted in the background and motivation, minimally invasive therapies are attractive
treatment options for SCI due to their ability to conform to heterogeneous lesions and limit the extent of
damage associated with the implantation of a pre-formed scaffold. In this chapter, I evaluate an injectable
thermo-responsive soluble collagen gel incorporating genipin, an amine reactive covalent cross-linker
with low cytotoxicity and fluorogenic attributes. Unlike previous studies, genipin is being investigated as
an in situ covalent cross-linker that will continue to act on the gel after injection. Physical
characterization studies show that the addition of genipin provides control over the mechanical and
degradative behavior of the gel, to meet design specifications of an injectable material for neural tissues.
Additionally, an improved in situ assay to predict the extent of cross-linking reaction is investigated.
Encapsulation of mesenchymal stem cells (MSCs) and neural stem cells (NSCs) within collagen-genipin
gels was performed to show the gels support cell viability and proliferation, and thus serve as a cyto-
compatible material.
3.2. Background and Motivation
While there have been many injectable scaffolds reported in the literature for a wide range of
tissues, only a few have been injected into the spinal cord.[1] Several injectable polymeric scaffolds that
have been proposed for SCI include: agarose, polyethylene glycol (PEG) conjugates, self-assembling
peptides, hyaluronic acid/ methylcellulose, and collagen.[2-6] Natural polymers (biopolymers) are
advantageous because they contain intrinsic motifs for cell adhesion and are readily degraded in vivo.[7,
8] Biopolymer gels also mimic the morphology and mechanical properties of the native extracellular
matrix (ECM).
Collagen is commended as an injectable biomaterial because of its inverse gelation property,
which enables it to be applied as a chilled solution that undergoes a gelation reaction upon warming to
body temperature. [9, 10] Cells can be mixed into the liquid collagen precursor and the suspension can be
injected into a defect. The gelation reaction occurs in vivo within minutes to form a fibrillar scaffold that
entraps viable, functional cells and therapeutics.
Even though type I collagen is not a principal component of the ECM of the central nervous
system (CNS), collagen gels have been widely shown to support the growth and differentiation neural
cells, including cortical neurons, astrocytes, and neural progenitor cells. [11] Of importance was that other
gel types including a sugar poly(acrylate) hydrogel and agarose were not able to support neural cell
growth "as a result of a lack of cell adherence, small pore size and, possibly, harshness of synthesis
conditions".[12] Subsequent investigations demonstrated functional synapse formation among neurons
grown on collagen gels. 13 1 Furthermore, collagen gels have been shown to support neural progenitor
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proliferative capacity, neuronal differentiation potential as well as and the formation of functional
cortical-like networks.[14, 15] Injectable collagen solutions also support rat neural stem/precursor cells
migration through the gels, and differentiation into neurons, astrocytes, and oligodendrocytes within the
gel culture.[16] Other work demonstrated the capability of chick dorsal root ganglia cells grown in
collagen gels to extend neurites within the gels, with the degree of neurite extension related to the
concentration (mechanical stiffness) of the gel. [17] Furthermore, collagen can inhibit glial proliferation
and thus may decrease glial scar post-spinal cord injury (SCI).[18]
Collagen gels can be fabricated to have mechanical properties similar to the native spinal cord,
and thus direct cell behavior. Neurons prefer compliant substrates (0.1-1 kPa) and will elongate along a
gradient in mechanical properties, while fibroblasts or scar-forming glial cells prefer stiffer matrices (1-10
kPa) and proliferate in the stiffened ECM after SCI. [17, 19-21]
Despite the advantageous biochemical properties of collagen, the material itself is intrinsically
weak and requires additional modifications to improve its stability especially when implanted in vivo.
While collagen has been applied as a gel scaffold in vivo, no cross-linkers have yet been employed to
safely covalently cross-link collagen in vivo.[5] A novel and critical aspect of the current work is the in
vivo cross-linking of the in situ-forming collagen gel using genipin, a plant extracted iridoid compound
which reacts with primary amines in collagen to produce intrahelical, interhelical, and intermicrofibrilliar
cross-links (Figure 3-1).[22] Genipin is 3000-fold less cytotoxic than glutaraldehyde, and has anti-
inflamnmatory, anti-fibrotic, neurogenic, and neuroprotective properties, which make it not only a cross-
linker but a therapeutic agent on its own.[23-29]
/J~4~~+ PA 8I(
O _CH3 No 0CH OCH3
XAg collagenprimary amines genipin
in collagen genipin crossfinked collagen
Figure 3-1: Cross-linking of genipin and collagen. From H. Sundararaghavan et al.
Genipin cross-linked collagen is absorbent at 595 nm and fluoresces at 630 mn.[30] This
absorbance and fluorescence (590 nm excitation and 630 nm emission filters) thus provides a convenient
tool for following the cross-linking and degradation of genipin cross-linked collagen gels. While
collagen-genipin fluorescence has been correlated to its mechanical properties, few studies have looked
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kinetics of the cross-linking reaction, and none have accounted for the effects of gel absorbance on the
observed fluorescence.[30] Specifically, the inner filter effect, which causes a loss in proportionality
between the observed intensity and concentration of the flourophore, was not accounted for.[3 1]
3.3. Overall Goal and Hypotheses
The goal of this study was to evaluate the use of genipin as an in vivo cross-linker for an
injectable collagen gel scaffold. Fluorometric, rheology, and degradation assays were used to evaluate
the kinetics of genipin cross-linking, the effects of cross-linking on the gelation time, modulus of
elasticity and enzymatic degradation resistance. Unlike previous studies, genipin was being investigated
as an in vivo cross-linking agent that would not be rinsed out prior to use and would continue to act on the
scaffold after gelation. The effect of genipin on select stem cell populations was also investigated.
The hypotheses for this chapter are:
1.) The addition of genipin to collagen gels will result in increases in cross-link dependent properties of
degradation resistance and shear modulus.
2.) The kinetics of genipin crosslinking of collagen gels is reflected in the absorbance and fluorescence
changes of the material.
3.) The viability of cells exposed to genipin will be dependent on cell type, concentration of genipin, and
whether they are exposed during the in situ formation of the gel.
3.4. Methods
3.4.1 Materials: Soluble rat-tail type I collagen (3.91 mg/ml) in acetic acid (BD Biosciences, Franklin
Lakes, NJ), genipin (Wako Pure Chemical, Japan), type I collagenase (163 U/mg) (Invitrogen, Carlsbad,
CA). Buffers were purchased from Invitrogen and were cell-culture grade.
Collagen Gels: Ice cold lx phosphate buffered saline (PBS), 5x PBS, IN NaOH and soluble rat tail
collagen were combined in that order to obtain 2 mg/ml collagen solutions at pH 7.5 with Ix ionic
strength. For gels containing genipin, a stock solution of genipin in 5x PBS (3 mg/ml), made
immediately before mixing, was used in place of a volume of 5x PBS to obtain the desired genipin
concentration (0-1mM). Thermal gelation of the collagen solutions was induced by warming to 37*C in
an incubator.
3.4.2 Absorbance & Fluorescence Measurements: Measurements were taken using a PerkinElmer
Wallac 1420 multilabel plate reader with fluorescence technology (Waltham, MA) at 595 & 630 nm
(absorbance) or excitation 595 nr, emission 630 nm (fluorescence). Collagen solutions were plated into
96 well plates (100 p1/well) and placed in a 37'C incubator (n=12 independent wells). At regular time
58
intervals, the plates were taken out of the incubator and measured. Well plates were kept covered and at
100% RH to reduce evaporation. The plates were allowed to cool to RT for 20 min to avoid the effects of
temperature variation on the fluorescence intensity.
The fluorescence was corrected for the internal filter effect as described by Palmier, et al. [32]
Aex+Aem
Fcorrected =F Fbse,,, *10 2
where Aex and Aem are the measured absorbance at the excitation and emission wavelengths respectively.
The fluorescence data corresponding to varying collagen concentrations with a fixed genipin
concentration of 0.5 mM were normalized to the t=1 h value to eliminate the baseline variation in
fluorescence due to the differences in collagen matrix density.
3.4.3 Rheological Testing A rheometer (TA instruments AR-G2, New Castle, DE) with a cone and plate
geometry (40 mm 2*), was used to determine the gelation time and the storage and loss moduli of the gels
(n=3-4). The test conditions employed a constant stress of 0.1 Pa at a frequency of 1 rad/s. Based on our
pilot tests, these conditions were chosen to be in the linear viscoelastic regime of the gelled materials and
did not interfere with the gelation process. The bottom plate was held at 8'C before the materials were
tested at 37 0C to prevent premature gelation. A light mineral oil, with a lower viscosity than collagen,
was applied around the edges of the cone to reduce evaporation. The gelation time, or gel point, was
defined as the time at which the shear storage (G') and loss modulus (G") were equal.
For pre-formed scaffolds, a parallel-plate geometry (8 mm plate) was used to apply a constant
shear stress of 1 Pa at a frequency of 1 rad/s. Rheology was performed at a fixed gap of 1044 m at
~35% compression based on heights of collagen 0 mM gels that best recapitulated the modulus at 1 hour.
Sandpaper (400 grit) was applied to both top and bottom platens to avoid gel slippage. Collagen-genipin
gels (2 ml) were cast into a 12 well plates and an 8 mm biopsy punch was used to obtain samples for
testing. The samples were swollen for 1 hour in lx PBS and transferred to the stage of the rheometer.
3.4.4 1-D Degradation Assay Collagen gels (0.5 ml, n=3) containing varying amounts of genipin (0-1
mM) were pipetted into a 2 ml cryotube and allowed to gel for a defined amount of time at 37 *C between
1-27 h. Type I collagenase (0.1%, 1 ml, 163U/mg) in Ix PBS with CaCl2 , was added on top of the gel
and the vial was placed on a shaker table in a 37*C warm room at 150 rpm. After 5 h, the degradation
medium was removed, the gels were rinsed with deionized water, frozen, lyophilized overnight, and
weighed. The removal time was set by the degradation time for non-cross-linked collagen gels. The dry
weights of the scaffolds were compared to the weights of identical gels exposed to 1x PBS buffer for the
same amount of time; data are reported as % weight remaining.
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The collagenase concentration (0.1 wt%, 163 U/mg) was chosen to provide a standardized,
accelerated assay for gel degradation, in order to compare the effect of genipin concentration on gel
robustness. The concentration is much greater than what would be found in an inflamed body setting.
An additional degradation assay was conducted with modifications to account for the greater
robustness of the gels allowed to cross-link for longer times (i.e., 24 h or greater). Collagen-genipin gels
(0.5 ml) were plated in a 24-well plate and allowed to cross-link for 24, 44, or 72 h. Subsequently, 0.5 %
collagenase (1 ml) was added for two hours before gels (n=3) were processed and measured as above.
3.4.5 3-D Degradation Assay Collagen-genipin gels (0.5 ml, n=3) with varying genipin concentrations (0-
1mM) were cast in 2-ml cryotubes and incubated at 37'C for 1 or 24 h. The gels were transferred from
the cryotubes into 24-well plates and swollen in PBS for 1 h. The gels were then exposed to collagenase I
(0.1%) on a shaker table (150 rpm); control gels were exposed to PBS instead of collagenase. After 30,
60, 90, or 120 minutes, the collagenase was removed and the gels were washed with PBS on a shaker
table for 20 min. The remaining gel samples were collected, lyophilized overnight, and weighed. The
dry weights of the gels were compared to the weights of control gels; data are reported as % weight
remaining.
3.4.6 Swelling Ratio Collagen-genipin gels (1 ml, 16-mm diameter, 3-4-mm thick, n=43) with varying
genipin concentrations (0-1mM) were cast in 24-well plates for 1 or 7 d and then swollen in PBS for 24 h
at RT. The disks were scooped up using tweezers and weighed immediately afterwards to obtain the
swollen weight. After lyophilization, the disks were weighed to obtain the dry weight. The swelling ratio
was calculated using the following equation:
Swelling ratio =-
tV'd (2)
where W, is the swollen weight and Wd is the dry weight.
Linear or polynomial regression lines were fit to the data to achieve an R-squared of 0.95 or
higher. Half-life times were calculated as the amount of time required to enzymatically degrade the gel to
50% of its original mass.
3.4.7 Gel morphology Environmental scanning electron microscopy (ESEM) was used to observe gel
morphology and pore architecture. Hydrogel samples were fixed in 4% paraformaldehyde and 2%
glutaradehyde in a buffered solution for 1 h at room temperature. After three 10-min washes in PBS and
two 10-min washes in diH20, the samples were then dehydrated for 15 min in a series of graded ethanol
of 50, 75, 90, 95, 100, 100, 100% concentration respectively. Dehydrated specimens were then critical
point dried from ethanol in CO 2 (Autosamdri - 815, Tousimis (Rockville, MD)). The dried gels were
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mounted on aluminum stubs using carbon tape, and examined under ESEM (FEI/Philips XL30 FEG
ESEM) in low-vacuum conditions with an accelerating voltage of 12-15 kV.
3.4.8 Stem Cell Seeding Marrow-derived pig mesenchymal stem cells (MSCs), prepared as previously
described at 400,000 cells/ml, were encapsulated within collagen hydrogels containing various amounts
of genipin.[33] Complete medium (DMEM-LG, 10% FBS, 1% penicillin-streptomycin) was pre-warmed
in 24-well plates prior to gel plating. Gel solution (0.5 ml) containing MSCs was carefully added to each
well to ensure the gel settled to the bottom of the well. This plating technique was done to simulate an
environment where the genipin could leach out of the system and react with the surrounding environment
(i.e., in the case of cerebrospinal fluid). Media were replaced at 4, 24, and every 48 h thereafter.
Additional viability assays configurations were conducted as follows. Gel solution without genipin (0.4
ml) containing MSCs was carefully added to each well as above. After allowing the gel to set overnight, a
6 mm biopsy punch was taken from the center of each 24 well plate and transferred to a new well
containing 0.5 ml of media spiked with genipin (gel disk assay). The media was then removed from the
center of the original gel and 100 [d of collagen genipin gel was pipetted in and allowed to set for 2 h
before adding 0.4 ml cell culture media (peneumbra and edge assay). The effective genipin concentration
in each assay is given by:
V
= col_,-gege
Cassay = Ccol-gen-gel v + v + v (3)
Vmedia cell-gel col-genwgel
Neural stem cells (F. Gage, Salk Institute, La Jolla, CA) were plated at 90,000 or 400,000
cells/ml. The media were supplemented with 1% penicillin-streptomycin, N2 supplement, and 20 nn/ml
FGF to prevent differentiation.[34] Media was replaced after 3 h.
3.4.9 Cell viability Live/dead staining was performed using Calcein AM and Ethidium homodimer
(Invitrogen). Cell-encapsulated gels were stained and imaged using a fluorescent microscope. Three
random sections of each gel were measured, totaling 500-1500 cells/gel. The cell count was analyzed
using Image J software (NIH, Bethesda, MD).
3.4.10 Cell proliferation Cell-seeded gels were collected after 1 and 7 d post-seeding. The samples were
first washed in PBS and stored at -20'C until assayed. After lyophilization, samples were digested
overnight with Proteinase K (100pg/ml; Sigma) in Tris-HCl-buffer (50 mM Tris, 1mM CaCl 2, pH 8.0) at
600 C. Fluorometric quantification of DNA content in the digests was performed using a Quant-iT
PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA). Aliquots of pellet digest were diluted 1:10 in
Tris-EDTA buffer (TE, 10mM Tris, 1 mM EDTA, pH 8.0) and processed according to the kit protocol
with fluorescence read at 485nm/535nm for 1.Os against a lambda DNA standard on a microplate reader
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(Wallac Victor2 1420 Multilabel Counter, PerkinElmer Life and Analytical Sciences, Inc., Wellesley,
MA).
3.5 Results
3.5.1 Absorbance and fluorescence
The cross-linking of collagen and genipin molecules induced a blue/purple color change, which
could be measured by absorbance at 595 nm as well as a strong fluorescence at the excitation wavelength
of 595 nm and emission of 630nm, which served as a unique measure of cross-linking.
For a fixed concentration of collagen, the rate of increase and saturation value of fluorescence
intensity was dependent on genipin concentrations (Figure 3-2a). Lower genipin concentrations
continued to increase in fluorescence for a longer period of time, up to 165 hours (h), most likely due to
the decreased frequency of molecular collisions. Further analysis showed the fluorescence intensities
were linearly proportional to the log of genipin concentration for all times. The fluorescence of collagen
gels without genipin was relatively constant after the onset of gelation. The absorbance of 2 mg/ml
collagen gels increased dramatically with genipin concentration (Figure 3-2b). This difference was much
greater than for fluorescence data on the same gels. The rate of increase and final optical density was
dependent on genipin concentration and higher concentrations reached a saturation point more quickly.
Little or no change in absorbance occurred with collagen gels alone after the first hour when the gelation
was complete.
For a fixed concentration of genipin, the rate of increase for fluorescence intensity as well as the
saturation fluorescence, was proportional to the collagen concentration due to the higher density of free
amines (Figure 3-2c). The fluorescence intensity began to plateau at about 24, 48 and 78 h for 1-3 mg/ml
collagen respectively, again due to the density of free-amines. Further analysis showed the fluorescence
intensities were linearly proportional to collagen concentration for all times. The initial absorbance of the
fixed genipin gels was dependent on the collagen concentration since denser matrices had a higher
opacity, however the kinetics of absorbance increase was similar between all gels and reached a saturation
value at approximately 97 h (Figure 3-2d). A linear dependence of absorbance with collagen
concentration is clearly seen when the data were re-plotted with absorbance versus collagen concentration
(Figure 3-3).
To further elucidate the reaction kinetics of the genipin cross-linked collagen gels, an assay was
used to detect genipin released to medium (Figure 3-4). Collagen-genipin gels were incubated in equal
volumes of Dulbecco's modified Eagle's Medium (DMEM) containing amino acids. The DMEM
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contained phenol red, which can interfere with certain fluorescence measurements, but had no effect on
the absorbance recorded in this experiment.
DMEM reacted with free genipin within the gels leading to an intense blue/purple color and an
increase in absorbance at 595 nm, but little change in fluorescence of the DMEM. At each time point, the
difference in absorbance before and after removing the media from on top of the gels was measured. The
difference in absorption represented the amount of genipin reacting with the DMEM. After 196 h it was
observed that no further genipin could be removed from the gels at all concentrations measured.
b.
a.
- -
V 3-
0 20 40 60 80 100 120 140 160 180
tme [h]
5.
5.
S0MM
-- 0.05 mM
0.5mMM
-5MM
d.
0.450
0.400
0.350
0.300
0.20
0.200
0.150
0.100
0.050
0.000
0.250
I --
* 1
0 20 40 60 80 100 120 140 160 180
time [h]
-- 1 mg/mi
2 mg/ml
-
- 3 mg/ml
0.200
0.150
0.100
S0.050
0.000
r
0 20 40 60 80 100 120 140 160 180
time [h]
. -t---" -- -- --
0 20 40 60 80 100 120 140 160 180
time [h]
Figure 3-2. a.) Fluorescence measurements (excitation 595 nn/ emission 630 nm) of 2
mg/ml rat tail (type I) collagen gels containing 0-5 mM genipin, n=12 mean ± stdev b.)
Absorbance (595 nm) measurements of the samples in (a) c.) Fluorescence measurements
(ex. 595 nm/ em. 630 nm) of 1-3 mg/mI rat tail (type I) collagen gels containing 0.5 mM
genipin, n=12 mean ± stdev d.) Absorbance (595 nm) measurements of the samples in
(c). The internal filter correction was used in fluorescence measurements to account for
overlap of ex and em spectra. Figures c & d were normalized to t= 1 h to remove optical
density differences with collagen concentration.
63
.8
16000
14000
12000
10000
8000
6000
4000
2000
0
C.
- OmM.
- - 0.05 mM
0.5mM
-5mM
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
U
---.1 mg/ml
-2mg/mi
- 3mg/ml
T
JL
L
T
0.250
0.200
0.150
0.100
0.050
0.000
-0.050
2 3
collagen [mg/ml]
-1 h
-5 h
7.5 h
-21 h
-24 h
-47 h
72.5 h
-78 h
97 h
-168 h
Figure 3-3: Re-plot of figure id with absorbance versus collagen concentration for all times. Of note
is the linear dependence between absorbance and collagen concentration.
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Figure 3-4: Genipin leaching assay where the difference between the gel absorbance with and without
cell-media on top was used as a surrogate for how much free genipin was available to react with the
amino acid rich media.
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3.5.2 Mechanical and gelation studies
The principal metrics derived from the rheological testing were: gel point (time at which the shear
storage modulus G' = the shear loss modulus G"); G' at 1500 seconds; and rate of shear storage modulus,
G' increase (Table 3-1). The rate of increase was taken in the linear approximation of the G' versus time
curve (R2 > 0.99). Examples of the rheological data at 37'C are shown in (Figure 3-5).
Table 3-1. Rheological evaluation of initial gelation kinetics of rat-tail collagen- genipin gels at 37*C.
n=3-4, mean± SD
Genipin [mM] Gel point [s] G' [Pa] at 1500 s Rate of increase G' [Pa/s]
0 51.1 1.5 20.8 ± 0.9 2.9 x 10-3 ± 0.4 x 10-3
0.25 50.4 0.9 31.5 ± 5.7 8.5 x 10 3 ±2.5 x10
0.5 49.4 0.7 33.8 E 4.7 10.2 x 10-3 2.8 x 10~1
1.0 47.0 4.6 45.1 6.0 17.4 x 10-3 g3.1 x 10-3
- - -- -
- - - -
.
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Figure 3-5. Example of rheological data showing the immediate effect genipin has on strengthening
collagen gels.
The gel point for the non-cross-linked collagen gel was 51 s. There was an 8% decrease in the gel
time for the gels cross-linked with the highest concentration of genipin (1mM; Table 1). There was no
significant effect of genipin concentration in gel point by 1-factor ANOVA (p=0.22 ). G' for the collagen
gels cross-linked with 0.25 mM genipin was 50% higher than the value for the non-cross-linked gel, and
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the modulus for the samples cross-linked with ImM was over 2-fold higher than the non-cross-linked G'
value (Table 3-1). One-factor ANOVA demonstrated a statistically significant effect of genipin
concentration on storage modulus (p=0.022; power=0.99). Fisher's PLSD post hoc testing showed that
all group comparisons were statistically significant except for 0.25 versus 0.5 mM genipin. The rate of
increase in G' increased from 3-fold to about 6-fold higher for the 0.25 and 1 mM genipin concentrations,
compared to the non-cross-linked gels (Table 3-1). One-factor ANOVA demonstrated a statistically
significant effect of genipin concentration on the rate of increase of the storage modulus (p=0.001;
power=1). Fisher's PLSD post hoc testing showed that all group comparisons were statistically
significant except for 0.25 versus 0.5 mM genipin.
In order to fine tune of the gel time and shear modulus of the gels, the pH and ionic strength of
the gel were varied. Additionally, the interference of cell culture media and lipid microtubules with the
gelation processes was explored. The shear modulus of the collagen and collagen-genipin gels at 600 s
were directly proportional to the amount of NaOH added to the sample (increasing pH) (Figure 3.6). The
modulus peaked at pH 8-8.5 for collagen gels and 9-9.5 for collagen genipin gels (2mg/mI, 0.5 mM), after
which the modulus sharply declined (Figure 3-6). For all gels tested, the gel time remained constant with
pH up till approximately pH 9 where it began to increase. Unlike changes in pH, the moduli of the
collagen-genipin gels was not significantly affected by the ionic strength of the gel (Figure 3-7a),
however the gel time was strongly proportional on ionic strength (Figure 3-7b). Combining a decreased
ionic strength with increased pH produced stiffer gels with shorter gelation times (Figure 3-7ab). The
addition of cell medium to collagen-genipin gels in place of PBS buffer did not have an effect on the gel
time or short-term modulus as compared to using PBS buffer (Figure 3-8). This relation held true for the
pH range of 7-8.5. The addition of LMTs to the gels had no significant effect on the gel time or modulus
at 0.1 mg/ml, however at 0.4 mg/ml the LMTs began to interfere with the gel causing a decrease in
modulus and increase in gelation time (Figure 3-8).
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Figure 3-6: Dependence of rheological properties on pH of collagen (2mg/ml) and collagen (2mg/ml)-
genipin (0.5 mM) ± cell culture media gels, Left axis (top 3 curves) shear modulus at 600s. Right axis
(bottom 3 curves gel time. All gels were at lx ionic strength. n=3 mean ± stdev.
" "iG'
66*G' higher pH
100
80
Zi
0 1 2 3
Ionic Strength (x PBS)
4 5
60
40
20
--""gel time
jjp F - ~el time hger pf
0
0 1 2 3 4 5
Ionic Strength (x PBS)
Figure 3-7: Dependence of rheological properties on ionic strength of collagen (2mg/ml)-
genipin (0.5 mM) gels a.) Shear modulus at 600 s, blue line= pH 7, red line= pH 8 b.) Gel
time, redline no marker- pH 7, red line black marker= pH 8. n=2-3 mean ± stdev.
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The G' of collagen-genipin gels over a longer cross-linking period was determined by rheological
testing of preformed samples, tested 24, 48, and 72 h after gelation (Figure 3-9). The time required for
G' to reach a plateau value was dependent on the amount of genipin, with 1 mM samples saturating in
properties within the first 24 h and the samples cross-linked with 0.5mM genipin saturating at 48 h
(Figure 3-9). The gels cross-linked with the lowest genipin concentration appeared to continue to
increase in modulus through 72 h. The 72 h modulus for the gels cross-linked with 1 mM genipin
concentrations was 220 ± 33 Pa, compared to approximately 28 ± 0.6 Pa for the non-cross linked gel
(Figure 3-9). Two-factor ANOVA revealed statistically significant effects of time and genipin
concentration on the modulus (for both, p=0.000 l; power-- 1). Fisher's PLSD post hoc testing showed
that all group comparisons were statistically significant.
15 -
o10
10
C6
Media (n=9) LT (f c (n=3) Gel time
-10
Figure 3-8: Interference effects of cell culture media and lipid microtubules (LMT 0. 1 mg/mI, LMT
conc 0.4mg/ml) on the rheologic properties of collagen-genipin gels. Shear modluls blue bar, gel time
green bar. Values represent relative changes in property as compared to an identical sample without
the specified additive. n=3-9 mean ± stdev.
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Figure 3-9: Long term rheology studies on preformed scaffolds, elucidating the saturation in gel
properties. N=3-4 mean ± stdev.
3.5.3 Degradation studies
To complement the photometric, fluorometric, and mechanical testing data, a series of l-D and 3-
D degradation studies were performed to assess the effects of the degree of cross-linking imparted by
genipin (Figures 3-10, 3-11).
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Figure 3-10. a.) I-D degradation assay of collagen-genipin gels showing the immediate effect of
adding genipin on the robustness of the gels. n=3 mean ± stdev b.) Longer term degradation assay of
collagen gels.
The I -D degradation curves for the % weight remaining after 5 h of exposure to 0.1 %
collagenase, reflecting the degradation resistance of the gels, increased with genipin concentration and
maturation time (i.e., 1, 4, and 27 h of incubation; Figure 3-10a). Of note was the 3-fold increase in %
weight remaining of 0.25 mM genipin gels matured for only one hour as compared to non-cross linked
gels. The degradation resistance of the gels cross-linked with the lowest genipin concentration was
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almost 4-fold higher for the samples, which were allowed to mature for 27 h prior to exposure to
collagenase (Figure 3-10a). Two-factor ANOVA revealed statistically significant effects of the
maturation time prior to the degradation assay and genipin concentration on the % weight remaining (for
both, p=0.0001; power=1). Fisher's PLSD post hoc testing showed that all group comparisons were
statistically significant.
Degradation experiments were also conducted on gels allowed to cross-link for 24, 44, and 72 h
(Figure 3-10b). The gel cross-linked with the lowest genipin concentration (0.25mM) for 72 h did not
undergo a weight loss, under the collagenase exposure of the test. Virtually no weight loss was similarly
detected for the gel cross-linked for the shorter time period of 44 h, when cross-linked with 0.5mM
genipin. The samples allowed to gel for 24 h demonstrated no weight loss when cross-linked with 1 mM
genipin. A % weight remaining greater than 100%, was due to the entrapment of high concentration
collagenase within the gel.
A 3-D model for degradation was used to further investigate the gel's resistance to degradation.
Collagen-genipin gels were incubated for 1 and 24 h, Gels matured for 24 h showed greater resistance to
degradation than those matured for 1 h (Figure 3-11). Furthermore, an increase in genipin concentration
increased the gel's resistance to degradation, reflected in a higher % weight remaining. Half-life
calculations (Table 3-2) showed that gels matured for 1 h exhibited half-life times from 23.3 ± 7.2 mi
for collagen-only gels to 90 ± 11 min for 1.0 mM genipin gels. Gels matured for 24 h exhibited half-life
times up to 260 40 min for 1.0 mM genipin gels. ANOVA testing revealed a significant effect of
maturation time (p<0.001) and genipin concentration (p<0.001) on half-life.
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Figure 3-11: a.) 3-D degradation assay, collagen-genipin gel that has been matured for 1 h,
degraded for 30, 60, 90, 120 min b.) 3-D degradation assay, collagen-genipin gel that has been
matured for 24 h, degraded for 30, 60, 90, 120 min. *Data in collaboration with Dr. Karen Ng
Table 3-2: Half-life calculation of collagen-genipin gels after degradation in 0.1% type I
collagenase, from figure 4. n=3, mean SD. *Data in collaboration with Dr. Karen Ng.
Half-life [min]
Genipin [mM]
1 h maturation 24 h maturation
0 23.3 ± 7.2 38.8 ± 1.4
0.25 54.6 ± 1.5 94 11.4
0.5 66.1 2.7 181.1 ± 47.2
1 89.5 10.7 260 ± 40
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3.5.4. Swelling ratio and gel morphology
The swelling ratio of collagen-genipin gels formed with different concentrations of genipin was
calculated (Figure 3-12). The swelling ratio of collagen alone is 77.2 ± 1.5 and 89.7 ± 22.8 at I and 7
days (d), respectively. With the addition of 0.25mM genipin, the swelling ratio increases to 109.6 ± 17.4
and 117.6 ± 9.2 at 1 and 7 d, respectively. With the further addition of genipin, the swelling ratio
decreases, indicating that the swelling capacity was reduced due to more cross-links.
Collagen-genipin gels exhibited fibrillar network of collagen fibers with diameter of about 75 nm
(Figure 3-13). Furthermore environmental scanning electronmicroscopy (ESEM) imaging revealed that
140
120
100 -
0
c 0)
t 60 -Day1
-+-Day7
40
20
0
0 0.2 0.4 0.6 0.8 1 1.2
Concentration of Genipin ImM]
Figure 3-12: Swelling ratio of non-cell-seeded gels (n=3) *Data in collaboration with Dr. Karen Ng.
pore size decreased with increasing genipin concentration, supporting the swelling ratio results.
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Figure 3-13. ESEM images (gels critically point dried)A: collagen only B: collagen + 0.25 mM
genipin C: collagen + 0.5 mM genipin D: collagen + 1.0 mM genipin. *Data in collaboration with Dr.
Karen Ng.
3.5.5 Stem cell-seeded collagen gels
Goat and pig MSCs could be incorporated into the collagen-genipin gels and survive the gelation
process. These cells could also be incorporated in the gel after being injected with the gel solution into an
equal volume of media. Live-dead staining was used to assess cell viability at 1,3,7, and 10 d post
gelation (Figure 3-14a). Viability was maintained at similar levels to the control (0 mM genipin group)
up to concentrations of 0.5 mM at 10 d. Also of note was that unlike non-cross-linked gels, genipin-
containing gels did not undergo contraction by MSCs.
Proliferation studies on MSC-encapsulated collagen-genipin gels (Figure 3-14b) shows that there
was a significant increase in DNA content for MSCs encapsulated in collagen-only and 0.25mM genipin
gels. Specifically, DNA content increased from 0.053 + 0.006 pg to 0.278 ± 0.028 pg (a 6-fold increase)
for collagen-only gels and increased from 0.057 E 0.011 pg to 0.383 ± 0.022 ptg (a 6-7-fold increase) for
0.25mM genipin gels. For genipin concentrations 0.5 mM or greater, DNA content levels were
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maintained or decreased from I to 7 d. The morphology of of MSCs within the gel is shown in (Figure 3-
15)
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Figure 3-14. a.) Porcine mesenchymal stem cell viability assay using a live/dead stain at up to 10 days
post encapsulation in collagen-genipin gels (n= 6 gels) b.) pMSC proliferation (n=6).
*Data in collaboration with Dr. Karen Ng.
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Figure 3-15: Fluorescence micrographs of live-dead cell staining of pig MSCs in collagen-genipin
gels at 7 days. A. Live: collagen-only B. Live: 0.25mM genipin C: Live: 0.5mM genipin D: Dead:
collagen-only E: Dead: 0.25mM genipin F: Dead: 0.5mM genipin
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Figure 3-16. NSC viability assay using live dead stain at 24 hours using 2 cell
4 gels) mean ± stdev.
seeding densities. (n=
Neural stem cells were more sensitive to the genipin contained within the gel solutions. At genipin
concentrations of greater than 0.25 mM there was a significant decrease in the viability of NSCs
(Figure 3-16). Higher cell seeding densities were not beneficial for enhancing cell viability.
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Figure 3-17: a.) Pictures of peneumbra (with box indicating region of evaluation) and disk in media
cell viability assay configurations. Encapsulated in gel data is from figures 2-14, 2-16 b.) MSC
viability assay using live dead stain at 24 hours using a several assay configurations. N=4-6 mean
mean stdev. c.) NSC viability assay using live dead stain at 24 hours using a several assay
configurations. N=4-6 mean mean ± stdev.
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To further elucidate the effect a collagen-genipin gel would have on cell populations in vivo,
several configurations of the viability assay were examined. The configurations changed the ratio of
genipin containing volume (in media or in the gel) to cell seeded gel volume, resulting in different
effective genipin concentrations seen by the cells. There was a strong dependence of cell viability on
assay configuration for both mesenchymal and neural stem cells (Figure 3-17). To further elucidate this
phenomena, the effective concentration of genipin seen by the cells was determined (equation 3).
Plotting the viability vs effective concentration resulted in a linear trend for both cell types (Figure 3-18).
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Figure 3-18. a.) Figure 2-17 b plotted as a function of viability vs. effective genipin concetration
within the assay as determined by equation b.) Figure 2-17 c plotted as a function of viability vs.
effective genipin concetration within the assay as determined by equation 3. Linear regression was
taken on the values in red which represent viabilies >0.
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3.6. Discussion
3.6.1. Cross-linking of collagen and genipin:
Acid solubilized collagen is a thermogelling material, which undergoes a sol-gel transition upon
wanning above 4'C, when brought to physiologic pH and ionic strength, to form a fibrillar gel
network.[35] The reaction kinetics are temperature-dependent, occurring on the order of seconds to
minutes close to 37'C.[36] The telopeptide regions among triple helices play an important role in the
formation and stabilization of the collagen fibrills.[37] Collagen has approximately 90 amine groups per
collagen molecule, dispersed throughout the triple helical and telopeptide regions.[38] These primary
amine groups provide cross-linking sites for genipin.
Genipin reacts non-specifically with primary amine groups to produce a secondary activated forn
of genipin, which can subsequently polymerize with other genipin molecules.[39] The ability of genipin
to polymerize allows for the formation of intrahelical, interhelical, and intermicrofibrillar cross-links
throughout the fibrillar collagen gel. The wide variety of covalent cross-links gives genipin-cross-linked
collagen gels a high resistance to collagenase degradation as multiple parts of the collagen molecule and
collagen fibrils can be linked together.[40]
In our study, swelling studies and scanning electron microscopy (SEM) images showed
decreasing pore size and swelling ability with increased genipin concentration and maturation time.
These findings are consistent with previous results that examined the pore morphology of
collagen/chitosan-genipin gels.[41] The exception was 0.25 mM genipin, which exhibited a higher
swelling ratio. This observation may be attributed to the increased strength of the gel, which allowed the
gel to stand under its own weight and entrap water as opposed to the collagen-only gels, which sagged
under their own weight. After I day there was little change in swelling properties of the gels, which
reflects that most cross-linking occurs over the first 24 hours.
3.6.2. Absorbance and fluorescence properties
In the presence of oxygen, genipin-bound amines turned blue in color and increased in
absorbance at 590 nm.[39] The blue pigment is believed to be composed of polymerized genipin
molecules containing up to 44 monomer units of genipin with more highly absorbent pigments consisting
of higher molecular weight chains.[42] Therefore, the confounding factor of genipin polymerization
makes it difficult to use absorbance as an absolute indicator of the extent of cross-linking of collagen gels.
The cross-linking of collagen molecules with genipin also fluoresces at 630 nm.[30] This is a
unique marker for collagen cross-linking and does not occur strongly with amino acids alone despite high
absorbance at 590 nm (data not shown). Similarly, the reaction of genipin with amines on chitosan
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polymers, induces a characteristic peak fluorescence at 470 nm with an absorbance maximum at 369
nm.[43] The fluorescence of collagen-genipin gels can therefore be used as a surrogate in situ
measurement of cross-link dependent gel properties such as stiffness and degradation resistance.
However, since the absorbance and fluorescence spectra of the gel overlapped, there were effects of a.)
the absorbance of incident light before it reached the point at which luminescence was observed and b.)
re-absorption of emitted light before it left the gel.[3 1] Therefore a correction for the interference caused
by the internal filter effect as described by was used to restore the fluorescence-concentration
proportionality. [32]
Exploration of absorbance and fluorescence characteristics over a broad range of genipin
concentrations from 0-5 mM with a fixed collagen concentration of 2 mg/ml, yielded a linear relationship
between fluorescence and log (genipin concentration) for all times. A linear relationship between
fluorescence and collagen concentration existed from 1-3 mg/ml, using a fixed concentration of 0.5 mM
genipin, for all times. As the genipin concentration increases, the equilibrium number of reacted amines
increases, but must saturate as the potential number of free-amines remaining decreases. As collagen
concentration is increased using a constant genipin concentration, the equilibrium is shifted and a greater
total number of amines can be reacted.
There was a direct relationship between both genipin and collagen concentration and rate of
fluorescence increase, and higher genipin concentrations or lower collagen concentrations caused a more
rapid plateau in fluorescence intensity. Together, these results show that the reaction rate is dependent on
the concentration of both free amines and genipin, which affects the frequency of molecular collisions.
The saturation time of gel fluorescence is decreased as the concentration of genipin increased, thus
increasing the collision frequency, or density of free-amines decreased at a constant genipin, thus
increasing the ratio of genipin:collagen.
Of particular interest to our study, the saturation of fluorescence in gels containing 0.5 mM gels
occurred at approximately 48 h, corresponding with the saturation of both mechanical properties (via
rheological measurements of pre-formed gels) and degradation resistance (via long term degradation
assay) of the gel. There was also a large increase in fluorescence of the gels over the first 24 h, which
mirrored the results of mechanical and degradation experiments. The saturation point of absorbance for
the same gels was almost twice as long, as 96 h, potentially due to the additional absorbance gained from
polymerizing genipin.
The absorbance of genipin proved useful as a metric of genipin leaching from the gel. Overall,
genipin was a slowly acting cross-linker, taking days to lose its activity. While most of the cross-linking
appeared to happen over the first 24-48 h, active genipin remained within the system for up to a week. To
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further elucidate the reaction kinetics of genipin and collagen gels, an assay for the leaching of genipin
from the gels was created (see Experimental section). After 196 h it was evident that all samples returned
to baseline collagen values (Figure 3-4). These results confirmed that genipin remained in the gel for an
extended period of time to resist degradation and could act as a therapeutic itself after implantation.
3.6.3. Mechanical and degradation properties
For in vivo applications, the properties of an injectable material will be difficult to predict shortly
after implantation. Therefore, in situ rheology and short-term degradation studies were conducted to
explore the immediate effect of genipin on gel properties. The concentrations explored in these
experiments were based upon the cell viability data presented in this paper.
The addition of genipin to solutions of collagen resulted in a slight decreasing trend in the gel
point (G'=G") at 37'C. While a difference in gel point for collagen-genipin gels of varying genipin
concentration could not be determined by the testing setup at 37'C, a lower temperature above the LCST
of collagen (28'C) was employed to observe the improvement in setting properties with genipin (data not
shown) although this would not correlate to the actual application of the gel.
A more substantial dose dependent effect was noted in the rate of increase in shear storage
modulus (G'). After the initial gelation period, the moduli of collagen-genipin gels exhibited a linear rate
of increase in modulus, proportional to the concentration of genipin cross-linker (Figure 3-5). G' at 1500
seconds served as a comparison point between gels that relates to the time at which the surgical procedure
would be complete and the gel properties will begin to be affected by endogenous effects. By 1500
seconds (~23 minutes) 0.5 and 1 mM genipin containing gels were -50 and 100% stiffer than non-cross-
linked collagen gels respectively. While the G' of the collagen-only gel saturated by 1 h, gels containing
various concentrations of genipin were still increasing in modulus signifying that the cross-linking
reactions were still taking place.
The gelation of soluble collagen is primarily dependent on three factors, temperature, ionic
strength of the solution, and pH. Since the gelation temperature of an injectable gel is fixed, the pH and
ionic strength of the solution can be tuned. Lowering the ionic strength of the solution favors a more
rapid gelation as noted in Figure 3-7. A low ionic strength, there is a decrease in the driving force for
"salting in" (solubilizing) of collagen monomers. Additionally, fewer electrolytes in the solution increase
the interaction between charged amino acids on collagen, leading to aggregation and gelation.[44] At
higher pH, there is less lateral aggregation resulting in slender tightly packed fibers (decreased fiber
diameter, decreased pore size, and increased fiber length), which would lead to stiffer gels as noted in
Figure 3-6 but no change in gelation speed.[44] The effects of pH on collagen gels containing genipin
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were more profound than collagen gels alone Figure 3-6. Genipin has an optimum cross-linking reaction
rate at pH of 8-9 and at higher pH; there is an induction of self-polymerization of genipin monomers to
form long bridges between cross-linking sites.[45-47]
The saturation of G' as determined by pre-formed rheology studies, indicated that all gels treated
with 0.25-1 mM genipin reached a similar modulus but the time course to reach the final modulus was
dependent on genipin concentration. The modulus of all gels at 72 h (saturation modulus) was in the
range of moduli for spinal cord parenchyma tissue.[48]
Standardized degradation assays can provide simple metrics to predict an important in vivo
property of the gel; its persistence to provide a provisional stroma for axons and supportive cell
populations. It also provides a reliable high-throughput method for comparing the extent of cross-linking
in collagen gels with respect to both genipin concentration and maturation time.
3-D degradation experiments were conducted at I and 24 h and for degradation times of 30-120
min to establish a kinetic profile for gel degradation, from which a half-life was obtained as a comparative
metric for each gel. Significant increases in gel strength were obtained with 0.25 mM genipin even after a
maturation time of 1 h. The degradation resistance increased with genipin concentration due to the
increased rate of reaction at higher concentrations. This trend was also observed in gels that were
matured for 24 h.
Linear I-D degradation experiments were used to explore the effect of cross-linking on gel
stability in a controlled manner by only exposing a single constant area surface to the degradation
medium. Due to the significant differences in gel strength with time, two linear degradation assays were
conducted for short (<1 day) and long (> I day) maturation times. Consistent with the 3-D degradation
experiment, the short term 1 -D degradation assay (Figure 3-10a) showed that even after a maturation
time of 1 h, gels of all genipin concentrations provided substantial resistance to collagenase-associated
degradation, with 3, 4.5, and 5 times the dry gel weight remaining as compared to non-cross-linked gels
for 0.25, 0.5, and 1 mM genipin respectively. Longer maturation times or increasing genipin
concentration led to more robust gels. The long-term degradation assay (Figure 3-10b) was used to
determine an approximate saturation point for cross-linking of the material. The saturation in gel
properties closely followed the pre-formed gel rheology data. After 72 h maturation time, all gels showed
very little degradation even after exposure to collagenase for 24 h.
Overall, genipin has a more substantial impact on the degradation properties of the collagen gel
compared to its impact on the gel's mechanical properties. Since genipin has the ability to form cross-
links of multiple lengths, it is possible that the combination of short- and long-range cross-links provide
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more substantial degradation resistance to the gels but not as much stiffness because stiffness is more
dependent on the number of shorter links to oppose collagen fiber motion.
3.6.4. Correlation of fluorescence, mechanical, and degradation properties (long term behavior of
collagen-genipin)
Correlation between mechanical, degradation, and fluorescence studies over 72 h showed the long
term action of genipin in collagen. In each of the experiments, free genipin molecules were not flushed
out of the system and were allowed to react with the collagen throughout the full time course of the
experiment. By 72 h, all genipin concentrations tested (0.25-1 mM) reached a similar saturation point in
modulus, degradation resistance, and fluorescence. The main difference between concentrations was the
time it took to reach the plateau value G'. Therefore one can focus on tuning the properties of the system
based on the amount of genipin required to obtain the desired properties before excess genipin diffuses
out of the gel. The point at which they saturated in these properties was dependent on the concentration
of genipin and was consistent across assay methods.
3.6.5. Cell-biomaterial interactions
Our studies showed that genipin is well tolerated in many stem cell types at concentrations
capable of producing robust gels. Mesenchymal and neural stem cells have the potential to provide
therapeutic benefit after SCI by reducing inflammation, modulating the wound environment, and
replacing lost cell populations.[49] Pig MSCs were capable of being encapsulated within the gel
scaffolds, surviving the gelation process, and remaining viable for 10 days within the gel (Figure 3-14a).
Substantial numbers of MSCs survived at genipin concentrations up to 0.5 mM. The morphology of cells
at genipin concentrations of 0.25 mM was also similar to the control collagen gels, exhibiting an
elongated spindle-like shape (Figure 3-15). Short-term experiments using NSCs (Figure 3-16) showed
that these cell types are less tolerant of higher genipin concentrations and survived in gels containing up
to 0.25 mM genipin. One potential reason for this observation was the sensitivity of the cells to medium
conditions which are changed as the genipin reacted with amino acids and proteins within the media.
Since the cytotoxicity of a biomaterial is highly dependent on its application (i e. cell
encapsulating vs. acellular construct adjacent to healthy tissue), a more detailed investigation of
cytotoxicity from genipin exposure was conducted. The relative volume of genipin, contained in a gel or
in the media, compared to the volume of cells showed a strong correlation to cell viability for both MSCs
and NSCs Figures 3-17, 3-18. This type of response allows for the determination of a tolerable level for
genipin in the gels based on the intended application of the gel and was used as the rationale for choosing
genipin concentrations for experiments in this thesis. For example, 1 mM genipin was used to create a
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stiffer more robust gel for injection into a spinal cord defect (chapter 6) where the volume of genipin
containing gel is low compared to the surrounding cell/tissue volume, while 0.25 mM genipin was used in
the astrocyte outgrowth assay (chapter 4) due to the relatively high genipin:cell volume.
Genipin at 5 tg/ml (22 tM) has neurotrophic properties similar to nerve growth factor (I ng/ml)
via the neural nitric oxide synthase pathway.[24, 26] Genipin interacts with fibroblasts to inhibit their
differentiation into myofibroblasts above 25 Ig/ml (0.11 mM) and decreases their expression of collagen I,
a-SMA, and TGF-P.[29] Similar effects have been noted with hepatic stellate cells. [28, 50] The
similarity of stellate cells to astrocytes may be beneficial to reduce glial scarring after SCI. Additionally,
genipin has known anti-inflammatory properties.[27] Together these properties make genipin not only a
cross-linking agent for collagen but a therapeutic agent itself.
84
3.7. References:
[1] Macaya D, Spector M. Injectable hydrogel materials for spinal cord regeneration: a review. Biomed
Mater. 2012;7:012001.
[2] Comolli N, Neuhuber B, Fischer 1, Lowman A. In vitro analysis of PNIPAAm-PEG, a novel,
injectable scaffold for spinal cord repair. Acta biomaterialia. 2009;5:1046-55.
[3] Jain A, Kim Y, McKeon R, Bellamkonda R. In situ gelling hydrogels for conformal repair of spinal
cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials. 2006;27:497-504.
[4] Gupta D, Tator CH, Shoichet MS. Fast-gelling injectable blend of hyaluronan and inethylcellulose for
intrathecal, localized delivery to the injured spinal cord. Biomaterials. 2006;27:2370-9.
[5] Joosten E, Bar P, Gispen W. Collagen implants and cortico-spinal axonal growth after mid-thoracic
spinal cord lesion in the adult rat. J Neurosci Res. 1995;41:481-90.
[6] Tysseling-Mattiace VM, Sahni V, Niece KL, Birch D, Czeisler C, Fehlings MG, et al. Self-assembling
nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. Journal of
Neuroscience. 2008;28:3814-23.
[7] Mano JF, Silva GA, Azevedo HS, Malafaya PB, Sousa RA, Silva SS, et al. Natural origin
biodegradable systems in tissue engineering and regenerative medicine: present status and some moving
trends. Journal of the Royal Society, Interface / the Royal Society. 2007;4:999-1030.
[8] Willerth S, Sakiyama-Elbert S. Approaches to neural tissue engineering using scaffolds for drug
delivery. Advanced Drug Delivery Reviews. 2007;59:325-38.
[9] EHRMANN R, GEY G. The growth of cells on a transparent gel of reconstituted rat-tail collagen. J
Natl Cancer Inst. 1956.
[10] Elsdale T, Bard J. Collagen substrata for studies on cell behavior. J Cell Biol. 1972;54:626-37.
[11] O'Connor S, Stenger D, Shaffer K, Ma W. Survival and neurite outgrowth of rat cortical neurons in
three-dimensional agarose and collagen gel matrices. Neuroscience Letters. 2001;304:189-93.
[12] O'Connor SM, Andreadis JD, Shaffer KM, Ma W, Pancrazio JJ, Stenger DA. Immobilization of
neural cells in three-dimensional matrices for biosensor applications. Biosensors and Bioelectronics.
2000; 14:871-81.
[13] O'Shaughnessy TJ, Lin HJ, Ma W. Functional synapse formation among rat cortical neurons grown
on three-dimensional collagen gels. Neuroscience Letters. 2003;340:169-72.
[14] Ma W, Tavakoli T, Chen S, Maric D, Liu JL, O'shaughnessy TJ, et al. Reconstruction of Functional
Cortical-like Tissues from Neural Stem and Progenitor Cells. Tissue Engineering Part A. 2008;14:1673-
86.
[15] Ma W, Fitzgerald W, Liu Q-Y, O'Shaughnessy TJ, Maric D, Lin HJ, et al. CNS stem and progenitor
cell differentiation into functional neuronal circuits in three-dimensional collagen gels. Experimental
Neurology. 2004;190:276-88.
[16] Watanabe K, Nakamura M, Okano H, Toyama Y. Establishment of three-dimensional culture of
neural stem/progenitor cells in collagen Type-I Gel. Restorative Neurology and Neuroscience.
2007;25:109-17.
[17] Willits R, Skornia S. Effect of collagen gel stiffness on neurite extension. Journal of Biomaterials
Science, Polymer Edition. 2004; 15:1521-3 1.
[18] Eccleston P, Mirsky R, Jessen K. Type I collagen preparations inhibit DNA synthesis in glial cells of
the peripheral nervous system. Experimental Cell Research. 1989;182:173-85.
[19] Sundararaghavan HG, Monteiro GA, Firestein BL, Shreiber DI. Neurite Growth in 3D Collagen Gels
With Gradients of Mechanical Properties. Biotechnol Bioeng. 2009;102:632-43.
[20] Georges P, Janmey P. Cell type-specific response to growth on soft materials. Journal of Applied
Physiology. 2005;98:1547-53.
[21] Georges P, Miller W, Meaney D, Sawyer E. Matrices with compliance comparable to that of brain
tissue select neuronal over glial growth in mixed cortical cultures. Biophysical journal. 2006;90:3012-8.
[22] Sung H, Chang W, Ma C, Lee M. Crosslinking of biological tissues using genipin and/or
carbodiimide. J Biomed Mater Res A. 2003;64:427-38.
85
[23] Sung HW, Huang RN, Huang LL, Tsai CC. In vitro evaluation of cytotoxicity of a naturally
occurring cross-linking reagent for biological tissue fixation. J Biomater Sci Polym Ed. 1999;10:63-78.
[24] Suzuki H, Yamazaki M, Chiba K, Sawanishi H. Characteristic properties of genipin as an activator in
neuronal nitric oxide synthase. J Health Sci. 2007;53:730-3.
[25] Yanazaki M, Chiba K. Neurotrophic effects of genipin on Neuro2a cells. J Health Sci. 2005;51:687-
92.
[26] Yamazaki M, Chiba K, Mohri T, Hatanaka H. Cyclic GMP-dependent neurite outgrowth by genipin
and nerve growth factor in PC12h cells. European journal of pharmacology. 2004;488:35-43.
[27] Koo H, Lim K, Jung H, Park E. Anti-inflammatory evaluation of gardenia extract, geniposide and
genipin. Journal of ethnopharmacology. 2006; 103:496-500.
[28] Imanishi Y, Maeda N, Otogawa K, Seki S, Matsui H, Kawada N, et al. Herb medicine Inchin-ko-to
(TJ-135) regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture
and attenuates development of liver fibrosis induced by thioacetamide administration in rats. J Hepatol.
2004;41:242-50.
[29] Kitano A, Saika S, Yamanaka 0, Ikeda K, Reinach PS, Nakajima Y, et al. Genipin suppresses
subconjunctival fibroblast migration, proliferation and myofibroblast transdifferentiation. Ophthalmic Res.
2006;38:355-60.
[30] Sundararaghavan H, Monteiro G, Lapin N. Genipin-induced changes in collagen gels: Correlation of
mechanical properties to fluorescence. Journal of Biomedical Materials Research Part A. 2008;87A:308-
20.
[31] Kubista M, Sjoback R, Eriksson S, Albinsson B. Experimental correction for the inner-filter effect in
fluorescence spectra. Analyst. 1994; 119:417-9.
[32] Palmier MO, Van Doren SR. Rapid determination of enzyme kinetics from fluorescence:
Overcoming the inner filter effect. Analytical Biochemistry. 2007;371:43-51.
[33] Sun X-D, Jeng L, Bolliet C, Olsen BR, Spector M. Non-viral endostatin plasmid transfection of
mesenchymal stem cells via collagen scaffolds. Biomaterials. 2009;30:1222-31.
[34] Palmer TD, Takahashi J, Gage FH. The Adult Rat Hippocampus Contains Primordial Neural Stem
Cells. Molecular and Cellular Neuroscience. 1997;8:389-404.
[35] Forgacs G, Newman SA, Hinner B, Maier CW, Sackmann E. Assembly of Collagen Matrices as a
Phase Transition Revealed by Structural and Rheologic Studies. Biophysical journal. 2003;84:1272-80.
[36] Palmer MP, Abreu EL, Mastrangelo A, Murray MM. Injection Temperature Significantly Affects In
Vitro and In Vivo Performance of Collagen-Platelet Scaffolds. Journal of Orthopaedic Research.
2009;27:964-7 1.
[37] Sato K. Possible Involvement of Aminotelopeptide in Self-assembly and Thermal Stability of
Collagen I as Revealed by Its Removal with Proteases. Journal of Biological Chemistry. 2000;275:25870-
5.
[38] Pieper JS, Hafmans T, Veerkamp JH, van Kuppevelt TH. Development of tailor-made collagen-
glycosaminoglycan matrices: EDC/NHS crosslinking, and ultrastructural aspects. Biomaterials.
2000;21:581-93.
[39] Touyama R, Takeda Y, Inoue K, Kawamura I, Yatsuzuka M, Ikumoto T, et al. Studies on the blue
pigments produced from genipin and methylamine .1. structures of the brownish-red pigments,
intermediates leading to the blue pigments. Chem Pharm Bull. 1994;42:668-73.
[40] Ma L, Gao C, Mao Z, Zhou J, Shen J. Enhanced biological stability of collagen porous scaffolds by
using amino acids as novel cross-linking bridges. Biomaterials. 2004;25:2997-3004.
[41] Yan L-P, Wang Y-J, Ren L, Wu G, Caridade SG, Fan J-B, et al. Genipin-cross-linked
collagen/chitosan biornimetic scaffolds for articular cartilage tissue engineering applications. Journal of
Biomedical Materials Research Part A. 2010;95A:465-75.
[42] Park J, Lee J, Kim H, Hahn T, Paik Y. Isolation and characterization of water-soluble intermediates
of blue pigments transformed from geniposide of Gardenia jasminoides. J Agr Food Chem.
2002;50:6511-4.
86
[43] Chen H, Wei 0, Bisi L, Martoni C, Prakash S. Reaction of chitosan with genipin and its fluorogenic
attributes for potential microcapsule membrane characterization. Journal of Biomedical Materials
Research Part A. 2005;75A:917-27.
[44] Achilli M, Mantovani D. Tailoring Mechanical Properties of Collagen-Based Scaffolds for Vascular
Tissue Engineering: The Effects of pH, Temperature and Ionic Strength on Gelation. Polymers.
20 10;2:664-80.
[45] Slusarewicz P, Zhu K, Hedman T. Kinetic characterization and comparison of various protein
crosslinking reagents for matrix modification. Journal of materials science Materials in medicine.
2010;21:1175-81.
[46] Mi F, Shyu S, Peng C. Characterization of ring-opening polymerization of genipin and pH-dependent
cross-linking reactions between chitosan and genipin. Journal of Polymer Science Part A: Polymer
Chemistry. 2005;43:1985-2000.
[47] Mi F, Sung H, Shyu S. Synthesis and characterization of a novel chitosan-based network prepared
using naturally occurring crosslinker. J Polym Sci Pol Chem. 2000;38:2804-14.
[48] Flanagan LA, Ju YE, Marg B, Osterfield M, Janmey PA. Neurite branching on deformable substrates.
Neuroreport. 2002;13:2411-5.
[49] Barnabe-Heider F, Frisen J. Stem cells for spinal cord repair. Cell Stem Cell. 2008;3:16-24.
[50] Imanishi Y, Maeda N, Matsui H, Takashima T, Seki S, Arakawa T, et al. Suppression of Rat Stellate
Cell Activation and Liver Fibrosis by a Japanese Herbal Medicine, Inchinko-to (TJ 135). Comp Hepatol.
2004;3 Suppl 1:S11.
87
Chapter 4
Permissiveness of Collagen-Genipin gels
Containing FGF-2 to Infiltration by
Primary Astrocytes using an In Vitro
Cellular Outgrowth Assay
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4.1 Introduction
In this chapter, the permissiveness of genipin-cross-linked collagen hydrogels to infiltration by
primary cortical astrocytes was investigated using a 3-D cellular outgrowth assay. The ability of FGF-2
either freely loaded within the gel or encapsulated within LMTs to alter the cell-biomaterial interaction
and facilitate the population of the gels with astrocytes was analyzed in detail. That the astrocyte
infiltration of the gel may be due to the combined processes of migration and proliferation is compatible
with the intended use of the gel and would demonstrate that the gel is permissive of both processes. The
effect of genipin on astrocyte viability and movement into the gel was examined to better understand how
these cells would react to the use of this collagen cross-linking agent. The in vitro studies presented in this
chapter of the thesis helped to guide the selection of materials and growth factors to best enhance
astrocyte ingrowth and framework formation in vivo.
4.2. Background and motivation
The astrocyte is one of the main endogenous cell types modulating the native response to SCI.
Following injury, astrocytes undergo many phenotypic changes including: hypertrophy; proliferation;
increased expression of glial fibrillary acidic protein (GFAP) and a-smooth muscle actin; and release of
numerous growth factors, cytokines, and ECM molecules including axon growth inhibitory chondroitin
sulfate proteoglycans (CSPGs) [1, 2]. The onset of glial scarring occurs approximately 3 days post injury
and begins to stabilize by about 28 days [3]. The scar serves to separate the viable nerve tissue from the
necrotic damaged tissue as well as from the invading inflammatory and mesenchymal cells, but has the
drawback of preventing axon regeneration through the damaged areas of the cord. Astrocytes may extend
a few processes into the defect area but are primarily localized to the border zone.
Despite their growth inhibitory phenotype after injury, astrocytes also hold a highly important
role after SCI to limit the extent of secondary damage by providing trophic support to for neurons and
oligodendrocytes: restoring a homeostatic environment; limiting the accumulation of toxic metabolites
such as glutamate from damaged neural tissue; restoring the blood brain barrier; and limiting the
infiltration of inflammatory and mesenchymal cells [4-6]. Perhaps even more valuable is the potential for
astrocytes to facilitate regeneration after SCI by forming a framework necessary for axon growth and
guidance [7-9]. Prior work has shown that transplanted dorsal root ganglion cells have been able to send
processes down both intact and degenerating white matter in vivo, seemly guided by astrocytic processes
[9, 10]. The many roles that the astrocyte can play in supporting a regenerative response make the case
for facilitating its infiltration into the SCI defect, by providing a lesion-filling matrix pernissive of
astrocyte infiltration capable of delivering a pro-migratory factor and permissive of astrocyte migration.
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Fibroblast growth factor-2 (FGF-2) is a promising molecule to consider for increasing the
population of astrocytes within a biomaterial matrix after injury. FGF-2 is a potent growth factor released
by astrocytes after injury to the CNS, which is both a mitogen and chemoattractant for astrocytes [11, 12]
and may contribute to the limitation of injury and induction of progenitor cells after SCI [13]. In addition
to its action on astrocytes, FGF-2 has many other positive effects on neural cell populations. FGF-2
increases the survival of mature neurons in vitro [14, 15], and promotes the survival and proliferation of
NSCs and maintains them in an undifferentiated state [15, 16]. FGF-2 can prevent oligodendrocyte
apoptosis after injury and can induce mature oligodendrocytes to dedifferentiate and proliferate [13, 14].
It is also a mitogen and chemoattractant for oligodendrocyte precursor cells [13, 14, 17]. Together these
results suggest that FGF-2 can promote remyelination of spared axons after injury. Furthermore, FGF-2
is a potent angiogenic factor and accelerates revascularization of the injury site, which is critical for repair
of injured tissue [18].
However, the use of FGF-2 in spinal cord injury necessitates the use of controlled delivery system
to mitigate the detrimental effects of FGF-2 overstirnulation. FGF-2 has been implicated in stimulating
astrogliosis both in vitro [12, 19] and in vivo [20-24]. FGF-2 has also been shown to disrupt myelin
production in mature oligodendrocytes, cause reactive changes in oligodendrocyte progenitor cells, and
increase accumulation of microglia at high concentrations in vivo [21]. In prior studies FGF-2 has been
delivered to the spinal cord through a variety of means including: direct injections into the parenchyma;
sub-dural osmotic mini-pumps; and intrathecal polymer-drug implants [25-29]. However, the penetration
of FGF-2 into the cord is very limited, potentially due to its sequestration in the ECM [28, 30], and such
methods do not deal with the creation of a provisional stroma to allow for the repopulation of the cavitary
defect, which occurs after SCI. To this end, an injectable gel conducive to cellular ingrowth, could
provide a useful treatment for SCI due to its ability to serve both as a scaffold and as a medium for
delivery of therapeutic agents.
In order to provide additional control over the release of FGF-2 from the scaffold, a secondary
release vehicle, lipid microtubules (LMTs), was commended for this study. LMTs are self-assembled
structures with high drug loading capacity, can serve to protect FGF-2 during in situ cross-linking of the
gel. LMTs, which can sustain controlled delivery of proteins for weeks by varying the average length of
the tubules via the self-assembly conditions [31], have been used in prior models of SCI to deliver brain-
derived neurotrophic factor and chondroitinase ABC [32, 33]. These studies reported sustained release
and preserved bioactivity of proteins over a period of two weeks. Additionally, the LMTs were non-
cytotoxic and non-inflammatory at concentrations of 8.3 mg/ml.
4.3. Overall Goal and Hypotheses:
90
The overall goal of this study is to develop an injectable collagen-genipin hydrogel capable of
being infiltrated with astrocytes, in order to ultimately test the hypothesis in vivo that astrocyte infiltration
of a gel-filled defect in SCI will stimulate neurite ingrowth into the defect and reduce the astrocyte
scarring around the defect.
The hypotheses of this chapter are:
1.) Infiltration and population of collagen gels with astrocytes will be enhanced through the use of FGF-2
incorporated within the gels.
2.) The action of genipin on both the cross-linking of the collagen gel and directly on the astrocytes will
impede their growth into the gels.
3.) Encapsulation of FGF-2 within LMTs will enhance the infiltration of astrocytes into the gels
particularly at low FGF-2 concentrations and in the presence of genipin.
4.4. Methods
4.4.1 Experimental design
The effects of genipin cross-linking of collagen gels and the effects of 2 concentrations of FGF-2
as freely incorporated and LMT-contained protein on cell infiltration into various gel formulations and on
cell proliferation were evaluated. Using an outgrowth assay the following metrics were evaluated: the
total number of cells penetrating into the gel (which may include proliferating cells), the number of cells
present at various distances within the gel, and the average distance to the furthest penetrating cell within
the gel. In order to begin to assess the relative contribution of proliferation versus migration on the
number of cells infiltrating the gels, two experiments were performed: 1) a proliferation assay to evaluate
the mitogenic effects of FGF-2 dose on the astrocytes, in monolayer culture; and 2) staining of astrocyte-
infiltrated gels with Ki-67 to provide an indication of the percentage of cells in the gels undergoing
mitosis Given that the morphology of astrocytes may reflect their reactivity, the percentage of cells
infiltrating the gels with select morphologies was determined.
4.4.2 Materials
Soluble rat-tail type I collagen (3.54-3.91 mg/mL) in acetic acid (BD Biosciences, Franklin
Lakes, NJ, USA), genipin (Wako Pure Chemical, Japan), I ,2-bis-(triscosa-10,12-diynoyl)-sn-glycero-3-
phosphocholine (DC8 ,9PC) (Avanti Polar lipids, Alabaster, AL, USA), human fibroblast growth factor-2
(Peprotec, Rocky Hill, NJ, USA). Buffers were purchased from Invitrogen (Grand Island, NY, USA) and
were cell-culture grade.
4.4.3 Collagen gels
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Ice cold lx phosphate buffered saline (PBS), 5x PBS, IN NaOH, and soluble rat tail type I
collagen were combined in that order to obtain 2 mg/mL collagen solutions at pH 7.5 with lx ionic
strength. For gels containing genipin, a stock solution of genipin in 5x PBS (3 mg/mL), made
immediately before mixing, was used in place of a volume of 5x PBS to obtain the desired genipin
concentration of 0.25mM. This genipin concentration was employed based on its favorable gelation time,
modulus and degradation rate for central nervous system applications, and the lack of cytotoxicity.[34]
FGF-2 was loaded into the gels by adding the appropriate volume of 100 [tg/ml FGF-2 or I
mg/ml FGF-2-LMTs in lx PBS. Thermal gelation of the collagen solutions was induced by warming to
37 'C in an incubator.
4.4.4 Lipid microtubules
LMTs were prepared using a self-assembly method as previously described [3 1]. DC8 ,9PC lipid
was dissolved in 55 0 C ethanol. 55 0 C DI water was then added to bring the final lipid concentration to 1
mg/ml in 70% ethanol. The lipid solution was held at 55 0 C for 6 h and then slowly cooled to 25'C,
heated to 33'C, and finally cooled back down to 25'C at 10C/hr in a microprocessor-controlled
circulating water bath (Cole-Palmer, Vernon hills, IL, USA). The LMTs were then stored at room
temperature for two weeks in the dark. Before usage, 50 mM trehalose (Sigma, St. Louis, MO, USA) was
added to the LMT solution overnight to preserve the tubular structure during lyophilization. The LMTs
were then centrifuged (1500 g, 10 min) and the supernatant was removed. LMTs were re-suspended in DI
water and lyophilized overnight. LMTs were loaded with recombinant human FGF-2 in 5% trehalose by
rehydrating the dried LMTs overnight in 40 pl of FGF-2 solution with one of 2 concentrations: 0.11 or I
mg/ml per mg of lipid, referred to as "Low" and "High," respectively. Un-encapsulated growth factor
was removed by diluting the LMTs to 0.5 mg/mI with lx PBS, centrifuging (1500 g, 10 min), and
removing the supernatant. LMTs were re-suspended in lx PBS at I mg/ml prior to loading into the gel.
The amount of protein encapsulated within the LMTs was estimated as previously described via
the total internal volume of the LMTs and the concentration of loading solution [31]. High levels of
fluorescently labeled protein can be seen within the LMTs immediately after loading and following 6
days of release after being encapsulated within a collagen gel (Figure 4-1). The amount of FGF-2
contained in the Col-FGF gels corresponded to approximately the maximum theoretical amount
encapsulated within the LMT-FGF containing gels.
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a.) b.)
Figure 4-1: 40x fluorescent images of LMTs loaded with fluorescein isothiocyanate conjugated
BSA. a.) immediately after loading and rinsing steps b.) After 6 days embedded in a collagen gel
submerged in lx PBS. Scale bar= 20 micrometers
4.4.5 Astrocyte culture
Cortical astrocytes were harvested from post-natal day 2 Sprague Dawley rats according to prior
published procedures yielding a >95% pure population of cortical astrocytes [35]. The astrocytes were
seeded into 2 mg/ml type I collagen gels at 1 million cells/ml. 1 ml of the gel was poured into each well
of a 12 well plate and allowed to set for 15 min at 37'C. I ml of cell culture media: DMEM high glucose
with glutamate, 10% fetal bovine serum (FBS), and 1% Penicillin/Streptomycin antibiotics, was then
added and the astrocytes were cultured overnight. A 6 mm biopsy punch was used to create the core cell-
seeded disks for the outgrowth assay.
For the cell priming experimental groups, astrocyte-collagen gels were incubated for 24 hours in
either genipin or FGF-2 before being cut into 6 mm disks and used as the core of the outgrowth assay
setup. In these experiments, the encapsulating gel was the same as the Col group. The purpose of these
groups was to explore if either Gen or FGF-2 could alter the outgrowth response of astrocytes even if it
was not contained within the encapsulating gel.
4.4.6 Outgrowth assay
The outgrowth assay setup is illustrated in Figure 4-2. 200 RI of 2% agarose at 60'C was used to
coat the bottom of a 24 well plate to prevent astrocytes from moving along the bottom of the well plate.
After 2 hours of gelation, 200 [l of 2mg/ml type I collagen was added on top of the agarose to act as an
interface layer and was allowed to gel for 1 hour at 37'C. 6 mm disks of the astrocyte-seeded gels were
then gently placed into the center of the 24 well plates containing the agarose and collagen. Once in
place, 400 ul of the gel to be tested in the outgrowth experiment "encapsulating gel" was added and the
constructs were allowed to gel for 15 min at 37'C before adding 0.5 ml of cell culture media. The
93
medium was changed the following day and every 48 hours thereafter. Each group (Table 4-1) contained
4-8 gels, results were pooled from three independent experiments.
Medium
(500 ul)
6 mm astrocyte-seeded
collage gel core
(-75 ul vol)
+-- Experimental gel (400 ul)
Collagen gel (200 ul)
Agarose (200 ul)
Figure 4-2: Outgrowth assay setup consisting of a core astrocyte seeded collagen gel encapsulated
within a collagen gel containing the experimental factors (Genipin, LMTs, FGF-2). The
outgrowth/infiltration of cells into the encapsulating gel was examined at 10 days.
Table 4-1: Experimental groups for migration assay. Col, collagen; Gen, genipin.
n Group
5 Col 2 mg/ml collagen
4 Col + FGF primed cells Col + Astrocytes exposed to 150 ng/ml FGF-2 for 24 hr
5 Col FGF Low Col + 15 ng/ml FGF-2
6 Col FGF High Col + 150 ng/ml FGF-2
6 Col-Gen Col + 0.25 mM Genipin
4 Col + Gen primed cells Col + Astrocytes exposed to 0.25 mM genipin for 24 hr
8 Col-Gen FGF High Col + 0.25 mM Genipin + 150 ng/ml FGF-2
6 Col LMT PBS Col + 0.1 mg/ml LMT loaded with PBS
6 Col LMT FGF low Col + 0.1 mg/ml LMTs loaded with 0.11 mg/ml FGF-2
4 Col LMT FGF high Col + 0.1 mg/ml LMTs loaded with 1 mg/ml FGF-2
Col + 0.25 mM genipin + 0.1 mg/mI LMT loaded with 0.11 mgi
4 Col-Gen LMT FGF Low FGF-2
Col + 0.25 mM genipin + 0.1 mg/ml LMT loaded with 1 mg/ml
4 Col-Gen LMT FGF High FGF-2
4.4.7 Quantification of the number of cells infiltrating the gels, migration distance, and cell
morphology
The constructs were imaged from days 0 to 10 (principal quantification time-point). At day 10,
the gels were stained with calcein AM (20 Rg/ml) in lx PBS for 60 min at 37*C to visualize the live cells.
Gels were carefully removed from the 24 well plate, placed on glass slides, blotted dry, and imaged at 4x
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exposure on a epifluorescence microscope (Olympus BX-60, Center valley, PA, USA). 5-6 images were
taken around the perimeter of each gel. Each image was classified into one of four categories (short
isolated, spread, chain-like , and chain-like with clustering) based on the outgrowth pattern of the
astrocytes. For each image, the number of cell bodies crossing the interface into the encapsulating gel
was manually counted using the Image J cell counting software (NIH, Bethesda, MD). The number of
cells in the encapsulating gel was normalized to the interface length from which the analyzed imaged
were taken.
The distance from the interface to the furthest cell (via perpendicular line segment) was also
measured. Only cells in reasonable focus were counted. The average distance to the furthest cell was
then calculated for each group. The image with the furthest cell was then further quantified by measuring
the distance of each cell from the interface, creating an outgrowth distance histogram.
Following the calcein AM imaging, the gels were then fixed in 4% paraformaldehyde in PBS for
1 hour and permeabilized with 0.5% Triton-x 100 containing 5% serum for 40 min. The gels were stained
with I [tg/ml 4',6-diamidino-2 -phenylindole (DAPI) for 1 hour and rinsed 3x with lx PBS. The DAPI-
labeled gels were evaluated for the number of penetrating cells and the outgrowth distance to validate the
findings from the calcein AM-stained constructs. The high cell resolution in the DAPI images enabled
calculation of the outgrowth distance histogram using the Image J cell counter application. The X-Y
coordinates of the nucleus of the cell were subtracted from the X-Y coordinates of the gel interface to
determine the outgrowth distance (images were scaled to 62 pixels= 100 micrometers).
Given that the morphology of astrocytes can provide an indication of their reactivity, the
percentages of images with cells displaying the following morphologies was evaluated: isolated short,
highly spread, chain-like, and chain-like with clustering.
4.4.8 Cell viability and proliferation
Live/dead cell staining was performed using Calcein AM and Ethidium homodimer (Invitrogen,
Grand Island, NY, USA) in an assay simulating the conditions of the outgrowth assay. Constructs in the
same configuration as the outgrowth assay were used, except that astrocytes were seeded at 300,000
cells/ml in order to facilitate visualization. Genipin and/or FGF-2 were mixed into the encapsulating gel
at the defined concentrations. After 15 min of gelation, 500 tL of astrocyte medium was added on top of
the construct. The gels were incubated for 24 hr and then stained and imaged using an epifluorescence
microscope at 4x objective. Three to four random sections of each gel were measured, totaling 500-1500
cells/gel. The cell count was analyzed using Image J software (NIH, Bethesda, MD). Percentage
viability was calculated as the number of viable cells divided by the total number of cells measured per
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gel, multiplied by 100.
To assess the proliferation of primary cortical astrocytes in response to FGF-2, astrocytes in
monolayer culture were stimulated with 5x10-5 pg/ml to 50 ptg/ml FGF-2. Forty-eight hours after FGF-2
stimulation, cell proliferation was assessed by WST reduction assay (Dojindo, Rockville, MD, USA),
which detects dehydrogenase activity of viable cells. The cells were incubated with 10% WST solution
for I h at 37 0 C. Then the absorbance of the culture medium was measured with a microplate reader at a
test wavelength of 450 nm and a reference wavelength of 630 nm.
To evaluate the effect of proliferation under assay conditions, astrocyte outgrowth assay gels
(after 10 days culture) were fixed in 4% paraformaldehyde in PBS for 1 hour and perneabilized with
0.5% Triton-x 100 containing 5% serum for 40 min. The gels were embedded in paraffin, sectioned on a
microtome at 6 micrometers, and mounted on glass slides. A heat induced epitope retrieval was
performed with Tris/EDTA buffer at 95'C for 25 minutes. The gels were stained for the proliferation
marker Ki-67 using anti-rabbit Ki-67 sp6 clone (Abcam, Cambridge, MA, USA) at 1:100 dilution.
Detection was achieved through the EnVision kit anti rabbit HRP AEC+ (Dako, Carpinteria, CA). Nuclei
were counterstained using Mayer's hematoxylin.
4.4.9 Statistical analysis
One-way analysis of variance (ANOVA) with a Fishers PLSD post hoc test was used to
determine the statistical significance of the cellular outgrowth and viability data. Pair-wise comparisons
were performed using a Student's t-test assuming equal variances (a=0.05).
4.5. Results
4.5.1 Number of cells infiltrating into the gels
As early as I day, cell processes could be seen crossing the interface into the encapsulating gel
for FGF containing groups. By 2 days, several cells in the FGF-2 containing groups could be found
across the interface while process extension began in the collagen only group. No cells could be seen
crossing the interface in the genipin containing gels until day 3. By day 4 there were significant numbers
of cells crossing the interface for all groups. In a comparison of FGF-2 containing groups there was a
significant difference between the number of cells crossing the interface between days 4 and 6 but not
between days 6 and 10 suggesting a decrease in the rate of cells crossing the interface after 6 days.
However, the cells continued to migrate further into the encapsulating gel through day 10.
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By 10 days, there was more than a 10-fold difference in the number of cells within the
encapsulating gel between the groups with the greatest (Figure 4-3; Col-FGF High) and least amount
(Figure. 4-3; Col-Gen) of outgrowth. The collagen hydrogels without chemokine (groups labeled Col,
Col-Gen) or with PBS loaded LMTs induced minimal astrocyte recruitment. In contrast, collagen
hydrogels with FGF-2 loaded freely or within LMTs at 2 concentrations each dramatically increased cell
recruitment (Figure 4-3).
One-factor ANOVA with Fishers PLSD post hoc testing over all groups (Figure 4-3) showed a
statistically significant increase in the number of cells/mm interface present within the encapsulating gel
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Figure 4-3: Number of cells infiltrating into the encapsulating collagen gel normalized by the total
mm of gel interface imaged (solid, primary axis) and the average infiltration distance from the
interface to the furthest cell body for all gels (stripes, secondary axis). n= 4-8 gels, 5-6 images/gel (45-
50% of interface). Mean ± stdev (number) Mean ± SEM (length). Images used for examination were
taken at 4x using an epifluoresence microscope on calcein AM stained cells.
between the control Col gel and: Col FGF Low (p=0.00004), Col FGF High (p=1.159 x 10-"), Col LMT
FGF Low (p=9.5 1x10-3 ), Col LMT FGF High (p=3.6x10 8 ), and Col Gen LMT FGF High (p=0.00037).
There was a statistically significant difference in outgrowth number for FGF-2 concentration with Col
FGF High/Low groups (p=2.5 1x10-6), but not for Col-Gen LMT High/low or Col LMT High/Low groups.
There was no statistically significant difference between Col FGF High, Col LMT FGF High, or Col
LMT FGF Low. There was also no statistical significance between Col Gen LMT FGF High and Col
LMT FGF High. There was also no statistically significant difference between Col Gen LMT FGF High
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and Col Gen FGF High. While there was no significance between Col and Col Gen in the ANOVA
analysis, pair-wise comparison using a Student's t test showed a significant difference (p=0.00034).
The addition of genipin dramatically decreased the number of cells within the encapsulating gel
when no FGF-2 was present, however this effect was mitigated with the addition of FGF-2 either freely or
within LMTs such that the number of cells within the encapsulating gel approached non-genipin
containing gels. In the presence of genipin, FGF-2 within LMTs appeared to enhance outgrowth slightly
better than un-encapsulated FGF-2.
Priming cells with genipin prior to the outgrowth assay decreased the number of cells that
penetrated into the encapsulating collagen gel as well as their penetration distance as compared to
untreated cells. Conversely, priming cells with FGF-2 increased the number of cells within the
encapsulating gel as well as their penetration distance. However, the effect of priming the cells in either
case was not as dramatic as when collagen or FGF-2 was present within the encapsulating gel.
4.5.2 Infiltration distance and morphology of infiltrating cells
The average distance to the furthest cell in each image at 10 days showed a correlation
(R2=0.877) to the number of cells crossing the interface (comparing the data in Figure 4-3). In some
groups, cells could be found a distance of 1-2 mm in the gels. Generally, higher levels of FGF within the
encapsulating gel led to deeper penetration. Of special note is the presence of FGF-2 within LMTs (but
not blank LMTs) appeared to increase the infiltration distance of astrocytes into the gel over free FGF-2.
Col-Gen LMT FGF high also yielded longer infiltration distances than Col Gen FGF high.
One-factor ANOVA with Fishers PLSD post hoc testing over all groups in Figure 4-3 showed a
statistically significant increase in infiltration distance between the control Col gel and: Col FGF Low
(p=3.67x10-3), Col FGF High (p=7.92x 10-), Col LMT FGF Low (p=l.66x10-7), and Col LMT FGF High
(p=4.22x 10-9). There was a statistically significant decrease in infiltration distance between Col and Col
Gen (p=0.3.]4x10 3 ). There was no statistically significant difference with FGF-2 concentration for Col
LMT High/Low, Col Gen LMT High/Low, or Col FGF High/Low.
The distribution of cells within the encapsulating gel in select groups was further elucidated by a
distance histogram noting the position of each cell relative to the interface (Figure 4-4a). Non FGF
containing groups (Col, LMT PBS, and Col-Gen), had a high percentage of cells close to the interface
which rapidly decreased by 500-1000 [rm. Col FGF high, Col LMT FGF low and Col LMT FGF high all
had a more gradual decrease in the distribution of cells with distance, which tapered off between 1700-
2500 im. Interestingly, they all showed approximately the same linearly decreasing trend in the
percentage of cells within the encapsulating gel as distance increased (Figure 4-4b). The histogram of
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gels containing Genipin and FGF-2 (Col Gen FGF High and Col Gen LMT FGF High) had characteristics
in between control and FGF-2 containing gels, with a greater % of cells close to the interface and only
growing out to about half of the distance of other FGF containing gels. Histograms of the remaining gels
can be found in Figure 4-5.
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Figure 4-4: a.) Histogram of the total number of infiltrating cells at 100 pim intervals for select control
and outgrowth promoting gels. The image with the furthest infiltration distance in each gel was used
n=4-8. The count represents the sum total of infiltrating cells at the specified distance normalized by
the number of gels examined. b.) Distance histogram as in b, showing the percentage of cells at 100
tm intervals. n= 4-8.
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Figure 4-5 a.) Histogram of the total number of migrating cells at 100 pm intervals for groups not
shown in figure 4-4. The image with the furthest migration distance in each gel was used n=4-5.
The count represents the sum total of migrating cells at the specified distance normalized by the
number of gels examined. b.) Distance histogram as in b, showing the percentage of cells at 100 gm
intervals. n=4-5.
Of specific note was the morphology of the astrocytes within the encapsulating the test gels
(Figure 4-6). In non- FGF containing gels, several isolated cells per field of view could be seen crossing
the interface from the core gel into the encapsulating gel with little nearest neighbor interaction.
However, all of the FGF-2 containing gels exhibited instances of the chain-like outgrowth of astrocytes
similar to a network/framework. Figure 4-7 further quantifies the distinct cell outgrowth patterns noted
in the images taken including isolated short, highly spread, chain-like, and chain-like with clustering.
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Figure 4-6: Representative long distance outgrowth images of the interface between astrocyte
seeded and encapsulating gels for each group. T=10 days. Taken under a 4x objective using a
calcein AM viable cell stain and epifluorescence microscopy. The dotted line signifies the
interface. Scale marker= 1000 micrometers. Col= collagen (2 mg/ml), FGF primed cells=
astrocytes exposed to 150 ng/ml FGF-2 prior to assay setup, FGF low = 15 ng/ml FGF-2 freely
loaded in the gel, FGF High = 150 ng/ml FGF-2 freely loaded in the gel, Gen= genipin (0.25 mM),
Gen primed cells= astrocytes exposed to 0.25 mM prior to assay setup, LMT PBS= 0.1 mg/ml
LMTs loaded with PBS, LMT FGF low= 0.1 mg/mi LMTs loaded with 0.11 mg/mi FGF-2, LMT
FGF High= 0.1 mg/ml LMTs loaded with 1 mg/ml FGF-2.
101
100
. 90 -
80
tM 70
1 60 - - - - -__--_
0 --
am 30
S20
10
' 00
O .
C_0V 0
Chain MWgration (CM)
i Isolated short
I Spread (long)
Chain-like
U Chain-like with
clustering
CM with clustering
Figure 4-7: Quantification of the four main astrocyte outgrowth patterns observed in the outgrowth
assay. The percentage of images with each of the morphologies was calculated based on the total
images of each group (5-6 images/gel 4-8 gels/group). b.) Example images of each type of
morphology. Scale bar = 1000 [tm
4.5.3 Proliferation and viability
Analysis of the cellular density within the core astrocyte seeded gel was performed on select
control and high growth gels to determine the effect cellular overcrowding due to proliferation might have
played a role in the outgrowth phenomena (Figure 4-8). One-factor ANOVA with Fishers PLSD post
hoc testing of DAPI stained images of the center of the astrocyte seeded gels at 10 days showed no
significant difference in cell number between Col and any other group examined. Statistical significance
was only reached between Col FGF High and Col Gen (p=.0007), LMT PBS (p=.00339), and Col Gen
LMT FGF High (p=.00 13). Overall, there was also a trend towards a higher average number in the Col
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FGF High group and lower average number in Genipin containing groups. Cell counts at the edges of the
gel showed no statistically significant difference in the number of cells within the gel between Col and
any other groups.
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Figure 4-8: Number of DAPI stained cells in the center (solid, primary axis) and edge (stripes,
secondary axis) of select control and pro-outgrowth gels at day 10. 4x objective n=4 gels (center) 3-
4 gels (edge) mean ± stdev. Number of DAPI stained cells at the edge was normalized by the area
of core gel measured.
Further analysis of the proliferation of cells in the gels was performed on microtomed sections
from several astrocyte outgrowth assay gels embedded in paraffin using Ki-67 staining. Images taken at
lOx in the center of the astrocyte-seeded constructs revealed that only a small percentage of astrocytes
(estimated to be less than 15%) were proliferating after 10 days in culture. There were comparable
percentages of proliferating cells in control and FGF-2 containing gels (Figure 4-9).
It was noted that in monolayer culture, astrocytes increased in number by almost two-fold in
response to 48 hours of FGF-2 stimulation as measured by WST reduction assay. Interestingly, the effect
was relatively independent of concentration over several orders of magnitude and began to decrease by 50
tg/ml (Figure 4-10). One-factor ANOVA with Fishers PLSD post hoc testing over all FGF-2
concentrations showed a statistically significant difference in proliferation between control 0 [tg/ml and
all other concentrations examined except 50 Rg/ml. There was no significant difference between
proliferation of astrocytes exposed to FGF-2 concentrations between 5x10 5 gg/ml and 5 Rg/ml.
Additionally, the encapsulation of astrocytes within 0.25 mM genipin gels did not alter the viability
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(Figure 4-11).
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Figure 4-9: Ki-67 proliferation marker immunohistochemistry on select paraffin embedded
astrocyte outgrowth assay gels at 10 days. Images were taken at IOx in the center of the astrocyte
seeded core gel. Arrows highlight positive staining within the cell nucleus. Scale bar= 100 [tm.
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Figure 4-10: Proliferation assay of astrocytes in monolayer culture in response to FGF-2.
Forty-eight hours after FGF-2 stimulation, cell proliferation was assessed by WST reduction
assay, which detects dehydrogenase activity of viable cells. The cells were incubated with
10% WST solution for 1 h at 37*C. Then the absorbance of the culture medium was measured
with a microplate reader at a test wavelength of 450 nm and a reference wavelength of 630
nm. n=3, mean +/- stdev. *Data in collaboration with Dr. Kazuhide Hayakawa.
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Figure 4-11: 24 hour viability assay for genipin toxicity. Constructs were made in the same
configuration as the migration assay. Genipin (0-0.5 mM) and/or FGF-2 (150 ng/nl) were
added to the gels. After 24 hours, the constructs were stained with calcein AM and ethidium
homodimer and visualized at 4x with an epifluorescent microscope. Three independent fields
of view were taken at random for each gel. Percentage viability was calculated based on the
ratio of live to total (live+dead) cell count. n=4 gels mean ± stdev
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4.6. Discussion
4.6.1 Rationale for scaffolding to enable astrocyte infiltration after SCI
The microenvironment of the damaged spinal cord is unfavorable for the re-growth of axons.
Necrosis and the influx of inflammatory cells within the lesion core leads to the formation of a cystic
cavity which is walled off from viable neural tissue by a dense glial scar. Depending on the extent of
damage to the surrounding dura, a fibrous scar containing meningeal fibroblast and Schwann cell
infiltration may also be present within the defect. As a result, in addition to the barrier imposed by the
glial scar, the cavitary nature of the defect itself provides no framework for axonal growth. Therefore,
regeneration likely requires replacement of the lesioned area with a tissue regenerative matrix.
Endogenous astrocytes may be a promising candidate cell to target after injury since their native
response is to proliferate and migrate towards the damaged tissue and they have the capability to form the
framework for subsequent axon ingrowth. Renault-Mihara, et al., showed that enhancement of astrocyte
migration may be beneficial to regeneration. The group investigated systemic administration of a
glycogen synthase kinase-3 (GSK-3) inhibitor Ro3303544 for 5 days after SCI in mice in order to
promote astrocyte migration [36]. The inhibitor resulted in accelerated migration of reactive astrocytes,
which restricted inflammatory cell infiltration, spared myelinated axons, decreased scarring, and
promoted functional recovery.
4.6.2 Gel permissiveness of astrocyte infiltration
In the present study, injectable collagen-based hydrogels were evaluated in an astrocyte cell
outgrowth assay. The assay, at one time, enabled the evaluation of: 1) the permissiveness of the collagen
gels to astrocyte infiltration, through a combination of migration and proliferation; 2) the release and
retained bioactivity of the FGF-2 in the gels and in LMTs; and 3) the effects of genipin on cell motility.
All of the collagen gels containing FGF-2 elicited a pro-outgrowth effect on the astrocytes while the
collagen hydrogels without chemokine (group labeled Col, Col-Gen, or Col LMT PBS) induced minimal
astrocyte recruitment (Figure 4-3). Specifically, the groups Col FGF High, Col LMT FGF High, Col
LMT FGF Low, and Col Gen LMT FGF High all had substantial increases in infiltration over control
gels. Despite the wide range of FGF-2 concentrations and release rates, there was only a small difference
among the outgrowth inductive properties of the FGF-2 containing gels.
For the FGF-2 containing groups-Col LMT FGF low, Col LMT FGF High, and Col FGF
High-the distance histograms (Figure 4-4a) demonstrated a linear decrease in the number of cells as the
distance from the interface increased. Moreover, the plot of the percentage of cells versus distance
(Figure 4-4b) showed a fairly even distribution of cells as distance increased suggesting that cells
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exposed to FGF continued to penetrate deeply into the gel in contrast to groups without FGF-2, which
stayed clustered at the interface.
In groups without FGF-2, the distance histograms (Figure 4-4a) showed an almost exponential
drop off in the number of cells with increasing distance. The plot of the percentage of cells versus
distance (Figure 4-4b) revealed a high percentage of cells very close to the interface. The presence of 0.1
mg/ml LMTs was enough to slightly inhibit cell outgrowth from the astrocyte-seeded gel.
It was noted that the number of cells infiltrating the gels tapered off after 6 days (data not
shown) suggesting a decreased driving force for outgrowth. The deep penetration (>1 mm, and up to 2
mm in some gels) of astrocytes into the gel over 10 days shows that these gels hold potential to fully
bridge SCI defects in vivo of up to 4 mm if astrocytes are infiltrating from both ends. These distances are
also promising cases of human SCI, which typically have defects smaller than a spinal segment [37].
Early repopulation of the defect will be important for forming the regenerative template for axon growth.
4.6.3 Effects of genipin
Genipin had a significant effect on preventing cellular outgrowth from the astrocyte core gel.
This finding is supported by several studies noting the anti-proliferative, anti-migratory, anti-fibrotic, and
anti-contraction effects genipin on other cell types such as fibroblasts and endothelial cells [38, 39].
A genipin concentration of 0.25 mM was chosen for this study in order to lessen potential
confounding effects on outgrowth due to cytotoxicity. As seen in Figure 4-6 there was a high density of
viable cells in the genipin-containing groups. Viability assays conducted on Col-Gen gels in the same
configuration as the outgrowth assay, showed minimal toxicity with genipin concentrations of 0.25mM
and 0.5 mM (Figure 4-11), suggesting that the cytotoxicity of the surrounding gel was not a major factor
in the observed results. Additionally, the presence of FGF either within LMTs or freely in the gel did not
significantly impact the viability suggesting that FGF-2 did not have any additional protective effect
against genipin induced toxicity.
It is also possible that the additional strength and degradation resistance imparted by genipin on
the gels prevented cellular outgrowth, however at the concentration used especially in the presence of
amine rich media which readily reacts with free genipin, the increases would only be mild and would not
account for the dramatic decrease in cell outgrowth seen [34]. Further evidence that the genipin induces a
decrease in cellular infiltration primarily through its actions on the cells as opposed to its effects on the
physical properties of the collagen gel includes: a) priming cells with genipin decreased the outgrowth
even though there were only trace amounts of genipin in the encapsulating gel due to diffusion from the
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core; b) the addition of FGF-2 dramatically enhanced cellular outgrowth although genipin was still
present; and c) genipin decreased the proliferation of astrocytes as noted in Figure 4-10.
One of the most dramatic increases (~1200%) in cell outgrowth among groups occurred when
FGF-2 LMTs were added to Col-Gen gels. The effect of FGF-2 still exhibited a lag period with cells
emerging from the gel after 3-4 days corresponding to a timeframe when the genipin was most likely fully
reacted with collagen and amines in the media and the cells could also degrade the cross-linked collagen
fibers. From the distance histogram and percentage of cells (Figure 4-4a,b) the groups containing both
genipin and FGF-2 group had a higher percentage of cells closer to the interface that the corresponding
FGF-2 group without genipin. This was most likely due to the early inhibition of outgrowth by genipin.
It is also important to note that adding free FGF-2 directly to Col-Gen gels was less effective in
promoting outgrowth than if it was loaded within LMTs, suggesting that may react with FGF-2 reducing
its bioactivity. These results suggest that the use of growth factors such as FGF-2 protected within a
secondary release vehicle such as LMTs, would be required to maintain an early cell permissive
environment within the Col-Gen gels.
Of note is that the concentration of genipin used in this study was lower than would be proposed
in an in vivo study. Since the volume of cell-seeded gel was much smaller than the volume of genipin
containing gel there was a large amount of free genipin relative to the volume of cells. In vivo the reverse
would be true and the volume of injected collagen-genipin gel would be much lower than the surrounding
tissue, thus mitigating the cytotoxicity of higher genipin concentrations while still allowing for substantial
increases in gel strength.
4.6.4 Cell phenotype
In groups without FGF-2, there was little to no chain-like outgrowth phenomena and only a few
isolated cells left the gels. However, in many instances for gels containing FGF-2, astrocytes moved in a
chain-like outgrowth fashion traveling in multiple straight lines out of the gel (Figures 4-6, 4-7). Of
specific note is the cells undergoing chain-like outgrowth had an elongated bipolar morphology similar to
radial glia, the immature cells that are supportive of axon growth during development [40]. With
increasing concentrations of FGF-2, the cells became more clustered as they left the gel forming more
disorganized clumps of stellate cells in addition to directed projections (chain-like with clustering) which
more resembled astrogliosis. The formation of directed growth is also a profound finding as it may create
an organized framework for axon migration in an otherwise non-oriented gel.
In animals capable of spinal cord regeneration, such as the newt [41] and zebrafish [42], GFAP-
positive glia serve as a bridge to facilitate axons crossing the injury site. Goldshmit, et al., showed that
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FGF signaling regulates the regenerative behavior of zebrafish glia post injury causing them to
dedifferentiate, proliferate, and migrate towards the injury site, then differentiate to adopt an elongated
bipolar morphology, and form axon growth permissive bridges across the lesion. Primate astrocytes
activated by FGF-2 adopted a similar morphology to that induced in the zebrafish glia and were able to
accelerate the defect closure in a scratch wound assay [42].
Similarly, transforming growth factor-a (TGF-a) has been show to induce the proliferation,
migration, and transformation towards a radial glia-like bipolar morphology of astrocytes and glial
progenitors, which allowing them to be highly permissive of axonal growth [43]. Intrathecal delivery or
endogenous overproduction of TGF-a (via adeno-associated virus injection) in mice was able to enhance
astrocyte infiltration and axonal growth within the injury site [43, 44].
While FGF-2 stimulates many pro-regenerative effects, it also has the potential to negatively
affect the injury site, especially at higher concentrations, which may induce gliosis or fibrosis. Many
studies support the astrogliotic effects of FGF-2 in vivo [20-24]. For example, normal brain astrocytes
exposed to high dosages of FGF-2 at 10 ug/rnl (administered to the cerebrospinal fluid) underwent
astrogliosis, while exposure to 0.5 tg/ml in CSF did not induce such changes [21]. In the same study, the
high FGF-2 dosage disrupted myelin production in mature oligodendrocytes, caused reactive changes in
oligodentrocyte progenitor cells (OPCs), and increase accumulation and activation of microglia [21]. The
lower dosage did not induce such effects and actually increased recruitment of oligodendrocytes. While
FGF-2 promotes the survival and proliferation of OPCs, it can also prevent their maturation; therefore,
high dosages could be detrimental to remyelination of newly growing and spared fibers [45].
Interestingly, injection of FGF-2 after an electrolytic injury in the brain of adult rats did not significantly
increase the level of reactive gliosis induced by the injury alone but rather accelerated the actions of the
astrocytes [20]. FGF-2 can also lead to fibroblast proliferation, which may increase the formation of scar
tissue in and around the cord [46] however, FGF-2 appears to have a positive effect on reducing scar
formation in skin wounds [47]. FGF-2 can also lead to an increased expression of endothelial cell
adhesion molecules, which could enhance the recruitment of monocytes, T cells, and neutrophils [48].
While in the present study it is unclear if the astrocytes in the encapsulating gels containing FGF-
2 will be beneficial towards regeneration in vivo, the observed chain-like outgrowth phenotype of many
astrocytes within the gels is promising. Future work should be done to best understand the phenotype of
the cells including growth factor (viz., brain-derived neurotrophic factor and neurotrophic growth factor)
and chondroitin sulfate proteoglycan production and expression of immature cell markers including
nestin, vimentin, and brain lipid binding protein.
4.6.5 Sustained delivery and dosage of FGF-2
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The FGF-2 concentrations investigated in this study showed that a wide range of dosages over
which FGF-2 may elicit pro-outgrowth effects. The range of FGF-2 concentrations investigated in this
study are appropriate for translation into an in vivo study. From our predictions the low FGF-2 LMT
group in total contained approximately 20 ng FGF-2 while the high FGF-2 group had up to 200 ng
(included encapsulated and the approximately 1% of un-removed protein from the rinse step). Prior in
vitro studies report migratory effects with as low as 20 ng/ml FGF-2 in media [11], which is comparable
to the results of this study. Literature reports of In vivo dosages of FGF-2 in models of SCI were used in
the in the range 168 ng- 21 pg total, released over 7-14 days [26, 27, 29, 49].
In the present study, it was difficult to distinguish the importance of a sustained release of FGF-2
as both free and encapsulated FGF-2 produced similar effects on the cells. There are several explanations
for this observation. Since, FGF-2 induces the expression of its own mRNA, exposure to FGF-2 may
trigger an autocrine response, within the astrocytes leading to sustained production of the growth factor
[50]. Astrocytes have been shown to secrete heparin sulfate proteoglycans (HSPGs) in vitro, particularly
when exposed to serum containing media [51]. HSPGs are essential to FGF-2 dimerization and FGF
receptor activation [52]. FGF-2 is known to strongly bind to HSPGs, so it is feasible that FGF-2 is
sequestered in the ECM surrounding the astrocytes [11]. Additionally, due to the set-up of the outgrowth
assay, it was not possible to create an "infinite sink" environment in which the growth factor could
dissipate into. At most, the growth factor concentration was decreased by 1/2 with each media change,
which occurred at 48-hour intervals. This could have given an effective sustained release in the group
containing free FGF-2 without a delivery vehicle.
Priming the astrocytes with a high concentration of FGF-2 prior to encapsulating them within a
collagen gel gave enhanced growth over non-primed cells, but did not stimulate the same degree of
infiltration, cell elongation, or chain-like outgrowth as an equivalent or I 0-fold less concentration within
the encapsulating gel. This experiment suggests that even a short exposure to FGF-2 is enough to
stimulate an increased outgrowth of astrocytes however; a more sustained external source of FGF-2 is
required for a more robust response and chain-like outgrowth.
Moving forward towards an in vivo study, there are several advantages of using a separate
delivery vehicle for FGF-2 within the collagen gels. The presence of FGF-2 LMTs appeared to increase
the penetration distance of astrocytes into the gel over groups containing free FGF (Figure 4-3),
suggesting that sustained release is important for enhancing continued movement into the gel. LMTs also
serve to protect the bioactivity of FGF-2 especially during the collagen-genipin cross-linking process.
Both the number of cells crossing the interface and their penetration distance in Col-Gen groups
containing FGF was enhanced when the FGF-2 was contained within LMTs (Figure 4-3). This also
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becomes more important as the concentration of genipin is increased. LMTs can prevent a bolus release
of FGF-2, which can have an adverse effect on gliosis and fibrosis and mentioned above. FGF-2 will also
have the potential to remain localized long enough to have a neuroprotective effects. For example,
several studies have investigated the benefits of administering FGF-2 to rodents after SCI. The delivery
of FGF-2 to moderate and severe contusion SCI via an infusion pump both rostral and caudal to the injury
resulted in enhanced functional recovery and tissue sparing [26, 49]. The authors suggested that the
beneficial effects of acute FGF-2 treatment are manifested over a 2-3 week time period after SCI. The
neuroprotective effect of FGF-2 can also be seen by enhanced tissue sparing 1-week post contusive injury
and a two-fold increase in surviving ventral horn neurons adjacent to the injury site, which, attenuated
respiratory deficits due to the injury [27, 29].
4.6.6 Proliferation
The proliferation and cellular localization data of the gel suggest that the outgrowth phenomenon
of the astrocytes was not principally due to proliferation. DAPI staining of the center of the gels showed
no significant difference in the cell number among groups, except for Col-Gen groups (Figure 4-8). The
number of cells at the edge of the gel was also fairly constant among groups with a slight increase in
number for FGF-2 containing groups. These findings are consistent with the Ki-67 immunostaining that
revealed that only a small percentage of astrocytes in the core of the outgrowth assay gel were
proliferating at 10 days, and that the number of proliferating cells was similar between control collagen
and FGF-2-containing gels (Figure 4-9). In monolayer culture, FGF-2 significantly stimulated astrocyte
proliferation in a 48-hour cell proliferation assay (Figure 4-10). Interestingly, the proliferation assay
exhibited an insignificant dose dependency over several orders of magnitude in FGF-2 concentration,
particularly in the ng/ml range relevant to the current study, and actually decreased proliferation at 50
ug/ml. Taken together these data suggest that the FGF-2-containing gels may have experienced a similar
initial burst in proliferation, with the subsequent outgrowth behavior dictated by non-proliferative FGF-2-
induced cell migration and changes in cell phenotype.
Faber-Elman, et al., previously explored the migration of astrocytes in response to the presence of
FGF-2, using a ID scratch wound assay [11]. The study showed that in response to 20 ng/ml FGF-2 in
the media, astrocytes repopulated the "wounded" area 800% more control cultures. They also
demonstrated that proliferation was not a key element of astrocyte migration in this assay as only 21-31%
of the repopulating cells in all cultures (FGF-2, control, or other growth factors) were proliferating cells.
Recently Lichtenstein, et al., showed that FGF-2 induces astrocyte migration through the activation of the
JNK and ERK or FAK signaling pathways [53]. Using a scratch wound assay, this group also showed
that FGF-2 accelerated defect closure whether or not a proliferation inhibitor cytosine arabinoside was
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added. They suggested that the acceleration was due to increased cellular polarity and migration as
opposed to proliferation.
The outgrowth assay set-up did not allow for the detection of a specific chemotactic effect
because the concentration of growth factor quickly equilibrated throughout the system In the current
work, the assay was not employed for the definitive differentiation contributing effects of proliferation
and migration on astrocyte infiltration of the gels. Future studies may be directed towards separating these
individual contributions by adding an anti-mitotic compound such as aphidicolin, demecolcin or
nocodazole to the assay. In the present study, the presence of FGF-2 had a profound effect on stimulating
infiltration of the gel, which in vivo could translate to robust repopulation of the gel-filled defect.
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Chapter 5:
Qualitative biocompatibility pilot study of
injectable collagen-genipin gels in spinal cord
injury
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5.1 Introduction and motivation
This chapter describes the early in vivo pilot tests of the injectable collagen-genipin gel in a
rodent hemi-resection model of SCI. The two formulations of gel used in this study were best guided by
the in vitro mechanical, cytotoxicity, and astrocyte outgrowth studies presented in chapters 3 and 4.
Evaluation was performed at 1 and 4 weeks post injury. It should be noted that the results in this chapter
are qualitative due to the low yield of acceptable samples for analysis due to issues with histological
processing. Nevertheless, the work presented here gave valuable insight into the feasibility of delivering
the gel into the defect and the biomaterial-tissue interaction of collagen-genipin gels with and without and
FGF-2 with spinal cord tissue. These results were later used to design a second-generation gel, which was
investigated in a complete detailed in vivo study using the same animal model (chapter 6).
5.2 Overall goal and hypotheses
The overall goal of this chapter is to investigate the feasibility and biocompatibility of injectable
collagen-genipin gels in a rodent hemi-resection model of SCI.
The hypotheses are:
1.) Collagen-genipin gels will undergo gelation sufficiently rapid enough to localize within the defect.
2.) Collagen-genipin gels are permissive to cellular infiltration
3.) A genipin concentration of 0.5 mM will not provoke a severe inflammatory response
4.) Cellular infiltration of the collagen-genipin gel will be enhanced by adding FGF-2 containing LMTs
into the gel.
5.3 Methods
5.3.1 Collagen gel fabrication Col-Gen and Col-Gen LMT FGF-2 gels were fabricated as
described in chapter 4. Briefly, ice cold Ix phosphate buffered saline (PBS), 5x PBS, IN NaOH, a stock
solution of genipin in 5x PBS (3 mg/mL), and soluble rat tail type I collagen were combined in that order
to obtain 2 mg/mL collagen solutions with 0.5 mM genipin at pH 7.5 with Ix ionic strength. LMTs loaded
overnight with 1 mg/ml FGF-2 were added to the Col-Gen LMT FGF-2 gels at 0.1 mg/ml.
5.3.2 Animal procedure Adult female Lewis rats (Charles River Laboratories, Wilmington MA)
weighing 200-220 grams were used in this study. Animal care and surgical procedures were performed at
the Veterans Administration Medical Center Animal Research Facility (Jamaica Plain, MA) and were
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approved by the VA Boston Healthcare System Institutional Animal Care and Use Committee (IACUC).
Protocol number 188-J.
The hemi-resection injury model is based off of the work performed by Cholas et al.[1] A
schematic and images of the injury model and surgical procedure is shown in Figure 5-1. The hair on the
back of the anesthetized rat was shaved and the skin was cleaned with Betadine. The rat was placed on a
flat operating board in the prone position and its limbs were gently fixed in an extended position using
rubber bands. Oxygen was continuously supplied to the rat during surgery. A longitudinal incision, 2
inches in length was made through the skin above the thoracic spine and the back musculature was
incised along the midline and dissected away from the vertebral column. A dorsal laminectomy was
performed between T7 and T1O using small bone rongeurs and microscissors. Bleeding from the muscle
was controlled by gelfoam or coagulation with a bipolar cautery. A 3 mm plastic template was placed in
the center of the exposed spinal cord and a lateral hemi-resection of the spinal cord was created by
making two lateral cuts (3 mm apart) on the left side of the spinal cord using ultra fine surgical scissors or
a surgical blade. A midline incision was then made between the lateral cuts using the dorsal spinal vein as
a midline marker. A 3 mm gap was created by removing the tissue between the two lateral cuts. Bleeding
was controlled using gelfoam placed into the defect site. Once hemostasis was achieved the gelfoam was
removed from the defect and the treatment was applied. In col-gen treatment groups, 30 microliters of gel
(kept on ice) was delivered into the defect using a computer-controlled microsyringe (Harvard apparatus)
over two minutes. After visual confirmation of gel filling and remaining localized within the defect, a
piece of collagen type I/III membrane (Bio-Gide, Geistlich Biomaterials, Wolhusen, Switzerland). In Col-
gen LMT FGF-2 treatment groups, 30 microliters of gel (kept on ice) was pipetted into the defect in two
15 microliter drops spaced 1 minute apart using a micropipette. After visual confirmation of gel filling
and remaining localized within the defect, a thin muscle fascia was placed extradurally over the defect
site (covering 2 mm past the spinal cord stumps at both ends) to serve as a dorsal barrier. Following
treatment and placement of the dorsal barrier, the overlying musculature was closed using 4-0 vicryl
sutures (Johnson and Johnson, Sommerville, NJ) and the skin was closed with wound clips.
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Figure 5-1: a.) Schematic of the left lateral hemi-resection SCI model and planes of sectioning for
histology. b.)Placement of the 3 mm plastic template on the thoracic spinal cord c.) Filling of the defect
site with collagen gel via catheter tubing connected to a computer controlled syringe pump d.) Gel filling
the defect e.) Placement of the Bioguide membrane over the defect.
Post-operative care of the animals included placement of the rat on a heating pad to maintain body
temperature, subcutaneous injection of 6 ml lactated Ringer's solution to compensate for blood loss during
surgery and dehydration, subcutaneous injection of antibiotics (cefazolin sodium 100 mg, 35 mg/kg,
Abbot Laboratories, North Chicago, IL), subcutaneous injection of an analgesic, Ketofen (5 mg/kg) and a
continuous supply of oxygen until the animals regained consciousness 4-6 hours later. After regaining
consciousness, the rats were transferred to their original plastic cage with wood chip bedding and free
access to food and water.
Analgesic (ketofen 5 mg/kg) was administered once a day for an additional 3 days post surgery for pain
relief, and antibiotics (ceftazolin, 35 mg/kg) was administered twice a day for I week post surgery to
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prevent bladder infection. Post operatively, the animals lacked a nonrnal micturition reflex and their
bladders had to be manually emptied every 12 hours using Crede's maneuver until bladder function
recovered.
5.3.3 Animal sacrifice, transcardial perfusion
Animal sacrifice was performed by transcardial perfusion. Rats were administered a dose of 150
mg/kg of sodium pentobarbital and secured to a surgical board. A thoracotomy was performed to expose
the heart, after which a needle attached to a peristaltic pump was inserted into the left ventricle and into
the ascending aorta. 100 ml of heparinized saline was circulated through the animal, followed by 150 ml
4% parafonnaldehyde. Following sacrifice, the spine was removed and placed in 60 ml 4% PFA at 4C
overnight. The following day, for the Col-Gen treatment group, the spine was trimmed of the overlying
musculature while leaving the vertebral bone and fascia over the defect intact. For the Col-Gen LMT
FGF-2 group, the vertebral bone surrounding the spinal cord was carefully and completely removed from
the surrounding vertebra using bone rongeurs, surgical scissors, and a scalpel. All of the spinal cords were
then immersion fixed in 4% PFA an additional 3 days at 4'C.
5.3.4 Histology and immunohistochemistry: Samples from the Col-Gen treatment group with
the vertebral bone still intact were decalcified in a 15% EDTA at 4C for 20 days prior to tissue
processing. The whole spinal column was then embedded in paraffin using a tissue processor
(HypercenterXP, Tissue Processor, ThermoShandon, Houston, TX). Serial sections of the defect were cut
at 6 urn with a microtome and mounted on glass slides.
Samples from the Col-Gen LMT FGF-2 treatment group were processed in two ways. For the
one-week time point, spinal cords removed from the surrounding vertebrae snap frozen in isobutene at -
30'c and embedded in OCT compound (Tissue-Tek, Sakura, The Netherlands). Serial sections were cut at
20 ptm on a cryostat (Leica Biosystems, IL, USA). For the four-week time point, spinal cords removed
from the surrounding vertebra were cut in half transversely through the center of the defect, one of these
halves was then cut coronally through the center of the tissue Figure 5-2. The samples were then paraffin
processed and sectioned as above.
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Figure 5-2: Schematic of the multi-plane sectioning
technique for four-week Col-Gen LMT FGF-2 samples.
Prior to paraffin embedding, the spinal cords were cut
in half transversely through the center of the defect and
then one of those halves was cut again coronally. The
tissue was embedded in a single block to yield two
coronal and one transverse plane per section.
Sections were stained with Masson's trichrome, hematoxylin and eosin, or IHC antibody. For
IHC staining, a labeled polymer HRP system (AEC+ system, Dako) was used to detect the presence of
antibody. Some sections were also counterstained with Mayer's Hematoxylin.
The following antibodies were used in the IHC staining of the paraffin sections containing the defect.
Hematoxylin None Sigma Nuclei- blue Cellular infiltrate
& Eosin GHS216 Cytoplastm-
HT 110232 pink
Col gel-pink
CD68 Citrate AR AbD serotec Red
(1:200) 95 0 C MCA341R
45 min 20 min Mouse
GAP-43 Citrate AR Abcam Red
(1:1000) 95 0 C AB12274 Blue
45 min 20 min Rabbit
Macrophages (M(D)
Regenerating Axons
Nuclear counterstain
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5.4 Results:
5.4.1 Appearance of the Col-Gen gel via Masson's trichrome staining
Paraffin embedded Col-Gen gels (both in vitro and in vivo) appear as light blue amorphous areas
with a few noticeable fiber like structures when stained with Masson's trichrome Figure 5-3.
a.)
c.)Fd.)
Figure 5-3: Appearance of the Col-Gen gel in Masson's trichrome stained paraffin sections a.) In vitro
containing primary astrocytes. Scale bar 200 ptm. b.) In vivo at one-week post injury. Coronal section.
Pale blue area is col-gen gel. c.) In vivo at four weeks. Sagital section, scale bar 1000 [im. d.) Polorized
light microscopy of the same image in c.) showing the high birefrigence of the endogenously produced
collagen matrix and relative lack of birefrigence in the col-gen gel. Of note is the reasonable amount of
amout un-degraded gel (light blue) within the defect of this animal at four weeks. Bands of elongated
fibroblast-like cells can be seen traversing through the gel in some areas while in others the gel is largely
unpopulated by cells.
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5.4.2 Response at one-week Col-Gen treated animals
The success of the surgery (proper anesthesia, controlled bleeding), was noted to have a
substantial impact on the severity of the spinal cord injury noted at one week Figure 5-4. At one extreme,
in one animal the bleeding was so extensive that it resulted in a hematoma encompassing the entire width
of the spinal cord. On the other extreme, one animal had a hemi-section injury with no damage to the
contralateral white matter.
a.) Figure 5-4: Masson's trichrome
stained coronal sections showing
the extremes in injury severity at
one week a.) Complete
destruction of the spinal cord and
large hematoma formation b.)
Hemi-resection injury with full
sparing of contralateral white
matter.
b )
At this time point, there is an expansion in defect area depending on the degree of secondary
damage after creation of the primary lesion. The lesion site is filled with cellular debris, red blood cells,
and foamy macrophages. There is a substantial degree of infiltration by connective tissue cells with a
fibroblast-like appearance that secrete a collagenous ECM. Varying amounts of non-degraded gel can be
found in the defect. Within the non-degraded gel, a low density of cells can be observed. Astrocytes are
localized to the border of the spared tissue. Figure 5-5.
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Figure 5-5: Coronal section of the defect in Col-Gen treated animals at I week a.) Masson's trichrome
staining showing a heavy infiltration of cells and the presence of a small amount of un-infiltrated gel.
Scale bar 1000 [tm b.) Magnification of the inset in a.) c.) GFAP staining showing astrocytes localized at
the border of the lesion. Astrocytes did not survive in areas of secondary damage.
The defect site and any areas of secondary damage/degeneration are heavily infiltrated by CD68+
macrophages. There is a significant amount of angiogenesis occurring by one week as noted by the
population of VWF+ endothelial cells within the defect, forming noticeable blood vessels. Several GAP-
43+ axons can be seen at the white matter bordering of the defect, however these cells do not enter the
defect Figure 5-6.
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Figure 5-6: Coronal IHC stained sections for a.) CD68 (macrophages) b.) VWF (endotheial cells/blood
vessels) c.) GAP-43 regenerating axons. By one-week the defect and areas of secondary damage are
heavily infiltrated by macrophages. There is a substantial degree of angiogenesis occurring within the
injury site but no regenerating axons can be found within the defect. Scale bar 1000 urm
5.4.3 Response at four-weeks Col-Gen treated animals
Hematoxlin and eosin staining of Col-Gen gel within the defect at four-weeks showed a normal
wound healing inflammatory response to injury. Connective tissue can be seen forming around the gel
and no atypical inflammatory cells (eosinophils, basophils, plasma cells) could be identified Figure 5-7.
Figure 5-7: Hematoxylin & eosin image
of the col-gen gel at 4 weeks post injury.
Endogenous connective tissue can be
seen adjacent to the gel. Few cells can be
seen within the non-degraded gel. There
is no noticeable presence of atypical
inflammatory cells (eosinophils,
basophils, or plasma cells). Scale bar 100
[LM
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At four-weeks the defect was filled with connective tissue and contained several cavitary areas.
Ingrowth of fibrous connective tissue was noted from the veterbra adjacent to the defect. A small amount
of non-degraded gel can also still be identified within the defect. Astrocytes could be seen growing into
the fibrous tissue on the lateral border of the defect. and a small number of blood vessels could be found
in the fibrous tissue of the defect. Figure 5-8.
b.)
C.)
Figure 5-8: Coronal sections of Col-Gen treated animal 4 weeks post injury. a.) Masson's trichrome
stained section illustrating the ingrowth of fibrous connective tissue from the vertebra adjacent to the
defect. A small amount of non-degraded gel can still be found within the defect. b.) GFAP IHC section of
defect showing a small band of contralateral spared tissue and an ingrowth of astrocytes into the fibrous
tissue on the lateral border of the defect. c.) VWF IHC section further into the defect showing a small
number of blood vessels within the defect. This sectional also shows region of greater tissue sparing
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5.4.4 Response at one-week Col-Gen LMT-FGF-2 treated animals
Analysis of Col-Gen LMT FGF-2 treated animals at one-week was limited to Masson's trichrome
staining. At one-week there is noticeable disruption to the tissue architecture around the defect area and
varying extents of dense connective tissue infiltration Figure 5-9. In one sample, a central region of blood
clot-gel mixture was found within the defect.
a.)
d.) MjE Mf
Figure 5-9: a.) Coronal section through the defect at one week for a Col-Gen LMT FGF-2 treated animal.
There is noticeable disruption to the tissue architecture around the defect area. There is a central region of
un-degraded gel/clot. Frozen section, Masson's trichrome, scale bar 1000 stm. b.) Higher magnification
image of the tissue inside the un-degraded gel/clot in a.) There is a fibrillar collagenous matrix inclusive
of many cells. c.) Gross-image of the spinal cord corresponding to the image in a.) -the central region
appears to contain substantial blood. d.) Coronal section through the defect of another animal from the
same treatment group showing substantially more fibrous tissue infiltration than the animal in a.)
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5.4.5 Response at four-weeks Col-Gen LMT-FGF-2 treated animals
At 4 weeks, the gross appearance of the spinal cord in several animals was severely stenotic and
histology analysis of the defect revealed the lesion consisted of dense collagen scar tissue Figure 5-10.
a.) Figure 5-10: a.) Gross image of a
spinal cord for a Col-Gen LMT FGF-2
treated animal at four-weeks displaying
severe stenosis. Corresponding b.)
Masson's trichrome c.) CD68 stained
transverse sections through the defect.
b.) The defect has been filled with dense
connective tissue which adhered to the
overlying fascia, pulling it into the
defect. There is substantial macrophage
infiltration and tissue destruction of the
contralateral white matter.
Four-weeks post injury, the defect site of all most animals (n=5/6) treated with col-gen LMT
FGF-2 was filled with a dense fibrotic scar with severe contralateral tissue destruction and fibrous tissue
infiltration Figure 5-11. Some areas of dense fibrous scar stained positive for GFAP indicating that
astrocytes were present in the newly formed tissue. The fibrous scar stained for numerous VWF positive
endothelial cells suggesting significant angiogenesis was taking place. Macrophages were present
throughout the areas of secondary damage and fibrous infiltration of the spinal cord tissue adjacent to the
defect. Macrophages were generally excluded from the areas of dense fibrous tissue formation within the
defect. Only one animal showed a half-width injury without significant fibrous/inflammatory infiltration
of the contralateral tissue. Within the defect of that animal, there was a dense fibrous scar surrounding a
cystic cavity with little astrocyte infiltration of the defect Figure 5-12.
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a.) b.1
c.) d.)
Figure 5-11: Transverse sections through the center the defect of an animal treated with Col-Gen LMT
FGF-2 which did not have a large degree of stenosis at the level of the defect. a.) Masson's trichrome
staining showing dense collagenous scarring on the defect side as well as fibrous infiltration of
contralateral white matter. b.) VWF staining demonstrating the high degree of vascularity in the fibrous
and spared tissue. c.) CD68 staining noting the heavy macrophage infiltration of the contralateral white
matter (note the correlation to the areas of fibrous infiltration in a.) very few macrophages can be seen in
the dense fibrous tissue of the defect. d.) GFAP staining showing growth of astrocytes into the fibrous
defect tissue. Also of note is the disruption of normal astrocyte morphology in the areas of
macrophage/fibrous infiltration.
a.) bFigure 5-12: Coronal
sections of a Col-Gen LMT
FGF-2 treated animal with
limited secondary damage.
a.) Masson's trichrome
stained section showing
dense a lateral dense
collagenous scar and cystic
center. Scale bar 1000 [tm
b.) GFAP stained section
noting limited astrocyte
infiltration into the defect.
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5.5 Discussion:
The discussion section of this chapter will be focused on the optimization of procedure and
methods for the in vivo study. A thorough quantitative investigation of the cellular response to gel
implantation and the associated functional recovery will be presented in chapter 6.
5.5.1 Application of a Col-Gen gel to the hemi-resection defect:
The presence of Col-Gen gel within the defect at one and four weeks post injury Figure 5-3b,c
demonstrates that the liquid solution of collagen can successfully gel inside of the defect and remain
localized to this area throughout the four-week survival period. Areas of un-degraded gel could easily be
identified from endogenous collagen production by its pale blue amorphous appearance and low
birefringence under polarized light microscopy Figure 5-3d. Areas of non-degraded gel could be found in
2/6 samples at one week and 3/8 samples at four weeks. As illustrated by Figure 5-7 there was a lack of
significant inflammatory infiltrate in or around the gel itself.
It is unclear why some areas of gel are largely devoid of cells at four weeks. The results from
chapter 4 suggest these gels are permissive of cell migration so it is possible that the areas of non-
degraded gel were walled off by infiltrating connective tissue cells and subsequently contracted making
them isolated from the rest of the infiltrating tissue and too dense for cells to penetrate. The bands of cells
in Figure 5-3b suggest that imperfections in the gel created by mixing with blood (noticeable in figure 5-
2b), which are more heavily infiltrated by cells then the original collagen gel.
By four-weeks, the defect evolves into a mixture of connective tissue and cavitary/cystic areas
with limited astrocyte in-growth Figure 5-8. This type of response is characteristic of an "open" lesion
where there is no longer an intact dura to prevent surrounding connective tissue cells from infiltrating the
defect.[2] While the Bioguide membrane provided some barrier to infiltrating cells, it did not prevent
their entry into the defect, particularly from the adjacent vertebrae Figure 5-8a.
5.5.2. Addition LMTs loaded with 1 mg/ml FGF-2 to the Col-Gen gel
Unexpectedly, the concentration of FGF-used in this study resulted in substantial fibrosis, spinal
cord stenosis, and contralateral tissue destruction by four-weeks post implantation Figures 5-10, 5-11.
One likely basis for this is an overstimulation of fibroblast proliferation, migration, and matrix production
in the meninges and connective tissue adjacent to the spinal cord. [3] Since a substantial amount of
fibrous tissue was found in Col-Gen treated animals without additional FGF-2, further stimulation of
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fibroblasts could lead to the observed results. FGF-2 can also lead to an increased expression of
endothelial cell adhesion molecules, which could enhance the recruitment of monocytes, T cells, and
neutrophils. [4] FGF-2 has also been reported to increase the accumulation of microglia in vivo [5] An
intensification of the inflammatory response due to this increased recruitment of cells could explain the
substantial destruction and macrophage infiltration of the contralateral tissue.
Also of note was the homogeneity in astrocyte infiltration of the defect Figures 5-11d, 5-12a.
One source of this variation could be the presence of physical barriers, which would block astrocyte
migration into the defect such as dense scar tissue and necrotic cavities Figure 5-12a. It is also possible
that the concentration of FGF-2 used caused significant astrogliosis resulting in the formation of a more
robust glial scar at the border of the defect. FGF-2 has been implicated in stimulating astrogliosis both in
vitro [6, 7] and in vivo [5, 8-11]. However, this effect is concentration dependent. Normal brain
astrocytes exposed to FGF-2 at 10 [tg/ml (administered to the cerebrospinal fluid) underwent astrogliosis,
while exposure to 0.5 pig/ml in CSF did not induce such changes [5] In the same study, the higher FGF-2
dosage also disrupted myelin production in mature oligodendrocytes, caused reactive changes in
oligodentrocyte progenitor cells (OPCs), and increase accumulation and activation of microglia [5].
From our predictions the Col-Gen LMT FGF-2 gels contained approximately 200 ng/ml FGF-2
(including encapsulated and the approximately 1% of un-removed protein from the rinse step) equivalent
to 6 ng total in the injected volume. This amount is much lower than Prior in vivo dosages of FGF-2 in
models of SCI, which ranged from 168 ng- 21 jig total, released over 7-14 days. [12-15] The discrepancy
between the observed and reported results suggest that either a much higher concentration of FGF-2 was
actually loaded into the LMTs or the nature of the hemi-resection defect (unlike the previously reported
contusion injuries) is substantially more prone to fibrosis.
5.5.3 Optimization of the procedure and methods for the animal study
In addition to the formulations of the Col-Gen gel treatments, several different procedures and
methods were tested in this study to determine the optimum way to conduct the remainder of the animal
studies. They included a.) Choice of dorsal barrier to cover the injury b.) Method of delivering the gel to
the defect site c.) Histological plane of sectioning d.) Frozen vs. paraffin sections e.) Decalcifying vs.
removing the spinal cord from the bone
In terms of selecting a dorsal barrier to cover the spinal cord after surgery, the Bio-Gide collagen
membrane used in the Col-Gen group was replaced by autologous fascia in the Col-Gen LMT FGF-2
group. The Bio-Gide membrane was replaced for two main reasons. Firstly, the thickness and weight of
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the membrane sometimes caused it to collapse into the defect thus impinging on the gel. Secondly, the
membrane was an additional biomaterial being placed within the defect and had the potential to cause an
inflammatory reaction separate from the collagen gel itself. The Bio-Gide membrane also did not appear
to prevent connective tissue infiltration of the injury site. Autologous fascia was chosen as a replacement
to the membrane because it is a thin, lightweight, non-reactive layer to cover the injury.
Using a computer-controlled syringe pump for the controlled delivery of the gel was effective but
was cumbersome to use during surgery and the large open nature of the hemi-resection defect did not
require precise delivery. The length of plastic tubing needed to operate the pump required it to be filled
with a much large volume of gel compared to the amount delivered to the defect. It also encountered
difficulty extruding the gel if an air bubble was caught within the line. Pipetting the gel directly into the
defect using a micropipette proved to be a simple and effective way to ensure proper filling and
localization of the gel. To provide some temporal control over the administration of the gel, the solution
was delivered in 2 equal boluses, which allowed some time for the gel to set within the defect. As noted
in Figure 5-9a the gel was still able to localize within the defect.
A coronal (also known as longitudinal) histological plane of sectioning was used in the Col-Gen
group while a multi-plane sectioning modality (transverse and two half longitudinal) was attempted in the
Col-Gen LMT-FGF-2 group. The multi-plane modality involved cutting the spinal cord in half through
the center of the defect and then cutting one of the halves in half, creating two pieces through the center
of the defect Figure 5-2. The longitudinal plane allowed for a top-down view of both spared and injured
sides of the spinal cord tissue, while the multi-plane sectioning allowed for simultaneous viewing of a
transverse and two longitudinal sections. While useful in theory, in practice the multi-plane sectioning
proved difficult to interpret as gross cutting of the spinal cord tissue resulted in off-angle planes and un-
even amounts of defect tissue contained in each half, which made comparisons between animals difficult.
All of the spinal cord tissues were embedded in paraffin except for the 1-week col-gen LMT
FGF-2 group. Frozen sections were employed to try and better preserve the gel at early time points
however, the low quality of cellular detail compared to paraffin sections limited the usefulness of this
method and it was not used further.
Most of the samples in the col-gen group were sectioned with the spinal cord still encased by the
decalcified vertebrae. Two of the 1-week col-gen group samples as well as all of the Col-Gen LMT FGF-
2 samples had the spinal cord removed from the bone before embedding in paraffin. Keeping the bone
around the spinal cord had the advantage of not disrupting the defect site prior to sectioning but due to the
differences in modulus between bone and spinal cord/defect tissue and areas of incomplete decalcification,
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many rips and tears occurred in the tissue, which made it difficult to interpret the contents of the defect
area in most samples. Removing the tissue from the bone prior to embedding carried the risk of
damaging or destroying the delicate tissue within the defect. However, given the high quality of the
sections obtained from spinal cords without the surrounding bone and success of preserving tissue during
removal from the bone, it was decided that all further samples were to be removed from the bone before
sectioning. Interestingly, samples which contained the vertebra were able to be sectioned much more
effectively if the paraffin blocks were melted, the tissue removed from the bone, and the sample re-
embedded.
Overall, the various processing and surgical methods used in this study, as well as the observed
tissue responses to Col-Gen and Col-Gen LMT FGF-2 treatments were very useful in guiding the
subsequent animal experiments and gel formulations. For the next set of animal experiments, specific
changes to the gel formulation were employed. They included increasing the concentrations of both
collagen and genipin to 3mg/ml and 1 mM respectively, in order to enhance their resistance to early
cellular infiltrate, and decreasing the FGF-2 concentration within LMTs by 50 fold to prevent the massive
fibrotic and inflammatory response seen in this study.
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Chapter 6:
Biomaterials-tissue interaction of a
second-generation collagen-genipin gel
containing FGF-2 in a rodent hemi-
resection model of SCI
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6.1 Introduction and motivation
Building upon the in vitro studies presented in chapters 3 and 4, as well as the pilot in vivo study
in chapter 5, this chapter investigates the use of an improved second generation collagen-genipin gel in
the hemi-resection model of SCI. Based on the biocompatibility of the 2mg/ml collagen 0.5 mM genipin
gel, it was determined that a higher concentration of genipin will be well tolerated. To this extent, a more
robust 3mg/ml I mM genipin gel was used to increase resistance to early connective tissue infiltration of
the gel and defect. Additionally, a 50 fold lower concentration of FGF-2 was employed to mitigate the
robust fibrous scarring and tissue destruction, which occurred in the pilot FGF-2 containing gel. Four
weeks was chosen as the principal investigation time for this study since it correlates to stabilization in
functional recovery, inflammatory response, and glial scar.[1] Therefore, the tissue matrix formed within
the defect at 28 days allows for a good comparison of the regenerative response between the groups.
6.2 Overall goal and hypotheses
The overall goal of this chapter is to provide an in vivo histological study of the early chronic
tissue response to injection of Col-Gen gels in a standardized hemi-resection defect in the rat spinal cord.
Specifically, the work in this chapter is aimed at elucidating how the presence of Col-Gen gels with and
without FGF-2 changes the extent of damage which occurs after a hemi-resection SCI, as well as the
composition of the tissue formation (cellular and extracellular) within the defect.
The hypotheses for this chapter are:
1.) The injectable Col-Gen gel cross-linked in vivo, will re-create a continuous tissue matrix after hemi-
resection SCI thus allowing for cellular population of the defect site after injury.
2.) The presence of FGF-2 containing LMTs within Col-Gen gels will have a neuroprotective effect,
resulting in an increased amount of tissue sparing after injury as compared to control animals.
3.) The presence of FGF-2 containing LMTs within Col-Gen gels will alter astrocyte localization after
injury and increase the number astrocytes within the defect
4.) The presence of FGF-2 containing LMTs within Col-Gen gels will result in an increased number of
endothelial cells and blood vessels within the defect
5.) Tissue bridges created via cellular infiltration and extracellular matrix deposition within the lesion site
will allow for the growth of regenerating axons into the defect.
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6.3 Methods
6.3.1 Collagen gel fabrication: Col-Gen and Col-Gen LMT FGF-2 gels were fabricated as
described in chapter 4. Briefly, ice cold lx phosphate buffered saline (PBS), 5x PBS, IN NaOH, a stock
solution of genipin in 5x PBS (3 mg/mL), and soluble rat tail type I collagen were combined in that order
to obtain 3 mg/mL collagen solutions with 1 mM genipin at pH 7.5 with lx ionic strength. LMTs loaded
overnight with 0.02 mg/ml FGF-2 were added to the Col-Gen LMT FGF-2 gels at 0.1 mg/ml.
6.3.2 Animal procedure: Adult female Lewis rats (Charles River Laboratories, Wilmington MA)
weighing 200-230 grams were used in this study. Animal care and surgical procedures were performed at
the Veterans Administration Medical Center Animal Research Facility (Jamaica Plain, MA) and were
approved by the VA Boston Healthcare System Institutional Animal Care and Use Committee (IACUC).
Protocol number 188-J.
The hemi-resection model used in this study was based on the work of Cholas et al.[2] The hair
on the back of the anesthetized rat was shaved and the skin was cleaned with Betadine. The rat was placed
on a flat operating board in the prone position and its limbs were gently fixed in an extended position
using rubber bands. Oxygen was continuously supplied to the rat during surgery. A longitudinal incision,
2 inches in length was made through the skin above the thoracic spine and the back musculature was
incised along the midline and dissected away from the vertebral column. A dorsal laminectomy was
perforned between T7 and T10 using small bone rongeurs and micro-scissors. Bleeding from the muscle
was controlled by gelfoam or coagulation with a bipolar cautery. A 3 mm plastic template was placed in
the center of the exposed spinal cord and a lateral hemi-resection of the spinal cord was created by
making two lateral cuts (3 mm apart) on the left side of the spinal cord using ultra fine surgical scissors or
a surgical blade. A midline incision was then made between the lateral cuts using the dorsal spinal vein as
a midline marker. A 3 mm gap was created by removing the tissue between the two lateral cuts. Bleeding
was controlled using gelfoam placed into the defect site. Once hemostasis was achieved the gelfoam was
removed from the defect and the treatment was applied. In gel treatment groups, 30 microliters of gel
(kept on ice) was pipetted into the defect in two 15 microliter drops spaced 1 minute apart using a
micropipette. After visual confirmation of gel filling and remaining localized within the defect, a piece of
thin muscle fascia was placed extradurally over the defect site (covering 2 mm past the spinal cord stumps
at both ends) to serve as a dorsal barrier. For the control group, the fascia was applied after hemostasis
was achieved.
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Following treatment and placement of the dorsal barrier, the overlying musculature was closed
using 4-0 vicryl sutures (Johnson and Johnson, Sommerville, NJ) and the skin was closed with wound
clips.
Left lateral hemi-resection (T8)
7f#l - 1
Pipette to fill
30 ml
Histological
Plane of analysis
Placement of biomaterial
Dural la ent
iilagn geten gel
Figure 6-1: a.) (Left) Schematic of the 3 mm T8 left lateral hemi-resection spinal cord injury noting
the histological plane of analysis (longitudinal section). (Right) Schematic of the biomaterial and
autologous fascia (dural replacement) position within the defect. b.) T2 weighted MRI of the
histological plane of analysis, showing the orientation histology sections will be presented in this
chapter. c.) Surgical pictures of gel implantation showing (Left) filling of the defect and (Right) dural
replacement using a piece of autologous fascia.
Post-operative care of the animals included placement of the rat on a heating pad to maintain body
temperature, subcutaneous injection of 6 ml lactated Ringer's solution to compensate for blood loss during
surgery and dehydration, subcutaneous injection of antibiotics (cefazolin sodium 100 mg, 35 mg/kg,
Abbot Laboratories, North Chicago, IL), subcutaneous injection of an analgesic, Ketofen (5 mg/kg) and a
continuous supply of oxygen until the animals regained consciousness 4-6 hours later. After regaining
consciousness, the rats were transferred to their original plastic cage with wood chip bedding and free
access to food and water.
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a.)
c.)
b.)
Analgesic (ketofen 5 mg/kg) was administered once a day for an additional 3 days post surgery
for pain relief, and antibiotics (ceftazolin, 35 mg/kg) was administered twice a day for I week post
surgery to prevent bladder infection. Post operatively, the animals lacked a normal micturition reflex and
their bladders had to be manually emptied every 12 hours using Crede's maneuver until bladder function
recovered.
6.3.3 Animal sacrifice, transcardial perfusion: Animal sacrifice was perfonned by transcardial
perfusion. Rats were administered a dose of 150 mg/kg of sodium pentobarbital and secured to a surgical
board. A thoracotomy was performed to expose the heart, after which a needle attached to a peristaltic
pump was inserted into the left ventricle and into the ascending aorta. 100 ml of heparinized saline was
circulated through the animal, followed by 150 ml 4% paraformaldehyde. Following sacrifice, the spine
was removed and placed in 60 ml 4% PFA at 4'C overnight. The following day, the bone overlying the
spinal cord was removed to enhance the exposure of the spinal cord to fixative while still maintaining a
straight configuration, and the cords were allowed to fix for another 2 days at 4'C. Alternatively, after
perfusion, the spine was trimmed of the overlying musculature while leaving the fascia over the defect
intact and drop fixed in 4% PFA at 4'C for four days.
6.3.4 Histology and immunohistochemistry (IHC): Prior to tissue processing, the spinal cord
tissue was carefully and completely removed from the surrounding vertebra using bone rongeurs, surgical
scissors, and a scalpel. The spinal cord parenchyma was embedded in paraffin using a tissue processor
(HypercenterXP, Tissue Processor, ThennoShandon, Houston, TX). Serial longitudinal sections of the
defect were cut at 6 tm with a microtome and mounted on glass slides.
Adjacent tissue sections were stained with Masson's Trichrome for general observation of the
cellular and extracellular matrix features of the defect, particularly the presence of collagenous tissue
within the defect. Sections from approximately the same level of cord (middle of the defect) were used
for trichrome and IHC analysis. A labeled polymer HRP system (AEC+ system, Dako) was used to detect
the presence of antibody. Some sections were also counterstained with Mayer's Hematoxylin.
The following antibodies were used in the IHC staining of the paraffin sections containing the defect.
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Masson's
Trichrome
None Sigma
HT15
Nuclei- black
Cytoplasm- red
Collagen- blue
Viable tissue
Fibrous Scar
Gel
GFAP Protease Dako Red Astrocytes
(1:1000) XIV Z0334
45 min 20 min Rabbit
CD68 Citrate AR AbD Red Macrophages (M(D)
(1:200) 95 0C serotec
45 min 20 min MCA341R
Mouse
a-SMA Citrate AR Sigma Red Contractile fibroblasts, pericytes
(1:400) 95 0C A2547
45 min 20 min Mouse
VWF Protease Dako Red Endothelial cells/blood vessels
(1:100) XIV A0082
60 min 40 min Rabbit
GAP-43 Citrate AR Abcam Red Regenerating Axons
(1:1000) 95 0 C AB12274 Blue Nuclear counterstain
45 min 20 min Rabbit
Laminin Protease Abcam Red ECM molecule
(1:100) XIV 11575 Basement membrane
30 min 40 min Rabbit
Fibronectin Protease Abcam Red ECM molecule,
(1:100) XIV Ab6328 Blood clot
30 min 40 min Mouse
CS-56 High pH Abcam Red ECM (Chondroitin sulfate
(1:200) AR 95 0 C Abl1570 proteoglycans)
60 min 20 min Mouse
P75 High pH Millipore Red NGF receptor (Schwann cells)
(1:200) AR 950 C AB1554
60 min 20 min Rabbit
(AR) Antigen retrieval solutions: Protease XIV (0.1% in tris buffered saline), Citrate (10 mM
sodium citratre, 0.05% tween 20, pH 6.0), High pH (Vector labs cat# H3301 pH 9.0)
6.3.5 Image quantification: Images were imported into Photoshop CS5 and processed to isolate
the areas of staining within the defect and obtain the area of the defect.[3] Positively stained cells were
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either counted manually or the percentage staining area was calculated using ImageJ 1.45s. (see appendix
for more detailed procedure of image analysis and validation of area-cell count relationship). This
procedure is similar to previously published studies on cell quantification after SCL.[4] For GAP-43
analysis, a grid (63784 pixels 2) was placed over the image, which broke the defect up into 20-30 sections
depending on its size. The number of boxes containing positive GAP-43 staining was counted for each
animal.
6.3.6 Functional Evaluation: Animals were evaluated each week until sacrifice using an open
field locomotor test. The rats were removed from their cages and videotaped walking in an open space.
Hind-limb function was evaluated using a scoring system modified from Wrathall et al. [5] The tine
required for each animal to recover bladder function, defined by the time till the animal had a completely
empty or very small (few drops of urine) bladder upon manual expression, was recorded.
Score Behavior
0 No hind limb movement, flaccid paralysis
I Non-weight bearing, spastic uncontrolled hind-limb movement
2 Non-weight bearing, controlled hind-limb movement
3 Partial weight bearing, wide gait, can get hind-limb under body once in a while
4 Partial weight bearing, more frequent stepping still has a wide gait
5 Full weight bearing, hind-limb under body most of the time, movement is slow/jagged
6 Full weight bearing, fast hind-limb movement but has some limp
7 Full weight bearing, normal gait
6.3.7 Statistical analysis and sample size determination
Our power calculation for sample size determination is based on the desire to determine
significant a 30% difference in a selected outcome variable with a 15% standard deviation, and with
ax=0.05 and =0.05.
The statistical significance of treatment on histomorphometric and IHC staining results were
determined by one-way ANOVA analysis using Fishers Post Hoc testing. Non-parametric data such as
functional score was analyzed for statistical significance using the Mann-Whitney U test, Wilcoxon
signed rank test, or Chi squared test.
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6.4 Results
6.4.1 Functional Evaluation
Wilcoxon matched pairs test showed a significant improvement in left leg functional score
between I and 4 week for Col-Gen (p=0.0277) and Col-Gen LMT FGF-2 (p=0.0 4 3 1) groups but not for
the control group. While there was a trend in increasing functional score for right and left hind-limbs with
Col-Gen and Col-Gen LMT FGF-2 treatment as compared to control, no statistical significance was found
in the scores between treatment groups for either leg at 1 or 4 weeks Figure 6-2a,b. To account for
differences in baseline functional score, each animal was used as its own control and the number
difference in functional score between one and four weeks was tabulated Figure 6-2c. There was an
increase but no statistical difference between animals improving by 2 more points on the functional scale
between control and Col-Gen LMT FGF-2 animals for both left and right legs.
Left (ipsilateral)
5
-3
0
1 wk 4wk lwk
Figure 6-2: Top: functional evaluation of left and right hind-limbs at I
Bottom: Tabulation of the improvement in functional score from week
right hind-limbs of each animal. N=6-7 Mean ± SEM.
"""'Control
Col-Gen
LMT FGF-2
4wk
and 4 weeks post injury.
I to week 4 on the left and
A reasonable correlation between the average of the left and right hind-limb functional scores of each
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Right (contralateral)
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Control 1 2 1 3
Col-Gen 0 0 4 2
Col-Gen LMT FGF-2 0 1 0 5
RIGHT
Control 0 3 3 1
Col-Gen 0 1 1 4
Col-Gen LMT FGF-2 1 0 1 4
-T- - -- - -
animal and the percentage of spared tissue in the peri-lesional area Figure 6-3a, width of the spared
contralateral white matter at its most narrow point Figure 6-3b, and time to the return of bladder function
Figure 6-3c. There was no notable correlation between the functional score and any other
histomorphologic or IHC staining metric. It should be noted that the R2 of Figure 6-3a increases to 0.713
if the outlying animal (74% spared tissue 3 functional score), which had a small half width injury in the
middle plane of the defect but extensive fibrous tissue infiltration of the dorsal columns and adjacent gray
matter, is removed.
Bladder function returned for 3/7 control, 4/6 Col-Gen treated, and 5/6 Col-Gen LMT FGF-2
treated animals during the 28 day survival period. Of note, one of the Col-Gen LMT FGF-2 animals,
which recovered bladder function at 3 days, lost the ability to void on its own at day 16 and continued to
have some degree of urine retention for the remainder of the study period. The average time to return of
bladder function for those animals, which did recover the ability to void was not significant between the
groups.
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Figure 6-3: Correlation of average
80 functional score (right & left hind-
limbs) with a.) Percentage of spared
tissue in the peri-lesional area
(R2=0.713 with removal of the
outlying animal). Red= control,
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6.4.2 Early analysis of the defect at one day and one week post injury
Several animals were sacrificed at one day and one-week post injury to provide a qualitative
assessment of the acute injury phase and integration of the Col-Gen gel with the surrounding tissue. After
one day, the Col-Gen gel can be localized within the hemi-resection defect and is mixed to varying
degrees with blood from the hemorrhage within the spinal cord parenchyma or bleeding into the defect
from the surrounding musculature Figure 6-4a. Notably, the gel is able to conform to the defect and bond
directly to the tissue Figure 6-4b.
b.
Figure 6-4: Masson's trichrome images of the defect site one-day post injury and injection of the Col-
Gen gel. a.) Image of a section towards the ventral aspect of the spinal cord showing blood (red)
mixing with collagen gel (blue) in the defect cavity. Contents of the defect cavity were pushed out
during histological sectioning. Scale bar 1000 [im a'.) Magnified image of the inset in a. Scale bar 500
[rm b.) Image of the section in the middle of the spinal cord demonstrating the close bonding of the
tissue with the implanted col-gen gel. Scale bar 400 um. Most of the gel in the defect was lost during
removal of the spinal cord from the vertebra after sacrifice. Images taken at a 4x or IOx objective.
Histology of the lesion site at one week reveals the varying degrees of secondary damage, which
occur after the initial hemi-resection injury Figure 6-5. At this time-point in both control and Col-Gen
treatment groups, the defect area is heavily infiltrated by cells, many of which appear to be of connective
tissue origin and appear to be synthesizing a collagenous ECM (noted by the light blue staining in
Masson's trichrome). At one week, most of the Col-Gen has been degraded/remodeled and a few areas of
un-degraded gel can be found (insets Figures 6-5 b',c').
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Figure 6-5: Masson's trichrome images of the defect at one week of control and Col-Gen treated
animals. a.) Longitudinal section of a control animal showing extensive secondary damage and
infiltration of connective tissue cells within the defect and the deposition of a collagenous ECM a'.)
Magnified image of the inset in a. showing a heterogeneous cell infiltrate b.) Longitudinal section of
an animal treated with Col-Gen gel showing extensive secondary damage and cellular infiltration b.)
Magnified image of the inset in b. demonstrating a small amount of un-degraded Col-Gen gel (light
blue amorphous deposits) c.) Longitudinal section of an animal treated with Col-Gen gel with little
secondary damage to the contralateral tissue c') Magnified image of the inset in c. demonstrating un-
degraded gel and gel blood mix. Images taken at 4x objective. Scale bar (a,b,c) 1000 [tm (a',b',c') 500
Rm.
To further elucidate the composition of the defect at one week, sections of Col-Gen animals were stained
with CD68, fibronectin, and laminin Figure 6-6. Agreeing with the hypercellularity noted at one week,
the defect is rich in fibronectin (component of blood clotting and matrix for cellular infiltration), laminin
(major component of the basal lamina), and macrophages (inflammatory cells and mediators of tissue
remodeling). VWF+ endothelial cells can be seen migrating in from the viable tissue. GFAP+ astrocytes
are absent from the defect. Interestingly, the fibronectin staining is most dense in the center while the
laminin, VWF, and CD68 staining is most dense at the edges of the defect.
146
a.
e.)
Figure 6-6: IHC staining for a. fibronectin b. laminin c. CD68 d. VWF and e. GFAP in sections
of Col-Gen gel treated animals corresponding to the section in figure 6-3b. Of note is the dense
fibronectin matrix significant of a blood clotting within the defect. Laminin reactivity is most prominent
in endothelial cells within the defect and cellular infiltration at the borders of the viable tissue.
Macrophages can be seen through the defect and increase in density towards the edge of the defect.
VWF+ endothelial cells can be seen migrating in from the viable tissue. GFAP+ astrocytes are absent
from the defect. Images taken at 4x objective, scale bar = 1000 [tm
6.4.3 Histomorphologic assessment of the extent of injury and new tissue formation within
the defect at 4 weeks
Depending on the degree of secondary damage occurring after the primary hemi-resection injury,
each of the animals in this study can be classified as having one of three major responses to injury
(Figure 6-7). The exact composition of new tissue formation within the defect (i e. percentage of dense
collagenous scar, loose granular matrix, cavitary macrophage filled) varied between animals and between
treatments. There was also a difference in the number of animals exhibiting each response depending on
treatment group, although the sample size was too small find statistical significance.
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Control Col-Gen Col-Gen LMT FGF-2
2/7 2/6 4/6
Type B 2/7 3/6 2/6
Type C 3/7 1/6 0/6
Not Observed
Figure 6-7: Representative longitudinal Masson's Trichrome stained sections through the center of the
spinal cord defect for each treatment group (columns) 4 weeks post injury demonstrating the three main
responses to injury (rows). Type A: half width defect; Type B: greater than half width with some tissue
sparing; Type C: full width defect. The number of animals in each treatment group exhibiting the
specific response type is listed above the image. 4x objective, scale bar =1000 [tm
Type A: Half width defect (Control n=2, Col-Gen n=2, Col-Gen LMT FGF-2 n=4). This injury
consists of a dense collagenous fibrous scar localized to the lateral border of the defect and a
cavitary/granular tissue core containing a high density of foamy looking cells varying degrees of non-
inflammatory cell infiltration and associated ECM. The dense tissue was usually aligned parallel to the
long axis of the spinal cord. The core area of Col-Gen LMT FGF-2 treated animals tended to have more
dense collagenous tissue and granular matrix than control or Col-Gen treatment groups, which displayed a
more cavitary inflammatory cell filled core.
Type B: Greater than half width defect with varying degree of tissue sparing (Control n=2, Col-
Gen n=3, Col-Gen LMT FGF-2 n=2). Animals exhibiting this response had significant but typically
incomplete destruction of the contralateral white and gray matter. The areas of additional tissue
destruction consisted predominantly of inflammatory cells and contained fewer infiltrating connective
tissue/glial cells than the tissue within the original defect. In the case of one control animal with this type
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of injury (not shown), the lesion site and areas of secondary degeneration were heavily infiltrated by
connective tissue cells and contained a dense collagenous tissue matrix.
TypeC; Full width defect with substantial connective tissue infiltration (Control n=3, Col-Gen
n= 1, Col-Gen LMT FGF-2 n=O). Animals with this response to injury had a defect, which spread to
encompass the entire width of the spinal cord and consisted of fibrous scar tissue in the center with
cystic/cavitary lesions on either side. In some cases, the collagenous tissue in the center was oriented such
that it "capped" off the distal and proximal ends of the spinal cord
At four weeks, the center of the defect was evaluated using Masson's trichrome staining to assess
the area of the defect, nature of the new tissue formation within the defect, and amount of viable tissue in
the peri-lesional area (Figure 6-8). Between treatment groups, there was a statistically significant
difference in the percentage spared tissue around the defect between control and Col-Gen LMT FGF-2
groups (p=0.0 18). There was no statistically significant difference found in absolute defect size,
percentage of scar tissue, or percentage of cavitary/granular tissue within the defect between treatment
groups.
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Figure 6-8: a.) Histomorphological characterization of the spinal cord defect and peri-lesional
area using Masson's trichrome stained longitudinal sections from the middle of the defect at 4
weeks post injury. Spared tissue is defined as parenchyma, which appears viable, without fibrous
infiltration or significant edema. Dense fibrous tissue is an area staining strongly for collagenous
tissue (blue). The cavitary/granular tissue is defined as as an area of moderate cellular ingrowth
within the defect without the presence of a dense collagenous ECM or an edematous area occupied
of foamy-looking cells. b.) Absolute defect area (dense fibrous + cavitary/granular tissue)
determined from Masson's trichrome stained sections. N=6-7 mean ± SEM
6.4.4 Immunohistochemical analysis of the cellular and extracellular composition of the
defect
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6.4.4.1 a-SMA:
The areas containing dense fibrous scar tissue within the defect largely stained negative for a-
SMA positive cells at 4 weeks (Figure 6-9) suggesting that myofibroblasts were not actively contracting
the matrix within the defect at this point.
Figure 6-9: a-SMA stained IHC image of the control Type C injury response shown in Figure 6-2.
Of note is the sparse distribution of positive staining cells in the center of the defect where there is
a dense collagenous ECM. A thin band of a-SMA positive cells can be seen at the lateral border of
the defect. Black lines were traced along the border of the defect with viable parenchyma. 4x
objective, scale bar =I000 [tm
6.4.4.2 Laminin:
Laminin staining was performed to assess the cellular infiltration of the lesion site and presence
of a growth supportive matrix for axon elongation into the defect (Figure 6-10). In all treatment groups,
laminin could be found on the border of and scattered throughout the defect and co-localized with the
presence of cellular infiltration and connective tissue formation. The density of laminin staining was
decreased in areas of dense collagenous scar and absent in purely cavitary areas. There was a statistically
significant increase in the amount of laminin within the defect area for the Col-Gen LMT FGF-2
treatment group as compared to control (p=0.005) Figure 6-10d.
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Figure 6-10: Longitudinal laminin IHC stained sections through the middle of the defect
(corresponding to the animal with a Type B response in figure 6-7) for a.) Control b.) Col-Gen c.) Col-
Gen LMT FGF-2 treatment groups. 4x objective, scale bar 1000 rIm. d.) Quantitative analysis of
laminin staining within the defect. N=6-7 mean ± SEM.
6.4.4.3 Astrocytes
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In the control group Figure 6-11 a, astrocytes could be found bordering the defect and sparsely
within the defect. In some cases astrocytes grew into the defect directly adjacent to the parallel oriented
fibrous scar on the lateral border of the defect. In the cases where the center of the defect was filled with
dense collagenous tissue, astrocytes could be seen growing into the less dense fibrous tissue but were
impeded from growing into the more dense tissue. Astrocytes were rarely present in the cystic/cavitary
areas of the lesion.
Similar to the control group, astrocytes in Col-Gen treated animals (Figure 6-11b) were
predominantly found at the borders, however the cells appeared to extend further into the defect than in
control animals. In one of the Type A response animals, astrocytes were observed growing out in
substantial number right below the fibrous scar on the lateral border of the defect from either side (image
shown in section 6.4.3.7).
In animals treated with Col-Gen LMT-FGF-2 (Figure 6-11c), astrocytes entered the defect
extensively within the granular tissue matrix of the defect site. Astrocytes grew out and extended
processes into the defect forming what appeared to be a network-like structure with other cells in the
defect. Few if any cells could be found in the dense fibrous scar tissue, even if it was adjacent to viable
tissue. Populations of astrocytes within the defect could be found mixing with fibroblast-like cells, which
stained positive for collagen in Masson's trichrome.
There was a statistically significant increase in the percentage of defect tissue staining for GFAP
was significantly higher in Col-Gen LMT FGF-2 treatment groups as compared to control (p=0.000055)
or Col-Gen (p=0.0455) groups (Figure 6-11d).
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Figure 6-11: Longitudinal GFAP IHC stained sections through the middle of the defect
(corresponding to the animal with a Type B response in figure 6-7) for a.) Control b.) Col-Gen c.) Col-
Gen LMT FGF-2 treatment groups demonstrating the ingrowth of astrocytes into the lesion site . 4x
objective, scale bar 1000 [im. d.) Quantitative analysis of GFAP staining within the defect. N=6-7
mean ± SEM.
6.4.4.4 Endothelial cells/angiogenesis
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VWF positive endothelial cells were distributed throughout the entirety of the defect area (Figure
6-12). The cells were present at a higher density in the more densely packed connective tissue areas as
compared to the cavitary/granular tissue regions. There was no statistical difference in the number of
VWF+ cells in the more dense fibrous tissue areas between the control and treatment groups. However,
animals treated with Col-Gen LMT FGF-2 gels has a substantial and increase in the number of VWF+
cells within the cavitary/granular tissue as compared to control (p= 0.00032) and Col-Gen (p=0.0056)
groups. There was also a statistically significant difference in the number of VWF+ cells over the entire
defect between control and Col-Gen LMT FGF-2 groups (p=0.0023) (Figure 6-12d).
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Figure 6-12: Longitudinal VWF IHC stained sections through the middle of the defect
(corresponding to the animal with a Type B response in figure 6-7) for.) Control b.) Col-Gen c.)
Col-Gen LMT FGF-2 treatment groups, demonstrating the presence of endothelial cells and blood
vessel formation within the lesion. The edges of the defect are outlined for clarity. 4x objective,
scale bar 1000 um. d.) Quantitative analysis of VWF staining within the defect. N=6-7 mean
SEM.
6.4.4.5 Inflammatory response: macrophages
Macrophages dominated the lesion site at 28 days post injury, localizing at high density within
the loose tissue matrix or cavitary/cystic areas and decreased with distance rostral and caudal to the defect
(Figure 6-13). Macrophages were largely excluded from areas of dense fibrous scar and could only be
seen sparsely throughout the dense tissue. It should be noted that macrophages were present in all areas of
the spinal cord, which were infiltrated by fibroblasts as part of the secondary damage process. This was
particularly evident in the degenerating dorsal columns; an area particularly prone to hemorrhage after
injury (figure not shown).
There was no statistically significant difference between control and treatment groups with
respect to the absolute area of unregulated CD68 staining within the defect and peri-lesional area at 4
weeks or the relative area of CD68 staining as compared to the original defect size (Figure 6-13d).
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Figure 6-13: Longitudinal CD68 IHC stained sections through the middle of the defect
(corresponding to the animal with a Type B response in figure 6-7) for a.) Control b.) Col-Gen c.)
Col-Gen LMT FGF-2 treatment groups, demonstrating the presence of macrophages within the
defect and peri-lesional area. The edges of the defect are outlined for clarity. 4x objective, scale
bar 1000 [tm. d.) Quantitative analysis of CD68 staining within the defect, area of upregulation
(primary axis solid bar), relative size of upregulated area vs original defect area (secondary axis
striped bar). N=6-7 mean ± SEM.
6.4.4.6 Regenerating axons
GAP-43 positive regenerating axons could be seen coursing into the defect from the edges of the
viable tissue Figure 6-14. The axons were closely associated with collections of non-inflammatory cells,
which infiltrated into the defect and could not be found alone in the cavitary macrophage filled regions of
the defect. No statistical difference could be found in either the percentage of the defect staining for GAP-
43+ axons or the number of fields of view within the defect containing GAP-43 axons (Figure 6-14d).
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Figure 6-14: Longitudinal GAP-43 IHC stained sections through the middle of the defect
(corresponding to the animal with a Type B response in figure 6-7) for a.) Control b.) Col-Gen c.)
Col-Gen LMT FGF-2 treatment groups, demonstrating the presences of regenerating axons with the
defect. Of note is the high number of regenerating axons streaming into the lesion for the Col-Gen
LMT FGF-2 animal in c. 4x objective, scale bar 1000 [tm. d.) Quantitative analysis of GAP-43
staining within the defect. Percentage of area staining within defect (primary axis, solid bars),
Percentage of fields of view within the defect with GAP-43 staining (secondary axis, striped bars).
N=6-7 mean ± SEM.
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6.4.4.7 Overview of marker co-localization in animals exhibiting a Type A response to
injury
For the purposes of facilitating the co-localization of IHC markers, a region of interest with active
neurovascular regeneration into the lesion was chosen for a Type A response animal in each treatment
group (control Figure 6-15, Col-Gen Figure 6-16, 6-17, Col-Gen LMT FGF-2 Figure 6-18). Serial
sections stained for Masson's trichrome and IHC antigens laminin, GFAP, GAP-43, VWF, and CD68
were combined into single figure for each group. Additionally, Col-Gen treatment group was stained for
CS-56, P75, and fibronectin Figure 6-17.
Regenerating GAP-43+ axons can be seen growing directly into the defect in close association
with cellular bridges. These areas are rich in laminin, astrocytes, fibroblast-like cells, and VWF positive
endothelial cells. While regenerating axons could be seen associating with astrocytes, they did not appear
to be the only cell able to support the axon growth. Fibroblast-like cells staining positive for collagen on
Masson's tricrhome were also commonly found in association with the axons. Axon growth was not
observed in the cavitary macrophage filled regions within the defect unless these tissue bridges were
present. Interestingly, the cellular bridges in the area directly below the parallel oriented fibrous scar
tissue on the lateral border of the defect created a niche for regenerating axons growth into the defect.
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Figure 6-15: Histological/IHC images of a control animal exhibiting a Type A response. a.)
Longitudinal Masson's trichrome image with a boxed region of interest. Scale bar 1000 rim. b-g.) IHC
of serial sections of the region of interest. Active growth of GAP-43+ regenerating axons can be seen
occurring on cellular bridges directly below the parallel oriented fibrous scar tissue on the lateral
border of the defect. The bridges are largely devoid of astrocytes but have a high density of VWF+
capillaries and stain positive for laminin. Axon growth is not observed in the cavitary macrophage
filled regions within the defect. Images taken at 4x objective, scale bar 500 ptm.
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Figure 6-16: Histological/IHC images of a Col-Gen animal exhibiting a Type A response. a.)
Longitudinal Masson's trichrome image with a boxed region of interest. Scale bar 1000 [tm b-g.) IHC
of serial sections of the region of interest. Active growth of GAP-43+ regenerating axons can be seen
occurring on cellular bridges directly below the parallel oriented fibrous scar tissue on the lateral
border of the defect. The bridges are highly populated of astrocytes and have a high density of VWF+
capillaries and stain positive for laminin. Axon growth is not observed in the cavitary macrophage
filled regions within the defect. 4x objective, scale bar 500 [tm
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Figure 6-17: Additional (non-quantified) IHC stains of the Col-Gen animal in Figure 6-14. Chondroitin
sulfate proteoglycans are present at the border of the defect but are not found within the defect itself. Schwann
cells and fibroblasts can be seen scattered through the defect.
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Figure 6-18: Histological/IHC images of a Col-Gen LMT FGF-2 animal exhibiting a Type A
response. a.) Longitudinal Masson's trichrome image with a boxed region of interest. Scale
bar 1000 [im. b-g.) IHC of serial sections of the region of interest. Active growth of GAP-43+
regenerating axons can be seen occurring on cellular bridges directly into the defect . The
bridges populated by astrocytes and have a high density of VWF+ capillaries and laminin.
Axon growth is not observed in the cavitary macrophage filled regions within the defect. 4x
objective, scale bar 500 [tm
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6.5 Discussion
6.5.1 Functional evaluation
Despite having a hemi-resection injury, the many of the rodents exhibited some level of
functional ability as early as a few days after injury. By four weeks several animals showed significant
ability to bear weight and walk on their impaired hind limb. It is well know that animals receiving lateral
hemi-section injuries can regain substantial recovery of their impaired side.[6, 7] However, there are
several deficits, mostly observed on the side of the lesion, which can persist including transiently
impaired body equilibrium, inter-limb coupling, and impaired skilled locomotion.[6] The observed
recovery from hemi-section injuries can occur through a multitude of mechanisms.[6] Un-injured
pathways can sprout connections capable of accessing spinal circuits distal to the lesion such as central
pattern generators (CPGs). Intrinsic changes in the existing spinal circuitry including the formation of
new or modified anatomical circuits, may allow for these sprouted axons to exert voluntary control over
them. In rodents, limited sprouting of the spared corticospinal and corticobulbar fibers have been shown
to establish new connections from the cortex to downstream targets.[8] Additionally, in non-human
primates, the ability to extensively use their impaired hand after cervical hemisection is attributed to the
pre-existing "cross-over" CST projections within the spared contralateral side of the spinal cord.[9, 10]
While the regeneration of lesioned axons through the defect site is limited, these axons can play a
triggering rather than controlling role by activating propriospinal pathways in more rostral segments
which can then organize the rhythmic output of the spinal cord generated by more caudal segments.[6]
Finally, the reorganization of local spinal circuitry and input from sensory afferents alone may be enough
to elicit rhythmic movement of limbs through CPGs.[1 1] Hence, it is difficult to tell what mechanism is
causing the increase in functional score seen in this study. Nevertheless, functional outcome and
functional improvement are important outcome metrics in the treatment of spinal cord injury.
The functional score of the animals in this study Figure 6-2 appeared to be more correlated with
the success of the surgery (degree of secondary damage caused by bleeding and trauma in the peri-
operative timeframe) than the treatment group. Of all the metrics analyzed, percentage of spared tissue in
the peri-lesional area and the width of the contralateral white matter at its most narrow point was the best
predictor of functional ability at 4 weeks (Figure 6-3b). To account for differences in the extent of injury
(baseline functional score), and to focus on the recovery from injury due to treatment, each animal was
used as its own control by comparing functional scores at 1 and 4 weeks post injury (Figure 6-2 bottom).
One week was used as a more stable platform to assess the recovery since it is after the acute
inflammatory phase.[1] The number of animals which improved by 2 or more points was greater in the
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col-gen LMT FGF-2 group but not statistically significant. Wilcoxon matched pairs test showed a
significant improvement in left leg functional score between 1 and 4 week for Col-Gen (p=0.0277) and
Col-Gen LMT FGF-2 (p=0.04 3 1) groups but not for the control group. This early beneficial effect of the
gel would seem to be related to its function in ameliorating the initial response to injury, perhaps by
aiding hemostasis or by preventing inflammatory cells from entering the defect. Cholas et al. also found
significant increases in one to four week hind limb score for animals treated with pre-formed scaffolds
containing mesenchymal stem cells or chondrotinase ABC but not for control animals [2]. This was
potentially due to their immunomodulatory and neuroplasticity effects respectively.
Main limitation of these comparisons is that the metric is non-linear so a 2-point increase from 0-
2 (translating to the shift from flaccid paralysis to significant but non-weight bearing hind limb
movement) cannot be equated to an increase from 3-5 (translating to a shift from partial to full weight
bearing). The number and diversity of metrics used for behavioral recovery after SCI including endpoint
measures, kinematic measures, kinetic measurements, and electrophysiological measurements make it
difficult to compare results between studies.[12] The usefulness of the metric is also dependent on the
type of SCI for which it was developed for since the deficits caused by each type of injury model are
unique. For the purposes of this study, a slightly more complex version of an established simpler scoring
metric [2], which did not require advanced training or specialized equipment was used to provide a
reasonable estimate of functional recovery between treatment groups. Future studies aimed at parsing out
more minute differences between animals should take advantage of more complex scoring metrics or
electrophysiological studies.
Closely related to the functional score, was the time it took for animals to recover bladder
function after injury. Although not all animals were able to recovered bladder function, the ones that were
able to had a recovery time, which ranged from under 1 day to 22 days suggesting that the mechanism of
recovery was due to either white matter sparing (early recovery) or re-wiring of neural pathways (later
recovery). Interestingly, one of the animals in the Col-Gen LMT FGF-2 group which recovered the ability
to void at 3 days post injury, lost that ability at day 16 suggesting a second event which caused
destruction of this pathway. This animal was noted to have a half-width injury in the middle of the defect
but extensive fibrous tissue infiltration of the dorsal columns and adjacent white matter, both of which are
involved in the micturition pathway.[13] This animal was also noted to have a decrease in functional
score of the right leg and no change in functional score of the left leg from one to four weeks.
Given the multitude of recovery mechanisms and the time course of axon regeneration as
mentioned above, it is not surprising that no correlation was found between the density of regenerating
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axons or tissue composition within the defect. The permissive composition of the defect in Col-Gen LMT
FGF-2 animals however, is promising towards the future regeneration of axons through the defect and is
an important area of future work to follow up on by looking at longer survival time points.
6.5.2 Histological evaluation
Defect and ECM
The present study compares the response to tissue response to injury in a hemi-resection model of
SCI. Although the control group did not have a therapy applied, the blood clot, which forms in the defect
after injury, provides a provisional matrix for cellular ingrowth. The "open" nature of a hemi-resection
injury facilitates the entry of inflammatory and connective tissue cells into the lesion site, which is unlike
"closed" contusion injuries that do not breach the dura mater. Consequently, the control groups in this
study also had significant tissue formation within the defect. However, the matrix formed by the blood
clot in control animals predominantly resolved into either a cavitary region filled with macrophages and
little tissue matrix or a highly dense collagenous scar filling the entire defect, both of which are not
favorable for nerve tissue regeneration. Therefore, the goal of the study was to examine if the presence of
a collagen-genipin hydrogel and the growth factor FGF-2 could facilitate the creation of a tissue matrix
within the defect containing elements that are more conducive towards axon regeneration.
Histology of the defect at 1 day Figure 6-4 shows that the collagen gel mixes to various degrees
with the blood that fills the defect after injury due to hemorrhage from the spinal cord parenchyma or
bleeding from the overlying musculature. This means that pipetting the gel directly into the defect did not
allow the gel to form rapidly or stiff enough to displace the continued bleeding into the defect. Indeed, the
dense staining of fibronectin Figure 6-6a within the defect at one week suggests the gel was substantially
mixed with blood, as soluble plasma fibronectin is deposited in areas of blood clotting to allow for the
attachment of cells.[ 14]The mixing of gel with blood is not necessarily an unwanted event. Blood can
create more pores and imperfections in the gel, which can facilitate cellular migration into the scaffold.
The formation of a fibrin-fibronectin clot in the areas of hemorrhage and blood-gel mixing serves as an
additional cell permissive scaffold. Finally, nucleated blood cells (leukocytes) contained within the gel,
have the capability to release pro-regenerative growth factors.[15]
By one week, connective tissue and inflammatory cells heavily infiltrated the defect of the Col-
Gen treated animals and little un-degraded gel could be found. Even though the gel contained 1 mM
genipin, the low weight percentage of collagen in the gel (0.3%) and the ability of the invading cell
populations to secrete proteases, caused the gel to be almost completely re-modeled/degraded by this
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point Figure 6-5b,c. It is also likely that genipin reacted with proteins in the blood thereby decreasing the
concentration available to cross-link the collagen gel.
By four weeks post injury, there was a noticeable stratification in the injury severity and degree
of collagenous scar fonnation within the defect between animals within the same group (especially in
control and Col-Gen groups) Figure 6-7. One hypothesis for this is the amount of bleeding into the defect
post injury. Blood forms a fibrin clot and platelets embedded within the clot release growth factors such
as PDGF, which enhance fibroblast infiltration and connective tissue formation. Blood also contains
peripheral leukocytes, which can cause substantial secondary damage [15], the presence of blood also
introduces secondary damage to the spinal cord through lipid peroxidation and ischemia from
vasospasm. [16] The hyper-cellularity of control or gel treatment groups noted at one-week post injury,
greatly changed by four-weeks. Largely evolved to a macrophage core with few cells and connective
tissue deposition. The dense fibronectin staining at one week largely disappeared Figure 6-17 and much
higher density of collagen was noted suggesting a remodeling of the defect area with an endogenous ECM.
Areas adjacent to the defect were also prone to invasion by connective tissue cells most likely fibroblasts.
The areas of fibroblast invasion, especially in the dorsal columns also co-localized with macrophage
staining suggesting that the population of macrophages in these areas released factors to attract fibroblasts
such as FGF-2. Given the discussion about the initial matrix present in control and treatment groups, it is
not surprising that the col-gen gel treatment group did not differ substantially (histologically and
functionally) from control groups since the matrix which formed within the defect was largely the same
except with the addition of the collagen and possible less direct initial exposure to invading inflammatory
cells. However, as described in more detail below, animals treated with Col-Gen LMT FGF-2 gels had a
lesion site, which was populated to a greater extent with astrocytes and endothelial cells and contained a
tissue matrix rich in laminin, thus creating an environment conducive to future axonal regeneration. The
addition of FGF-2 also had a neuroprotective effect as noted by the increase in viable tissue around the
defect and the absence of any animals exhibiting a full width defect, thus supporting our working
hypothesis (2).
Laminin is an extracellular matrix protein produced by fibroblasts, endothelial cells, Schwann
cells and astrocytes, most commonly found in the basement membrane of these cells or as membrane
independent isoforms important for cell adhesion and signaling.[17-19] Laminin and particularly its
membrane independent laminin yl chain is a particularly important substrate for axon growth during
development and regeneration.[17, 18, 20] Regenerating axons have been reported in several studies to be
in close association with a laminin matrix of Schwann cells and/or astrocytes within a defect area after
spinal cord injury. [20-23] Interestingly, axons are capable of regenerating through areas where growth
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inhibitory (CSPG) and growth promoting (laminin) molecules are present, suggesting that the axons
respond to a balance of attractive and repulsive cues. [21] The enhanced deposition of laminin within the
defect of Col-Gen LMT FGF-2 treated animals is reflective of the increased cellular infiltration of the
defect, especially by astrocytes and endothelial cells, and is a promising finding towards the creation of an
axon regenerative template within the lesion site.
In addition to axon growth promoting substrates, astrocytes and fibroblasts also produce growth-
inhibiting substrates after SCI such as chondroitin sulfate proteoglycans (CSPGs). [24] In this study,
sections were only preliminarily stained for CSPGs due to a.) Technical difficulty of using this antibody
in paraffin sections b.) Unclear interpretation for what the staining would mean in the context of
regeneration. Given the correct growth promoting cues such as laminin [21, 22], NT-3, NGF, and BDNF
[25], axons can extend past regions of CSPGs deposition within the lesion site. The increase of astrocytes
within the defect may result in a corresponding increase the CSPGs reactivity as well as laminin and
growth factor secretion which could promote instead of hinder axon regeneration. Interestingly, the
astrocytes within the defect do not appear to produce CSPGs, which could potentially indicate a shift
towards a less reactive phenotype Figure 6-17.
Inflammatory macrophage response
There was no statistical difference between the macrophage response to injury in either the
absolute area of macrophage infiltration or the relative area of infiltration as compared to the original
defect size suggesting that treatment with the col-gen or col-gen LMT FGF-2 gels neither promoted nor
lessened the inflammatory response to injury. This finding is important in showing that the presence of
the collagen gel and concentrations of both genipin and FGF-2 were well tolerated by the animals and did
not cause a severe inflammatory reaction. In comparison, Cholas et al. found a significant decrease in the
density of macrophages within the defect of animals treated with preformed collagen sponges compared
to control injuries [2]. This finding is not surprising as preformed scaffolds can greatly hinder cellular
infiltration of the defect compared to hydrogel scaffolds due to their persistence in vivo. As mentioned
earlier, the presence of macrophages is important for wound healing and regeneration due to their actions
in clearing the defect of cellular debris and releasing factors to promote angiogenesis.
Astrocytes
The use of Col-Gen LMT FGF-2 gels resulted in significant increases in GFAP staining within
the defect compared to control or Col-Gen groups, supporting our working hypothesis (3) Figure 6-11.
As a comparison, Cholas et al. reported that no GFAP staining was seen within the defect of animals
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treated with pre-formed collagen sponges after four weeks in a similar hemi-resection model of SCI [2].
In other species capable of regenerating their spinal cord such as the newt or zebrafish, GFAP+
glia (astrocytes) play an important role in bridging the defect after injury and templating the growth of
axons across the defect. [26, 27] In zebrafish, this process (proliferation and elongation across the defect)
is mediated by FGF-2 signaling. [27] Even in mammals, mature astrocytes are capable of supporting axon
growth down degenerating white matter tracks[28] and hold an intrinsic capability to support the
regeneration of axons.
Using an intrathecal administration TGF-a and an adenovirus induced overexpression of TGF-a in
the spinal cord parenchyma, White et al. was able to increase the proliferation and migration of astrocytes
into the lesion core after contusion SCI in mice. [22, 29] The astrocytes took on an elongated axon growth
supportive phenotype and at the borders of the defect there was a close association of laminin, GFAP, and
numerous GAP43+ axons. There was also an increase in NF positive axons within the defect as compared
to control groups.
Davies et al. transplanted astrocytes derived from embryonic glial-restricted precursors treated
with BMP-4 into dorsal column transection injuries in rats. [30] This study found the cells promoted
robust axon growth and restoration of locomotor function after the acute transection injury, promoting
growth of over 60% of ascending dorsal column axons into lesion, with 66% of these axons extending
beyond the injury sites. These cells formed a tissue bridge across the injury site and interestingly caused
astrocytes in the host tissue to orient their processes towards the lesion center.[30] Even more noteworthy
is that astrocytes differentiated from glial-restricted precursors treated with CTNF failed to promote axon
growth, survival, or functional recovery suggesting the importance of the specific astrocyte subpopulation
in the observed response. [31]
In the context of the current study, the elongated astrocyte processes oriented towards the center
of the defect (especially noticeable in Figure 6-11c,6-16d) are hypothesized to be of the growth
supporting phenotype while astrocytes on the border of the lesion with dense interweaved processes are of
the inhibitory glial scar phenotype (Figure 6-15d). Indeed, these areas of astrocytes are also noted to be
associated with GAP-43 axons (Figure 6-14c, 6-16c). As described in detail in chapter 4, the exposure of
astrocytes to FGF-2 causes them to increase their outgrowth into Col-Gen gels and produces a chain-like
movement of these cells similar to the framework described in the studies above. Although not
specifically quantified in this study, astrocytes growing into the defect of Col-Gen (especially right below
the parallel oriented scar) and Col-Gen LMT FGF-2 groups appeared to have an elongated phenotype,
which was not noticeable in control animals.
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Endothelial cells
FGF-2 is a potent angiogenic factor [32] and animals treated with Col-Gen LMT FGF-2 gels had
a significant increase in the number of VWF+ cells within the defect compared to control or Col-Gen
groups, thus supporting our working hypothesis (4) Figure 6-12. In contrast, work by Cholas et al.
showed that pre-formed scaffolds significantly decreased the density of blood vessels within the defect at
four weeks post injury compared to control animals [2].
Blood vessels are highly important for the support of new tissue growth into the defect. Local
vasculature is particularly important for axon regeneration. Dray et al. used two photon microscopy to
analyze the dynamics of vascular and axonal networks in the injured mouse spinal cord and found the
growth kinetics of sensory regenerating axons are strongly enhanced by their vicinity to posttraumatic
angiogenic vessels after SCI, however that vessels do not help axons to recover their initial
trajectories.[33] Therefore, the enhancement of the vascular network along with a framework of
astrocytes within the defects of Col-Gen LMT FGF-2 provides a supportive environment for future
axonal growth.
Regenerating axons and additional growth supportive cell types
Regenerating axons were identified using an antibody for GAP-43, a protein in the growth cones
of regenerating axons. Tetzlaff et al. showed that another commonly use axonal marker neurofilament
(NF) underestimated the extent of axonal regeneration as compared to GAP-43.[34] Therefore due to the
sensitivity of axon regeneration required at the relatively early time point of assessment (28 days post
injury) GAP-43 staining was chosen over NF.
GAP-43 positive axons closely followed the laminin matrix, astrocytes, and elongated fibroblast
like-cells within the defect Figures 6-15, 6-16, 6-18. There was also a network of blood vessels in close
proximity to areas of axon growth. Axons not found in either the macrophage filled cavitary areas or
dense collagenous scar tissue due to the lack of cellular and extracellular matrix support. Regenerating
axons were not always associated with astrocytes demonstrating that they were not the only or principal
cells responsible for axon growth into the defect. Interestingly, the presence of a dense parallel oriented
collagenous scar localized to the lateral border of the defect of control or Col-Gen treatment groups
templated the growth of astrocytes, endothelial cells, and axons right below it. In fact, most of the cellular
ingrowth into the defect for control or col-gen groups (excluding the full width fibrous defects) happened
right below this border unlike col-gen LMT FGF-2 groups where growth took place more distributed
throughout the lesion site. It is likely that other infiltrating cell types such as Schwann cells and
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fibroblasts provided a growth supportive matrix for axon regeneration Figure 6-17.[20, 35]
Transplantation of meningeal fibroblasts into spinal cord defects promoted the growth of peptidergic
axons from dorsal root afferents and, to a lesser extent, of supraspinal serotonergic fibers at the periphery
of the grafts. These fibroblasts were shown to produce multiple neurotrophic factors including beta-NGF,
NT3, aFGF and bFGF.[35] Typically, astrocytes exclude fibroblasts from areas of spinal cord tissue[19]
which was the case in many areas of collagenous scar within the defect, however there were notable
places within the defect where GAP-43 axons were traversing across collections of cells partially staining
for GFAP and staining for collagen Figures 6-15, 6-16, 6-18. Some of the tissue bridging cells in the
defect could also have been Schwann cells. Schwann cells stain strongly for laminin and it is possible that
some of the lamiin rich areas are due to the presence of these cells. Preliminary staining for Schwann
cells using a P75 antibody was employed in this study and warrants future investigation. It should be
noted that there are limited good markers for Schwann cells [19] as the commonly used markers S100b is
also expressed in astrocyte; P75 a NGF receptor is up-regulated in de-differentiated Schwann cells and is
also present in oligodendrocyte progenitors, macrophages and microglia; and peripheral myelin proteins
like PO will not stain non-myelinating Schwann cells. Overall, the findings of this study suggests that not
all of the cells in the axon supportive tissue bridges are astrocytes or typical fibroblasts and the identity of
these cells needs to be more well characterized in future studies.
Despite the differences in defect composition between control and treatment groups, no statistical
difference could be found in two measures of GAP-43 staining within the defect. There are several
potential reasons for this finding: Firstly, four weeks post injury represents an early time point of analysis
for the regeneration of sensory and motor axons after SCI. For example, cortical spinal tract (CST) axon
sprouting occurs between three weeks and three months post injury.[36] Also, the specific GAP-43
antibody used had a heterogeneous pattern of staining between slides, meaning that some sections
appeared faintly stained while others appeared heavily stained for the same animal. While the general
pattern remained the same, it was possible that areas with GAP-43 staining were missed or incorrectly
counted (i e. false staining of connective tissue elements which would look like regenerating axons)
during image analysis. Regenerating sensory axons from dorsal root ganglion cells are also known to
enter the defect after SCI and were not differentiated our analysis.[19] Finally, GAP-43 immunoreactivity
can be found in non-myelinating Schwann cells and Schwann cells in the distal stump of a peripheral
nerve four weeks after transection.[37] It is possible that infiltrating Schwann cells are also causing some
of the observed GAP-43 staining. Nevertheless, it was quite apparent that GAP-43 fibers could be found
within the defect tissue on tissue bridges (especially apparent in Figures 6-14c, 6-16c) containing laminin
and a network of blood vessels.
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Chapter 7:
Pilot ex vivo MRI study of the gel
implantation and tissue remodeling
after hemi-resection injury in rodents
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7.1 Introduction & motivation:
Magnetic resonance imaging (MRI) is a powerful clinical tool used to visualize pathomorphic
changes in the spinal cord parenchyma and predict the extent of neurological deficit after spinal cord
injury (SCI) in humans.[l] Experimental models show that MRI correlates with histopathologic findings
such as edema, hemorrhage, and secondary degenerative changes such as demyelination and cyst
formation.[2] Conventional MRl techniques for evaluation of spinal cord injury include the pulse
sequences: TI-weighted images, T2-weighted images, T2* susceptibility images, and short tau inversion
recovery (STIR) images.[3] For these pulse sequences, contrast is based on intrinsic properties of the
tissue (TI and T2 values). T2-weighted images are particularly useful for imaging the spinal cord
parenchyma for their ability to discern white matter, gray matter, edema, and hemorrhage. Another
imaging modality, diffusion-weighted MRI (DWI) measures the free diffusion of water molecules and can
provide a measure of white matter sparing, axon swelling, and myelin disruption after injury.[3]
Several studies have correlated in vivo and ex vivo MRI of SCI with its histopathology.[2, 4-7]
However, these studies all utilized a contusion type model and followed the natural progression of the
injury as opposed to assessing the effect of a treatment on lesion parameters. To these points, lannotti et al.
employed a 1.5T MRI to examine the growth of tissue into Schwann cell bridging transplants in a
hemiresection injury and had an 86% success rate of identifying tissue within the cables.[8] Also, Austin
et al. utilized MR imaging to assess the lesion volume of a clip compression SCI after treatment with a
drug releasing hydrogel implanted into the subarachnoid space.[9] However, both of these studies
employed field strengths of <7T, which suffered from low spatial resolution and did not allow them to
explore the composition of the defect in detail. There are currently, limited studies monitoring the
remodeling of a biomaterial gel after SCI or assessing the progression of a hemi-resection type SCI using
high-resolution MR imaging.
Utilizing MRI in the context of experimental SCI gives us the opportunity to non-destructively
analyze the extent of the lesion size and features, as well as allowing a single animal to be monitored
serially through the time course of regeneration. In this study, MRI was used to provide further insight
into the localization of the Col-Gen biomaterial within the spinal cord defect, as well as the extent of
secondary damage and progression of tissue remodeling after injury.
7.2 Overall Goal, hypothesis, and rationale:
The overall goal of this chapter is to use MR imaging (using a 9.4T MRI) to localize the
collagen-genipin hydrogel within the defect soon after injury (1 day) and monitor the remodeling of the
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gel at 1 and 4 weeks. The MR results will be correlated to histology of the defect in order to make
predictions about the composition of tissue in the defect. This study is meant to be a pilot experiment,
showing the feasibility of using the MR imaging modality for analyzing the remodeling of the defect and
biomaterial. Therefore, only a small number of samples were used in order to highlight important features
(such as gel localization) and allow for comparison between different treatment groups.
The hypotheses of this chapter are
1. By setting the T2 parameters based on the signal of the collagen gel, the material can be identified
against the contrast of the defect and viable tissue at I day post injury.
2. Using the gel based parameters and a surface coil, the MR images of the injury site (edema,
hemorrhage, degeneration) will have sufficient contrast and resolution to be correlated to the
histopathological features of the injury.
3. Changes in tissue architecture and density will be reflected in the MR imaging at later time points.
7.3 Methods:
7.3.1 Experimental groups:
I-day post injury:
Collagen-genipin gel (3mg/ml col 1 mM gen), n=1
I-week post injury:
Control, n= 1
Collagen-genipin gel (3mg/ml col 1 mM gen), n=1
4 weeks post injury:
Control, n=1
Collagen-genipin gel (3mg/ml col 1 mM gen), n=1
Collagen-genipin gel (3mg/ml col 1 mM gen) + LMT-FGF-2, n=1
7.3.2: Surgical procedures: The procedures used in this study were identical to the procedures in
chapter 6. Animals used for the MRI study, were also a part of the histomorphologic and functional
assessments of chapter 6.
7.3.3 MRI acquisition: Animals were sacrificed after I day, I week, or 4 weeks by transcardial
perfusion as described in chapter 6 (to account for the fragility of the tissue soon after injury, the 1 day
sample was perfused with 200 ml of PFA and post-fixed for 5 days at 4'C). The spinal column was
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removed and trimmed of the ribs and surrounding musculature leaving the spinal column and fascia intact.
The samples were immersed in fomblin oil prior to imaging to increase image contrast. MR imaging was
performed at the Beth Israel Deaconess Medical Center preclinical MRI core facility using a Bruker
Biospec 9.4T magnet with 20 cm bore horizontal magnet.
Imaging parameters: Sequence: 3D Rare, TR: 3000ms, TE: 80 ms, Matrix 192 x192x 192, FOV
1.3x 1.3 x 1.3 cm, Isotropic voxel 68 [tm3. T2 weighted images were employed in this study to provide
good contrast for the features of interest within the defect. The imaging parameters chosen were based on
a Col-Gen gel sample alone such that the gel would appear brighter than the gray matter. In general, for
T2 weighted images, water (edema, cerebral spinal fluid) appears bright, and hemosiderin (blood) or
proton dense tissues: fat (myelin in white matter) and fibrous scar tissue (scar) appear dark.
The RAW data files were reconstructed into a 3D volumetric reconstruction of the spinal cord
using OsiriX DICOM viewer version 5.6 (Pixmeo, Switzerland). The volumetric image was then cropped
to the correct plane corresponding to the histology sections as determined by the shape and size of the
defect and adjacent gray matter.
7.3.4 Histology and immunohistochemistry (lHC): Prior to tissue processing, the spinal cord
tissue was carefully and completely removed from the surrounding vertebra using bone rongeurs, surgical
scissors, and a scalpel. The spinal cord parenchyma was embedded in paraffin using a tissue processor
(HypercenterXP, Tissue Processor, ThermoShandon, Houston, TX). Serial longitudinal sections of the
defect were cut at 6 [tm with a microtome and mounted on glass slides.
Adjacent tissue sections were stained with Masson's trichrome for general observation of the
cellular and extracellular matrix features of the defect, particularly the presence of collagenous tissue
within the defect. For IHC labeling of macrophages, a mouse antibody against CD68 was used (AbD
serotec MCA34 IRA). A labeled polymer HRP system (AEC+ system, Dako) was used to detect the
presence of the CD68 antibody.
7.4 Results analysis of the defect:
7.4.1 One-day post injury: Col-Gen gel
Ventral aspect (bottom): The ventral aspect of the spinal cord defect (before the presence of gray
matter) appeared as a defect comprising half the width of the spinal cord with a jagged border. There was
a thin light border around the defect, which was presumably edematous. The inside of the defect was gray
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with a few pockets of black. Histology of the bottom of the spinal cord revealed that the defect contained
collage gel mostly mixed with blood Figure 7-1.
b.
c.
Figure 7-1: Bottom (ventral aspect) of the defect one-day after injury and implantation with a Col-Gen
gel. a.) Masson's trichrome stained section showing the defect and its contents (pushed out during the
sectioning and mounting process), which included gel (light blue) mixed with blood (red). Scale bar 1000
,um b.) Higher magnification image of the defect contents. Scale bar 200 tm c.) MR image corresponding
to the histological section showing the hemi-resection injury. The gel-blood mix appears dark gray within
the center of the defect. Areas of mostly blood appear black.
Mid level: One of the most prominent features of the middle of the spinal cord was the highly
edematous (bright on MRI and spacious on histology) white matter on the contralateral spared side of the
spinal cord immediately adjacent to the defect Figure 7-2. The center of the defect has multiple dark
areas containing blood, as well as brighter areas indicative of gel not mixed with blood. Un-mixed gel
could be found bound to the spared tissue and at the lateral border of the defect both in histology and
observed on MRI (hyper intense areas within the defect)
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a.)
Figure 7-2: Mid level of the defect one-day after injury and implantation with a Col-Gen gel. a.)
Masson's trichrome stained section exhibiting extensive swelling of the tissue contralateral to the defect.
A portion of Col-Gen gel (light blue) can also be seen within the defect, bonded to the edge of the viable
tissue and contains pockets of blood (red) b.) MR image corresponding to the histological section
showing the hemi-resection injury. The area of swelling can be seen as a bright region. Varying contrast
intensities can be seen within the defect corresponding to gel and blood. Scale bar 1000 im
Dorsal aspect (upper): Hemorrhagic areas of white and gray matter were noticeable immediately adjacent
to and extending several mm away from the center of the defect Figure 7-3. Many of the same features of
the mid level of the spinal cord were also apparent at this level. As compared to the mid-level sections,
there was a smaller amount of edema in the spared white matter adjacent to the injury and more gel could
be found at the lateral border of the defect, in addition to small pockets directly in contact with the spared
tissue. The center of the defect was difficult to preserve but showed areas of light and dark gray on MRI,
which indicates a mixture of gel and blood.
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a.)
Hemorrhage Gel
b.)
Figure 7-3: Top level (dorsal aspect) of the defect one-day after injury and implantation with a Col-Gen
gel. a.) Masson's trichrome stained section displaying swelling of the tissue contralateral to the defect. A
strip of Col-Gen gel (light blue) is noticeable on the lateral border of the defect. Extensive hemorrhage
can be observed in the white and gray matter outside of the defect b.) MR image corresponding to the
histological section showing the hemi-resection injury. Darker areas in caudal and rostral to the defect in
the gray and white matter correspond to hemorrhage. A moderate area of swelling can be seen as a bright
region right below the injury. A portion of Col-Gen gel not mixed with blood is observed as a bright band
on the lateral border of the defect..
7.4.2 One-week post injury: Control and Col-Gen gel
By I week the middle of the defect in both control and Col-Gen treated groups were highly
populated by cells and contained a substantial edematous tissue matrix seen as a bright region on MRI
Figure 7-4. Areas of secondary damage were clearly visible and could encompass up to the entire width
of the cord at the level of the defect. Macrophage density is highest at the borders of the defect. Very little
remaining gel could be found in the Col-Gen treated animal and it was not possible to distinguish it from
the surrounding tissue at this time-point. Darker areas within the defect most likely corresponded to
residual blood clots or dense endogenous tissue formation.
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Figure 7-4: a.) Masson's trichrome stained section middle of the defect one-week after injury for a Col-
Gen treated animal. b.) Corresponding MRI image to a c.) Inset of the center of the defect in a. d.) CD68
staining of the defect of a Col-Gen treated animal at I week post injury. e.) Masson's trichrome stained
section middle of the defect one-week after injury for a control animal. f.) Corresponding MRI image to e.
Extensive cellular infiltration can be seen in both control and Col-Gen treated defects. The areas of
cellular infiltration are mostly hyper-intense on MRI indicating it is loose/edematous in nature. The black
area on the bottom center part of f.) is most likely due to fomblin oil seeping into the tissue. Scale bar
1000 [m.
The dorsal aspect of both control and Col-Gen animals exhibited extensive connective tissue
infiltration and collagen deposition as well as destruction of the dorsal column white matter (Figures 7-5,
7-6). The density of collagen produced by infiltrating cells appeared to be greater in the control animal as
compared to the Col-Gen animal. A portion of the fascia overlying the defect could also be seen within
the defect of the Col-Gen animal Figure 7-5.
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a.)
Figure 7-5: Dorsal aspect of the defect area at one week for the Col-Gen treated animal a.) Masson's
trichrome stained section showing the extensive connective tissue infiltration of the entire width of the
defect, destruction of the dorsal column white matter, and overlying muscle fascia within the defect. b.)
MRI section corresponding to the image in a. regions of connective tissue infiltration and dorsal column
destruction appear bright. Pockets of back within the defect correspond to blood. c.) Transverse section
through the center of the defect showing the region of muscle fascia (bright spot on top right) which fell
into the defect.
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c.)
Figure 7-6: Dorsal aspect of the defect area at one week for the control animal a.) Masson's trichrome
stained section showing the extensive connective tissue infiltration of the entire width of the defect and
destruction of the dorsal column white matter,. b.) MRI section corresponding to the image in a. regions
of connective tissue infiltration and dorsal column destruction appear bright. Pockets of back within the
defect correspond to blood.
7.4.3 Four-weeks post injury: Control, Col-Gen, and Col-Gen LMT FGF-2 gel
By four-weeks post injury, MRI provides excellent contrast between the viable white and gray
matter, areas of secondary damage, and fibrous connective tissue regions of the defect for control Figure
7-7, Col-Gen Figure 7-8, and Col-Gen LMT FGF-2 Figure 7-9 animals. The three animals in this study
are also illustrative of the three major responses to injury found at 4 weeks as described in chapter 6.
In general, dark regions within the defect correspond to denser connective tissue, medium
contrast areas correspond to granular loose connective tissue, and bright areas correspond to areas of
edema/increased macrophage infiltration. In all samples, there was a noticeable atrophy of the white
matter close to the injury (mostly on the defect side) and a resulting curvature of the spinal cord towards
the side of the defect (indicated by bright CSF area contralateral to the defect).
The Col-Gen LMT FGF-2 sample exhibited significant secondary damage after the original SCI
Figure 7-9. A comparison of MRI and histological sections for this animal demonstrates the advantage of
using in situ MRI for assessment of the defect and secondary damage as compared to histological sections,
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which are prone to tearing in areas of very soft tissue such as macrophage filled cavities. Serial transverse
sections through the defect Figure 7-10 best illustrate the full extent of secondary damage in this animal.
a.)
C.)
Figure 7-7: Upper-mid defect images of a control animal four-weeks post injury exhibiting a type C
response to injury. a.) Masson's trichrome stained section b.) CD-68 IHC section c.) MRI section. Dense
collagenous scar tissue appear black on MRI, regions of cellular infiltration with a less dense matrix
appear gray, and edematous regions corresponding to the cavitary areas of dense macrophage infiltration
which appear bright on MRI. Areas of secondary damage with dense macrophage staining can be seen
spreading into the white matter.
184
al.)
b.)
c.)
Figure 7-8: Mid defect images of a Col-Gen treated animal four-weeks post injury, exhibiting a type A
response. a.) Masson's trichrome stained section b.) CD-68 IHC section c.) MRI section. Dense
collagenous scar tissue (blue on trichrome) on the lateral border of the defect appears black on MRI,
regions of cellular infiltration with a less dense matrix appear gray, and edematous regions corresponding
to the cavitary areas of dense macrophage infiltration within the defect appear brighter than the gray
matter on MRI.
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Figure 7-9: Mid defect images of a Col-Gen LMT FGF-2 treated animal four-weeks post injury,
exhibiting a type B response. a.) Masson's trichrome stained section corresponding to the upper middle
plane of the defect b.) CD68 stained section showing macrophage infiltration of the defect corresponding
to the plane of section in a.) c.) MR image of the planes in b.) d.) Masson's trichrome stained section
corresponding to the lower middle plane of the defect. e.) MR image of the planes in d.) A thin band of
fibrous tissue is noted on the lateral border of the defect (blue a,d black c,e). Cavitary fluid filled regions
are noted by the bright areas of MRI contrast.
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a.) b.)
e.) f. h.
Figure 7-10: Serial transverse sections through the defect of Col-Gen LMT FGF-2 treated animal at 4
weeks going a.) caudal through h.) rostral to the defect. Extensive secondary damage can be seen in c-e.
There is a band of fibrous tissue (dark) localized to the lateral border of the defect. Extra CSF on the left
side of the image in c-e reflect the curvature of the spinal cord towards the defect side. Atrophy of the
cord tissue on the caudal end of the lesion is noted by the extra CSF on the right (defect) side of the cord.
7.5 Discussion:
MRI of the hemi-resection SCI provided valuable insight into the progression of injury and
remodeling of the tissue within the defect.
7.5.1 Early extent of initial injury and gel localization: The collagen-genipin gel is capable of
conforming to and filling the defect area and is adhered directly to the spinal cord tissue Figure 7-2. The
MR images were able to capture several features of the injury, which could then be related back to the
histology including areas of edema (hyper-intense) and hemorrhage (very hypo-intense). The area of
edematous abnormal cord tissue adjacent to the defect (most evident on the contralateral side) helps us to
better understand the increased size of the lesion noted in I and 4 week samples caused by secondary
damage. Disruption of the cord tissue as a result of mechanical trauma results in areas of ischemia,
disruption of the blood spinal cord barrier, and infiltration of inflammatory cells. [10, 11] If these events
are severe enough, they will result in necrosis of the involved tissue. Likewise, it is possible that the
swelling noted in Figure 7-2 is transient and would have resolved without further injury resulting in the
half-width Type A responses seen at 4 weeks.
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CA) d.)
Although the gel was injected into a clean (non-hemorrhagic) defect, the gel was not devoid of
cells at I day due to mixing with blood in the post surgical period. The appearance of the gel in MRI
varied depending on the amount of mixing with blood. Since blood appears dark in T2 weighted images
due to hemoglobin, gel that was mixed with blood appeared gray Figure 7-1. Un-mixed gel (bright) was
localized more towards the lateral and dorsal side of the spinal cord. Collagen-genipin gels reach their
gelation point (G'=G") after approximately one minute at 37'C, however the gel structure is still very
weak until about 15 minutes.[12] It is possible that the overlying musculature or severed large anterior
artery and dorsal veins in the midline of the spinal cord had residual bleeding after hemostasis was
achieved during the surgical procedure. Blood from these sources would then be able to pool at the
bottom of the defect thus causing the newly formed gel at the bottom to mix or be pushed upwards and
away from the midline. Continued bleeding from the surrounding back musculature (a source of bleeding
during the surgical procedure) into the defect is another potential source of blood.
The mixing of gel with blood is not necessarily an unwanted event. Blood can create more pores
and imperfections in the gel, which can facilitate cellular migration into the scaffold. The formation of a
fibrin clot in the areas of hemorrhage and blood-gel mixing serves as an additional cell permissive
scaffold. Finally, nucleated blood cells (leukocytes) contained within the gel, have the capability to
release pro-regenerative growth factors.[13]
The limitations of the histology at one day prevent us from preserving most of the loose tissue
contained within the defect. Histological processing of samples at such an early time point presents many
unique challenges. The process of detaching the overlying fascia and removing the spinal cord from the
vertebra may result in a loss of some defect tissue, predominantly from the lateral border and dorsal
aspect. This was mitigated as much as possible with substantial post fixation in 4% PFA and careful
dissection technique. Paraffin processing of the tissue also results in shrinking of the spinal cord tissue
and the collagen gel due to the dehydration steps and high temperatures. Finally, sectioning the tissue may
result in rips and tears, which affects the very fragile clot/gel portions within the defect more than the
spinal cord tissue. Despite all of these factors, it was still possible to obtain histological images for
comparison with the MRI data. In histology, the gel had many appearances including a light blue
amorphous area for unmixed gel which was fully preserved during processing, light blue fibrillar
structures highly mixed with red blood cells for the gel-blood mix, and finally dense blue ribbon like
structures which border empty areas for gel that severely shrunk during processing Figures 7-1, 7-2, 7-3.
7.5.2: Secondary damage and cellular infiltration at one week post injury
188
At one-week, MRI of the defect shows a hypo-intense center surrounded by areas of hyper-
intensity, which spread into the surrounding spinal cord parenchyma Figure 7-4b,f. The areas of hyper-
intensity can be attributed to edema from inflammatory events causing secondary damage to the spinal
cord tissue adjacent to the defect. Within these regions, there is also substantial infiltration of elongated
connective tissue cells, which are secreting a collagenous matrix. It is unclear if the hypo-intensity within
the core of the defect is due to an increased density of tissue formation or the collection residual red blood
cells. Interestingly, this area of the defect has a lower density of macrophage staining Figure 7-4d
indicating something (either clot or fibrous tissue) is impeding their entry.
The control animal provided a good example of how the area of edema noted at one day in
Figure 7-2 can lead to an area of secondary damage Figure 7-4e. Unfortunately, in this sample there
were unexplained areas of hypo-intensity on the MR images, such as the circular region at the bottom of
Figure 7-4f where there is an abrupt cutoff in the CSF signal. One likely cause of this stems from the
removal of the bone and some fascia close to the defect prior to imaging in this sample, which could have
allowed fomblin oil to seep into the defect. Since the sample is immersed in fomblin oil prior to imaging
in order to remove contrasting interference from air or water surrounding a sample, the presence of oil
within the sample could have led to the observed results.
Towards the upper parts of the defect Figures 7-5, 7-6, it was also possible to distinguish the
inflammatory/fibrotic infiltrate of the dorsal columns stemming from the hemorrhage noted earlier in the
I day samples, as well as budging of the overlying fascia into the defect. The remarkable degree of
elongated fibroblast-like cells and fibrous tissue formation across the entire top of the defect in both
control and Col-Gen treated animals suggests these cells are entering the defect from the overlying
connective tissue and back musculature and are not impeded in doing so by the autologous fascia draped
over the defect after surgery. It is also possible that the sections are being taken through a portion of the
fascia, which was pressed into the defect during paraffin processing. However, the appearance of a
majority of the tissue is largely unorganized and unlike the architecture of the original fascia.
7.5.3: Remodeling of the defect by four weeks post injury
The animals examined at four-weeks post injury exhibited the three main responses to injury
described in chapter 6, Type A: half width defect Figure 7-8, Type B: greater than half width defect
Figure 7-9, Type C: full width defect Figure 7-7. The MRI modality used in this study was able to
effectively discriminate between the types of tissue present in the defect at this time-point for each type of
injury response. Unlike earlier time-points, there was very little or no blood remaining in the defect so
the hypo-intense dark regions corresponded well to the presence of dense collagenous tissue. There was a
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good correlation between the hyper-intense areas of the MR images and the cavitary macrophage filled
areas within the defect as well as areas of secondary damage to the surrounding gray and white matter.
The moderate intensity signal on MRI (gray) within the defect corresponded to cellular infiltration and
loose matrix formation.
In all samples, there was a noticeable atrophy of the white matter close to the injury (mostly on
the defect side) and a resulting curvature of the spinal cord towards the side of the defect (indicated by
bright CSF area contralateral to the defect). It is possible that the scar tissue that forms towards the lateral
border of the defect is pulling the cord towards the wall of the spinal canal.
One of the most compelling reasons to add in situ MR imaging for assessment of the defect and
secondary damage after spinal cord injury is highlighted in Figures 7-9,7-10. A comparison of MRI and
histological sections for this animal demonstrate the amount of information about the shape of the cavity
and degree of tissue sparing, which was lost due to tearing and disruption of the section in areas of very
soft tissue such as the macrophage filled cavities. Transverse sections through the defect Figure 7-10 best
illustrate the heterogeneous nature of the secondary damage in this animal.
Overall, the implications of the high correlation between histology-MRI mean that both
degenerative and regenerative changes in the spinal cord parenchyma after injury can be determined in
situ using MR imaging.
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Chapter 8:
Conclusions
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As a whole, this thesis follows the development of an injectable gel for the treatment of spinal
cord injury from materials characterization, through in vitro assessment of cell-biomaterial interactions,
and finally in vivo examination in a rodent hemi-resection model of SCI.
Materials characterization:
The reaction kinetics of collagen gels with the cross-linking plant-based extract genipin was
characterized using absorbance and fluorescence measurements as well as rheological testing and
degradation assays. Collagen cross-linked with genipin forned robust gels and were resistant to
enzymatic degradation, and had tunable gelation and mechanical properties. The pH and ionic strength of
the gel was also found to influence its shear modulus and gel time. The addition of LMTs (a secondary
drug release vehicle) at 0.1 mg/ml did not impair the gelation properties or stiffness of the material.
Of importance is that in vitro, collagen solutions were capable of undergoing gelation and cross-
linking when injected directly to a liquid medium. The same gels were also able of encapsulating cells
for up to 10 days while maintaining cell viability. Genipin diffusion out of the gel into the medium was
slow enough that a significant amount of genipin was retained to cross-link the gel, suggesting that when
collagen-genipin gels are injected into tissue, enough genipin will remain within the gelling solution to
provide substantial cross-linking in vivo. From the viability studies, there was a linear relationship
between the effective concentration of genipin cells were exposed in the assay and their viability. These
results suggest that 0.25-0.5 mM is an appropriate genipin concentration to use for a scaffold delivering
cells cells while 1 mM can be an applicable concentration for a scaffold forming in situ, which is in
contact with a relatively large volume of cells and tissue compared to the volume of the gel.
In vitro astrocyte infiltration studies:
Collagen gels alone and those covalently cross-linked with genipin, are permissive of astrocyte
infiltration. FGF-2 incorporated directly into the gels, or released by LMTs added to the gels, enhances
astrocyte infiltration into the gel and causes them move in a chain-like pattern. Cells can be found at
distances up to 2mm into select gels after 10 days, which has relevance to the clinical application in
which the gel is injected into astrocyte-surrounded defects up to 4mm in diameter. While exposure of
astrocytes to genipin, at concentrations up to 0.5 mM does not affect cell viability, it does impair the
ability of astrocytes to migrate. This genipin-induced impairment of astrocyte migration can, however, be
offset by the incorporation of FGF-2 directly into the collagen-genipin gel or in LMT's incorporated into
the gels. The results of this study paved the way for the in vivo evaluation of the effects of Col-Gen
hydrogels incorporating FGF-2 on the astrocyte infiltration of the gel-filled SCI defect
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In vivo rodent SCI:
The wound healing response to a hemi-resection SCI in rodents resulted in substantial early
connective tissue and inflammatory cell infiltration into the defect which resolved into varying degrees of
dense connective scar tissue, loose granular tissue, and cystic macrophage filled tissue. Interestingly, the
actual surgery and amount of bleeding in the peri-operative period appeared to have substantial effects on
the degree of tissue sparing and functional recovery of the animals regardless of the applied therapy.
The pilot animal studies using gels selected based on the in vitro astrocyte migration experiments
demonstrated that implantation of the gel was well tolerated by the animals. However, the formulations of
the gels were determined to be either too fragile or invoke too aggressive of a fibrotic tissue response (in
the case of the first generation FGF-2 containing gels). Therefore, the second more complete animal study
utilized a more robust collagen gel (50% more protein, 100% higher genipin concentration) with a 50 fold
lower concentration of FGF-2.
The results of the second animal study suggested that regardless of treatment group (control
injury, gel alone, or gel with FGF-2), regenerating axons could be found within the defect site on tissue
bridges staining positive for laminin and consisted of astrocytes, blood vessels, and fibroblast-like cells.
Importantly, the high concentration of genipin (1 mM) did not appear to elicit any adverse effects on the
spinal cord tissue. Interestingly, there seemed to be a niche for astrocyte, axon, and endothelial cell
ingrowth directly adjacent to the parallel oriented fibrous scar, which formed on the lateral border of the
defect in some animals. The addition of LMTs loaded with FGF-2 increased the number of endothelial
cells, astrocytes, and laminin, within the defect over control and Col-Gen treatment groups. The tissue
formed within the defect therefore has a greater potential for future axonal regeneration. The FGF-2
containing group also increased contralateral tissue sparing with trends towards a lower defect size, a
greater percentage of contralateral gray and white matter, more animals exhibiting a type A response to
injury. There was also a trend towards increased functional recovery with these animals.
MRI is a suitable modality to non-destructively observe the features of the injury in situ at a
reasonable resolution (68 tm) including defect volume, hemorrhage, edema, gel localization, and other
morphologic parameters. MRI was able to successfully distinguish the different tissue components (i e.
dense fibrous, granular, and cystic/edemedous/macrophage infiltrated tissue) within the defect and areas
of secondary damage at a high correlation to histology. At one day post injury, pure Col-Gen gel could be
distinguished from fluid/tissue within the defect, however mixing of the gel with blood altered its signal
significantly, making it difficult to distinguish from other tissues within the defect seen at later time-
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points. Additionally, MRI provided insight into the shape of the defect and spared tissue in cases were the
histological processing disrupted or altered sections.
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Chapter 9:
Limitations and Future Directions
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I. Limitations:
The work presented in this thesis provides a comprehensive exploration of the materials
characterization, in vitro, and in vivo development of an injectable gel for the treatment of spinal cord
injury. Despite the extensiveness of the assays performed, there were several limitations to the studies
conducted.
Materials characterization:
* Gels formed in situ on the rheometer could only be analyzed for a limited amount of time due to
constraints on instrument availability. Therefore, in situ experiments were able to capture the
initial period of gelation (<1 hr) but could not observe the saturation of genipin cross-linking,
which occurs over days.
- For pre-formed gels tested on the rheometer, care was taken to best match the parameters of the
machine (geometry height, shear speed, etc.) to yield consistent results with the data from the in
situ tests, however variability in properties was introduced based on the degree of gel
compression, contraction of the scaffolds due to cross-linking, degree of hydration, and potential
slipping between the gel and machine geometry.
e Collagen-genipin gels were tested in vitro under ideal conditions (i.e. without the presence of
blood and proteins), which would be found in vivo. The interaction of genipin with these amine
rich components could affect the final properties of the gel.
In vitro cell assay:
e Using the outgrowth assay, it was difficult to parse out the individual contributions of migration
and proliferation to the observed response. It should be noted however that this limitation is less
important in the context of this thesis since the overall goal was to increase the population of
astrocytes within the graft.
e Outgrowth assay was an idealized version of growth into the injectable gel, which did not include
other cell populations (i.e. leukocytes, endothelial cells, fibroblasts) that enter the defect site early
on and may begin to remodel the gel and release a variety of growth factors/cytokines that could
affect astrocyte behavior.
The astrocyte study did not go into detail in determining why certain groups of cells exhibited a
chain-like migration phenotype. The expression of cellular markers and release of growth factors
was not fully explored since it is currently unclear which would be beneficial or detrimental to
regeneration. Growth factor expression is also complicated by the relatively large mass of
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astrocytes in the center of the assay, which may be producing different factors than the ones
undergoing chain-migration.
* While FGF-2 exerts pro-migratory actions on astrocytes, its actions are more widespread and
cause a variety of effects on many other cell types, which could be both pro- and anti-
regenerative.
In vivo rodent experiments:
* While the hemi-resection injury provides a clear standardized model for the growth of cells into
the collagen-genipin gel contained within the defect, it is a large open injury, which exposes the
cord to peripheral blood cells and is easily infiltrated by surrounding connective tissue resulting
in scar formation. Therefore, a more ideal model for an injectable gel would be a closed defect
(i.e. contusion model) contained within the dura. This type of model is also more clinically
relevant to human spinal cord injury.
* The gel implantation procedure was not optimized with respect to injection time. The liquid gel
was pipetted directly into the defect since the gel was filling a large volume and controlling the
delivery time using an automatic syringe injector was cumbersome in surgery.
* Intraoperative and post operative bleeding into the defect from the surrounding muscle and bone
caused variations in the secondary damage to the spinal cord and degree of fibrosis. If the blood
continued to pool into the defect, it could impede the gelation of the collagen-genipin gel and also
displace it laterally and dorsally.
* By 1 week post injury, the 2 mg/ml col + 0.5 mM gen gel as well as the more robust 3 mg/ml col
+ 1 mM gen gel were heavily infiltrated by cells and little original gel could be identified within
the defect. This could have been due to an altered gelation effect (i.e. mixing with blood) leading
to a weakened material, or the gels not being intrinsically strong enough to withstand the
connective tissue infiltration induced by the present model. It would have been more ideal for the
gels to persist for 2-3 weeks to prevent early filling of the defect site with fibroblasts and
macrophages.
* Our analysis of the defect site was observed only up to 28 days post injury. While the defect is
largely stable at this time, the tissue is still actively remodeling and the astrocyte-blood vessel
network may continue to mature. Additionally, axon sprouting begins between 3 weeks and 3
months post injury so our data is only covering the beginning of this process.
e Histological processing of the tissue (in particular the gel and newly damaged tissue) was
technically challenging, which sometimes led to an incomplete picture of the lesion or
identification of the gel in situ.
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* Quantification of the histological sections was performed on one section per stain per animal, in
the middle of the defect. While this gives a good overall comparison between groups, a
volumetric approach would be required for a more complete assessment of the cellular response
to injury between groups.
* This study used an open field locomotor behavioral outcome metric to assess the functional
recovery after injury. In general, these metrics are useful in grading recovery after injury but are
limited in that they are non linear and do not take into account other important parameters of
recovery such as sensation, pain, and bladder function.
e MRI of the spinal cords in this thesis were performed in an ex vivo fashion. In order to translate
this work to live animals, techniques to account for artifacts due to respiration and blood flow
will have to be used.
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11. Future directions:
The work presented in this thesis lays the groundwork for further investigation of injectable gels
for the treatment of spinal cord injury. The areas of future investigation flow from both the limitations
and main findings of the current study:
Materials:
Increase the gelation speed of collagen-genipin gels: lowering the ionic strength of the gel was
touched upon in this thesis for this purpose, however there may be alternate ways. Follow up
studies on the long-term mechanical properties and microstructure of low ionic strength gels
should also be performed to ensure the properties are not significantly altered from prior gels.
Alternate injectable hydrogel materials with tunable mechanical and gelation properties such as
gelatin cross-linked with hydroxyphenylpropionic acid (HPA) can also be explored using the
assays described in this thesis.
In vitro:
e The chain-like migration phenomena observed in astrocytes exposed to FGF-2 should be further
investigated to determine how these cells are phenotypically different than the other astrocytes in
the gel. This may include gene activation, protein synthesis, cell surface marker expression, ECM
production, and growth factor secretion.
* Other stimulators of astrocyte outgrowth should be explored in the cell outgrowth assay described
in this thesis. Examples include growth factors (HGF, TGF-a, EGF, TGF-b) or molecules
(Ro3303544, a glycogen synthase kinase inhibitor), which show promise in their ability to
promote astrocyte migration into the defect site. Such factors may encourage a targeted migratory
effect on astrocytes, however caution should be taken since they may or may not have other
widespread effects on inflammatory and connective tissue cells.
e Incorporating macrophages or fibroblasts into the encapsulating gel in the cellular outgrowth
assay may be able to provide a better prediction of astrocyte growth into the gel in vivo.
In vivo:
* The experimental groups, which show promise at 28 days should be followed up at 2-3 months
post injury to observe any maturation of the astrocyte-fibroblast-endothelial cell network and
increased infiltration of the defect with axons.
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* A more thoroughly investigate the fibroblast-like cells which seemed to promote axon
regeneration within the defect should be conducted to determine what these cells are and why
axons tended to grow along the tissue bridges formed by these cells.
* The collagen-genipin gels developed in this thesis should be tested in other models of SCI to
determine their effectiveness in different contexts. For example, moving towards a contusion
model would be more clinically relevant and more appropriate for an injectable therapy due to the
closed contained nature of the injury. In this case, the injection procedure and gelation time must
be optimized to reduce intraparenchymal pressure and ensure the gel remains in the defect. It is
also plausible to utilize MRI to determine the area of cyst formation after SCI, aspirate out the
contents of the cyst, and inject the gel to fill the defect.
- Since the optimum time for administering an injectable therapy for SCI may be slightly after the
initial inflammatory response but before formation of the glial scar, future animal experiments
may want to administer the gel in the subacute phase of SCI (7-14 days post injury)
* MR imaging can be used to follow individual animals, serially through the course of regeneration.
The extent of the initial injury and zones of ischemia and hemorrhage can be identified and
predictions can be made and tested about the evolution of the secondary injury. Understanding
these factors will help us better comprehend and categorize the functional recovery of animals
based on their individual injuries and help us best compare the regenerative response. It can also
give us a sense of the neuroprotective effects of our therapies (limiting secondary damage).
- A more detailed histological-MR imaging comparison should be conducted to allow us to make
an accurate prediction of the composition of the defect based on the imaging data. These
experiments can include T2 mapping of the defect area, which would give us a signature
relaxation time for different tissue and gel components and increase our certainty in identifying
them. One can also incorporate information from other MR imaging modalities including TI and
diffusion tensor imaging (DTI) to discriminate between the tissue or gel within the defect.
- Finally, one may consider adding cells into the injectable scaffold for delivery into the defect site.
The exact type of cell should be determined by the intended goal of the therapy (i.e. replacement
of neurons, myelination, immunomodulation, secretion of trophic factors). Appropriate tests of
the gel containing the specified cells should be conducted to ensure the gel still fits within the
intended design parameters. Such tests include gelation time, gel mechanical properties, and cell
viability/behavior within the gels.
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Appendix:
Rheology procedure (gelation during testing):
For rat-tail collagen:
Instrument: TA instruments AR-G2 rheometer in a cone and plate geometry (40 mm 2 ) McKinley Lab
3-237 contact Sean Buhrmester for training [fatsean@mit.edu]
Parameters: Oscillation procedure, only check middle step
Experiment type: Time sweep for 60 min (really only use 1500 sec). Delay time 1 sec
Temperature: 37*C, don't click wait.
Mechanics: Controlled stress @ 0.1 Pa, I rad/s
Data collection: Sampling and conditioning time 10 sec each
Procedure:
*Sign up for time at calendar.yahoo.com (name: nonnewtonian password: deborah)
*Renember to sign in and out of the book
1.) Calibrate instrument, follow instructions on the sheet on top of the computer. *Make sample during
rotational mapping to save time. Use 1.5 ml centrifuge tubes and make 0.7 ml.
Keep collagen in refrigerator to keep it cold. There is no easy source of ice nearby.
2.) Change the bottom plate temperature to 8*C to prevent gelation
3.) Pipette 640 [tl onto the center of the stage (marked as slightly in front of the circle on the lower
platen). Make sure there are no bubbles (remove with pipette).
4.) Use the instrument control tab to lower the geometry to 500 rim, 100 [m, and finally 54 tm. Sample
must be even around the entire geometry and must come right up to the edge without overflowing.
5.) Start the run and wait 150 sec before applying light mineral oil, dropwise around the edge of the
geometry to prevent evaporation. The oil will spread so not much is needed.
6.) Data is automatically saved at every point to the file you specified. Data file automatically opens with
the TA Analysis program. Right click on the file name on the left-hand panel and click export to text. The
txt file will be in the same folder as the data file.
*To get the full data set you must close and reopen it at the end of the run!
7.) At the end of the run, press the stop button. Raise the geometry and clean it with a kipwipe. Wipe the
stage clean with a kimwipe.
8.) Turn the temperature back to 8*C, recalibrate geometry inertia and rotational mapping before the next
sample.
9.) Sample analysis: open txt file in excel.
Gelation time (G'=G" or delta =45). Plot delta vs time, zoom in on x-axis and make y-axis between 45-
46. The gel point will now be the intersection of the line on the x-axis.
Modulus at a specific time: Read directly from text file. It is a little easier to put all data on the same sheet
because all of the rows will be at essential the same time (+/- a few sec discrepancy per run).
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For an unknown sample:
1.) Determine the linear viscoelastic regime (LVR) of the material.
Allow material to gel in the machine
Perform a stress sweep from 0.0 1-10 Pa 6 pts/decade @ 1 rad/s
Want a stress that is in the linear range of the modulus vs. stress plot
2.) Determine frequency dependence of modulus
Frequency sweep at a controlled stress determined in 1.)
1 rad/s - 100 rad/s
3.) Determine if stress affects the gel procedure (i.e. prevents gelation)
Within the LVR find the stress at which the gel point no longer changes
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LMT Fabrication Procedure
Materials:
e 1,2-bis-(triscosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC 8,9PC) AKA
23:2 Diyne PC: 1,2-di-(1 OZ, I 2Z-tricosadiynoyl)-sn-glycero-3-phosphocholine
Cat # 870016 Avanti Polar lipids
e D4/D-Trehalose MW= 378.33 g/mol
e Ethanol
SDI H 2 0
e lx Phosphate Buffered Saline (PBS)
Temperature controlled water bath (Cole-Palmer 6-liter Programmable Controller Heated
Circulating Bath, 240VAC, CAT# EW-12116-35)
Fabrication Procedure:
1.) Preheat water bath to 55'C
2) In separate 15 ml conical tubes, warm 7 ml of 100% ethanol and 3 ml sterile water to 55'C
3) Dissolve 10 mg lipid in the 7 ml of warm ethanol
4) Slowly add the water to the lipid/ethanol solution and discard the empty water tube
5.) Use the following program to slowly cool the lipid solution at I *C in the water bath (total running
time of 51 hours)
Step Ramp(0 C)
1 55-55
2 55-25
3 25-33
4 33-25
Time (hr)
5
30
8
8
6) Incubate the lipid solution for two weeks at room temperature protected from light to allow the
microtubules to completely form
7) Add 50mM trehalose (18.9mg/ml) to the lipid solution and mix gently. Since trehalose is poorly
soluble in EtOH, dissolve the appropriate amount in I ml DiH 2O before adding. Incubate-
overnight at room temperature
8) Centrifuge the lipid microtubules for 10 min at 1500g, remove the supernatant
9) Resuspend the microtubules in 0.5 ml sterile water, freeze and lyophilize the microtubules overnight
10) Load the microtubules by rehydrating the dried microtubules in the protein solution of interest (40pl
per mg of lipid) and incubate overnight at 4'C. Be gentle with pipetting.
11) Add 2 ml lx PBS per mg microtubule, centrifuge for 10 min at 1500g and remove the supernatant
12) Repeat the rinse (step 11) and dilute to the desired concentration in lx PBS
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Astrocyte Migration Assay Procedure:
Media - 3
(500 ul)
--C Migration exp. gel (400 ul)
6 mm cell gel Collagen (200 ul)(-75 ul vol) Agarose (200 ul)
Materials:
Collagen gel: Always keep components on ice
o Type I rat tail collagen (BD Biosciences) 3.6-3.9 mg/ml
o 5x Phosphate buffered saline (PBS)
o IN NaOH
o lx PBS or cell culture media
o 3 mg/ml genipin in 5x PBS: make sure it solubilizes, then filter
o Lipid microtubules (LMTs): See LMT procedure document
o Growth factor of choice (ie. FGF-2)
Migration assay
o 12 well plate - for initial astrocyte seeding
o 24 well plate- for migration assay
o 6 mm biopsy punch
o forceps
o 2% sterile agarose solution
o Trypan blue & hemocytometer
Cell Culture:
o Media: DMEM high glucose + pyruvate + glutamate
o Media additives: 10% FBS, 1% Penn/Strep antibotics
o Accutase- for harvesting
Procedure:
Day 1:
e Obtain astrocytes from Charlestown. Use Styrofoam box with heating pack inside
- Harvest cells:
o Remove media & rinse with PBS
o Add warmed Accutase solution (3 ml for T25, 5 ml for T50) incubate 5-10 min. Tap
bottom of flask with palm of hand.
* By microscope: most cells should be seen floating
o Add equal parts media & transfer to centrifuge tube
N 300x g, 5 min
o Remove supernatant and re-suspend gently in I ml media
* Count on hemocytomter, 1:9 dilution w/ trypan blue
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0 #cells= Avg 4 squares * dilution * vol media * 104
Seed at lx 106 cells/ml in 2 mg/ml collagen gel
- Use Col, 5x, NaOH, cell culture media, cell suspension
- Want volume of # gels needed /7 rounded to nxt whole #
- Add 1 ml gel-cell solution to each well of a 12 well plate
- Allow to gel for 15-30 min then add 1 ml wann media
* Load LMTs with growth factor or PBS
o 40 [d/mg LMTs, keep in refrigerator
0 Previously I mg/ml, 0.11 mg/nl FGF-2 in 5% trehalose
* Coat bottom of 24 well migration plates with agarose
o Only have 2-3 groups/plate- temp control when plating & imaging
o Heat agarose solution to 60*C
o Pipette 200 [l on the bottom of each plate,
o Keep in hood overnight
Day 2:
* Coat 24 well plates with type I collagen solution
o 200 [tL, let gel in incubator for 30-60 min
* Rinse LMTs
o Transfer to 15 ml tube and re-suspend in 2 ml Ix PBS
o Centrifuge 1500 x g, 10 mi n
o Remove supernatant and re-suspend at I mg/ml
e Make 2 mg/ml collagen gel solutions
o Use spreadsheet to calculate volumes of all components
- Want final volume of 0.4 ml x (# samples +1)
o Make 3 mg/ml genipin soln in 5x PBS
m Mix thoroughly using vortex until solubilized, then filter (0.22 rim)
o Genipin groups were done at 0.25 mM
o For LMT groups load at 0.1 mg/mI
o Hold everything on ice till ready to plate
* Setup migration assay
o Biopsy punch 6 mm gels (7 per 12 well plate)
o Carefully remove with forceps and place in the center of the 24 well plate
o Immediately coat with 0.4 ml Col migration gel
o Incubate for 30 min before adding 0.5 ml media
Day 3-9:
e Replace media on all samples at 24 hours
* Replace every 48 hours thereafter
- Imaging can be done on the light microscope (usually Day 4,6)
Day 10:
* Imaging:
o Remove media from wells & replace with 0.5-1 ml staining solution
" 1-2 pl Calcein AM (Img/mI aliquots) per I nil PBS
- Incubate for 30-60 min
o Remove from well, place on microscope slide and blot dry along edges
" Image at 4x in fluorescent microscope 5-6 FOV along edge per gel
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0 Be sure to capture both interface and furthest cells even if it takes multiple FOV
o Also take an image at the center of the gel
* Fixation:
o Place gel into new well with 1 ml 4% PFA, leave at RT for I hr
o Rinse with lx PBS
o Add I ml 0.5% triton-x 100, leave for 30 min-I hr
o Rinse with lx PBS
o Add DAPI (5 mg/ml stock) I ml (1-2 [tl/10 ml PBS) leave overnight
* Imaging again for DAPI staining
Analysis: Using Image J
For each image:
e Measure the interface length between the cell seeded and migration gel
- Manually count the number of migrated cells using the cell counter function
o Careful to make sure you are catching each cell in Calcein AM images
e Measure the distance from the interface to the longest cell
o Measure using a line perpendicular to the interface
For the image with the longest migration (using DAPI images)
e Create a histogram of all the cells
o Using the cell counter function, place a marker at the interface of the gel
* If the surface is highly curved, you may have to place several markers after
rotating the image
o Mark the positions of each cell that has migrated
o Subtract the XY coordinates from nucleus of the cell from the XY coordinate of the gel
interface to determine the migration distance
m Images were scaled to 62 pixels= 100 microns
* Graphs
o # cells/mm interface
o Avg migration distance of longest cell
0 Averaged over all images of all gels per group
o Histogram of distance cells migrated
- 100 ttm intervals
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Image Analysis:
1.) Select your image for analysis in Photoshop
CS5
If recording a percent area, leave in default scale
(easier to switch between Photoshop and image J
Analysis- Record measurement (gives area of the
selection)
5.) Image- calculations- Green channel subtract
red channel.
This creates a new grayscale channel based only
on the red staining in the image
Image-mode-grayscale (deletes all other
channels
2.) Draw a border around the defect or region of
interest using the brush tool
6.) Select-inverse
Press delete and fill with black
3.) Select the region of interest using the quick
selection tool
4.) If recording an absolute area measurement:
Analysis- set measurement
4x histology= (542 pixels/] 000m)
Images with high background staining can be
thresholded to include only the appropriate
staining by
Image-adjustments-threshold
7.) Save as JPEG image
8.) Open in Image J 1.45S
Process-Binary- Make binary
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Analyze-analyze particles- size 0-infinity,
circularity 0-1
Use the "total area" for analysis (area of white in
the image)
9.) For percent area analysis:
% area= Abinary from image j/Aselct from photoshop
Validation: Correlation of cell number and area
1.) Primary cortical astrocytes seeded in a collagen gel. Gels were embedded in paraffin, sectioned at 6
tm and stained with Masson's Trichrome. Image taken at 4x objective
Original Image Counting Post processing as above
In vitro astrocyte seeded gel
R = 0.960
0 0.005 0.01 0.015 0.02 0.025 0.03
Area (mmA2)
Images of the spared white/gray matter of GFAP IHC stained slides were used to validate the method of
separating areas IHC staining and correlating area to number of cell bodies present. A number of
astrocytes in the images below are also hypertrophic.
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Counting Post processing*
*A slightly different image calculation (blue- inverse green instead of green -red) was used to obtain the
post-processed image due to the high GFAP staining intensity in the spared tissue from processes of
astrocytes whose bodies are not in the image. The concept of separation was still identical.
In vivo astrocytes in spared white/gray
matter
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Original Image
